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Au seuil de la chirurgie
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En chirurgie, comme à la guerre, les qualités de caractère, de décision prompte et
judicieuse sont d'importance majeure; ainsi que l'écrivait jadis Bretonneau à
Trousseau, "la pièce la plus importante d'un homme, c'est son caractère". Mais, cette
force morale, cette fermeté et cette égalité de l'âme peuvent aussi se developer par
l'expérience, par l'âge, par la culture volontaire; et, dans son éloge de Nélaton, Gyon
définissait, avec justesse, le vrai sang-froid chirurgical, "cette force d'esprit que don-
nent la prévoyance et le savoir".
In surgery, as in war, qualities of character, of prompt and judicious decision are of
extreme importance. Bretonneau at Trousseau Hospital once wrote: "the most impor-
tant part of a man is his character". This moral force, this firmness and equality of the
soul can, however, also be developed by experience, age and self-acquired culture. In
his praise of Nélaton, Gyon defined, with accuracy, the real surgical sangfroid: "this
moral strength obtained by foresight and knowledge".
In de chirurgie zijn, zoals in de oorlog, karakterkwaliteiten met een directe en
oordeelkundige beslissing van levensbelang. Zoals Bretonneau uit het Trousseau
ziekenhuis destijds schreef, "het belangrijkste deel van de mens is zijn karakter".
Maar deze morele kracht, deze vastberadenheid en deze zielsgelijkheid kunnen ook
ontwikkeld worden door ervaring, leeftijd en zelfverworven cultuur. In zijn lofrede
op Nélaton, definieerde Gyon zuiver de echte chirurgische koelbloedigheid, "deze
geestkracht die voortkomt uit een vooruitziende blik en kennis". 
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Introduction and aim of the thesis
9
INTRODUCTION
Short small bowel and short bowel syndrome are terms that are used to describe the
same disease process. In this thesis the term "short small bowel" has been chosen
since the problems start with the loss of a considerable part of the small intestine. In
some children there are sometimes relatively simple remedies to treat the conse-
quences of the intestinal loss. The more commonly used term "short bowel syn-
drome" describes what happens after the bowel resection.
"Short bowel syndrome is a term used for symptoms and pathophysiologic disorders
brought about by the removal of a large portion of the small intestine. Diarrhoea,
weight loss and malnutrition are the major features of the syndrome" [1]. It can also
be defined as "a state of significant maldigestion and malabsorption requiring a pro-
longed period of parenteral nutrition to provide for normal growth and development,
prevent dehydration, and replace electrolytes, vitamins and trace elements due to
extensive loss of the small bowel" [2]. 
The definition can also be extended to functional lesions: "Short bowel syndrome
is a disorder in which malabsorption occurs as a result of massive resection of the
small intestine, abnormal gut motility, or mucosal disorders that perturb absorption or
digestion" [3]. 
Other components of the syndrome are the development of end-stage complications
such as sepsis from catheter infections, metabolic disorders, the lack of venous access
due to thrombosis, cholestasis, cirrhosis and liver failure [4].
The normal length of small bowel is variable and in adults a length of 400 to 800 cm
is given. Weaver and co-workers [5], combining eight published reports on small
intestinal length from 1010 necropsy measurements, described a mean of 200 cm at
30 weeks of pregnancy, 275 cm at term, 380 cm at one year, 450 cm at five years, 500
cm at 10 years and 575 cm at 20 years. Measured differences in small intestinal
length varied between 68 and 386 cm for newborns, 104 to 591 cm (mean 344 cm)
from one month to one year and 232-485 cm (mean 396 cm) between one and five
years of age [6]. The causes of short small bowel (SSB) in children are many and are
mainly due to congenital or perinatal diseases. In premature infants, necrotizing ente-
rocolitis may necessitate an extended resection of small bowel and is the most com-
mon cause of short small bowel in the literature. Intestinal atresia and gastroschisis,
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which are pro-bably vascular in origin, also account for a large number of children
with an SSB (see Table 1). Volvulus of the small bowel with necrosis in children with
a malrotation may also necessitate an extended resection. Genetic defects [7] or defects
like a near total intestinal aganglionosis are rare causes of a short small bowel [2]. 
Table 1. Causes of Short Bowel Syndrome in neonates and children in % [2]
The incidence of short bowel syndrome is estimated at 2 to 3 per million population
per year in the United Kingdom, half of them being children and 4.8 per million
population per year in Canada [8]. In Sweden an estimate of 0.3 to 0.5 per 10,000
births of extreme short bowel in neonates is recorded [9]. The incidence in the
Netherlands is not yet known.
Bacterial overgrowth occurs frequently in SSB [10]. It is difficult to diagnose since
in normal bowel the amount of bacteria increases from about 103 colony forming
units/gram (cfu/g) food mass in the stomach and duodenum to 107 cfu/g food mass
in the ileum. Regular courses of enteral antibiotics to eliminate potentially patho-
genic gram-negative organisms can help, but may allow non-susceptible strains of
bacteria or yeasts to proliferate. 
SSB may also predispose to bacterial translocation, defined as the active or passive
penetration of viable microorganisms through the epithelial lining into the lamina
propria [11]. In the intestinal wall bacteria should be cleared by the host defense sys-
tem, but sometimes they may invade the mesenteric lymph nodes, the blood and even
other organs. This depends on the permeability of the intestinal wall and is influenced
by stasis, bacterial overgrowth and parenteral nutrition [12]. While enterobacteria,
staphylococci and enterococci are able to translocate, most anaerobes do not appear
to have this ability [11,13,14].
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Necrotizing enterocolitis 36
Intestinal atresia 21
Volvulus/malrotation 19
Gastroschisis 10
Hirschsprung's disease 7
Trauma 1
Others 6
AIM OF THE THESIS
This study is the result of 25 years experience in paediatric surgery. In this period we
were regularly confronted with children with a short small bowel. Some of them pre-
sented with many serious problems over a long time. This thesis presents an overview
of what we have learned during the treatment of these children. 
Studies in animals were performed in 1975 to determine which surgery might reduce
rapid transit times and improve intestinal absorption (Chapter 2.1). Chapter 2.2
describes the surgery we performed and provides a list of the patients with many of
the complications that occurred. Malrotation, an important congenital abnormality
that may lead to volvulus and necrosis of the small intestine, was studied to try to
identify the patients requiring surgery (Chapter 2.3).
One of the problems of children with an SSB is D-lactic acidosis. A profuse growth
of lactobacilli in the remaining bowel was found to be the basic cause of this aci-
dosis. Having found the microbiological and biochemical explanations, the clinical
significance for these children was sought and is presented in Chapter 3. 
The complications of long-term treatment of SSB are discussed in Chapter 4.
Immunological studies were performed to try to explain why children with both an
SSB and a parenteral access port are more susceptible to infection than children who
have a parenteral access port but a normal bowel (Chapter 4.1). Improvement of
bowel function during short-term treatment with growth hormone has been described
[15]. The short-term effects and in a later study the long-term effects of growth hor-
mone treatment were therefore investigated to try to decrease the use of parenteral
nutrition (Chapter 4.2). The absorption of oral drugs in patients with SSB is unpre-
dictable. The sparse literature on this topic is reviewed (Chapter 4.3). Small intestinal
transplantation is nowadays an accepted treatment, but still has a high morbidity and
mortality. The results are reviewed in Chapter 4.4.
Ethical problems in treatment, due to the acute loss of all small bowel are discussed
in chapter 4.5. 
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2.1 ANIMAL STUDIES ON SHORT SMALL BOWEL
RSVM Severijnen, JA Grotenhuis
Department of Paediatric Surgery, St Radboud Hospital, Nijmegen,
The Netherlands
INTRODUCTION
In an attempt to resolve the clinical problem of severe diarrhoea and malabsorption
in children with a short small bowel, a surgical experiment was performed on dogs.
The aim was to select the best surgical method to slow down the accelerated passage
through the shortened intestine and to improve absorption by producing a longer con-
tact time. Several authors [1-4] have described the technique of creating antiperi-
staltic segments in neonates for this. The method has also been recommended to
improve the low pH of the intestinal contents, which Flint considered to be one of the
causes of rapid transit [5].
In this study, we decided to create antiperistaltic segments and recirculating loops in
the canine small intestine after extended resection to see whether we could slow down
the intestinal passage and achieve better absorption.
METHODS
In 1975 we performed a surgical experiment on 10 adult beagle dogs at the Central
Animal Laboratory of the Catholic University in Nijmegen. Experiments on rats or
mice at that time were not considered to be able to answer our problem of rapid tran-
sit and improved absorption. 
In a series of different resection percentages, we selected two of the many opera-
tion techniques described by Hoffmann von Kapherr in 1972 [6]: resection with a 10
cm antiperistaltic segment or a recirculating circular loop (isoperistaltic or antiperi-
staltic according to Mackby) [7] in the small intestine (Table 1).
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Table 1. Type of operation and outcome in 10 dogs 
The D-Xylose test, with pentose-sugar is a marker for carbohydrate absorption. It is
mainly absorbed in the proximal jejunum, is not metabolised, but excreted into the
urine. Abnormal intestinal flora in a blind loop syndrome may consume the xylose. 
This test was performed some months postoperatively, after the intestinal adaptive
period. Following the oral administration of 0.5 gram xylose/kilogram body weight
in a 10% solution, blood samples were taken at 0, 30, 60 and 120 minutes.
A D-Xylose tolerance test and an indicantest were also performed on urine col-
lected during 0-8 hours and 8-24 hours after the duodenal administration of xylose.
In four dogs we resected 50 to 90% of the small intestine and created an antiperistaltic
ileal segment with an end-to-end one-layer anastomosis, sutured with atraumatic silk.
In three dogs, we resected 80 or 90% and created iso- or antiperistaltic circulating
loops with an end-to-side anastomosis.
In one dog, 80% of the small intestine was resected together with the ileocaecal
junction. In two dogs, 80% of the jejunum or ileum was resected, without any addi-
tional constructive surgery, except for a primary end-to-end anastomosis.
To judge the results of surgery, we evaluated clinical performance, weight against
time, fat and nitrogen excretion into the faeces and we performed D-Xylose tolerance
17
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Dog Resection    Residual bowel length (cm) Additional surgery Outcome
in % Jejunum Ileum
319 80 30 12 antiperistaltic segment died
320 0 130 130 antiperistaltic segment survived
321 50 30 90 antiperistaltic segment survived
350 80 10 40 none survived
369 80 42 12 recirculating loop died
(Mackby I)
371 50 90 30 antiperistaltic segment survived
374 80 10 53 recirculating loop survived
(Mackby II)
381 90 20 10 recirculating loop died
(Mackby I)
395 80 90 1 none died
398 80 65 0 ileocaecal resection died
tests, an indican test as a marker of bacterial overgrowth from pathological flora and
a radiological examination.
RESULTS AND DISCUSSION
The length of the canine small intestine measured at the time of surgery varied
between 240 and 450 cm. A major section was resected in all except one dog. In the
latter case a 10 cm antiperistaltic segment was constructed in the ileum to study its
isolated effect.
In the postoperative period we did not administer parenteral feeding to these dogs;
they only received intravenous fluids.
Severe diarrhoea and weight loss in the first six weeks led to the death of four dogs
within twelve weeks. One dog was put down after seven months because of his poor
condition. All these dogs had twelve cm of ileum, or less. Five dogs survived; all had
an ileal segment of more than 30 cm.
The dog that performed best on all the parameters had undergone 80% resection of
the jejunum, without any additional constructive surgery. The same resection proce-
dure on the ileum led to intractable cachexia and death within twelve weeks.
The D-Xylose test showed very wide variation in xylose blood levels in 5 control
animals, probably due to different rates of gastric emptying. Therefore we performed
a D-xylose tolerance test after duodenal administration of xylose: 75 to 95% of the
xylose was excreted in the urine in the first 8 hours.
The qualitative test of indican excretion in the urine was very often positive in the
second period of urine collection. The negative tests in the first 8 hours may have
been caused by the water (250 ml) the dogs drank after the xylose load. 
Fat excretion in the faeces should be zero, but it was between 5.1 and 10.2%, with
the best result again in the dog that underwent extended jejunal resection alone.
Nitrogen excretion was considered normal.
Radiological examination after two to six weeks showed recirculation of the barium
meal in the dogs with the Mackby loops. In the dog with an isolated anti-peristaltic
segment that did not undergo resection, gastric emptying time was over one hour. In
two out of the three dogs with a recirculating loop, gastric emptying was also delayed.
The other dogs showed normal gastric emptying. Anti-peristaltic movement was
clearly visible in the inverted segment. No serious distension of the small bowel was
seen in any of the dogs.
18
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We observed that the dog that performed best was the one with a simple end-to-end
anastomosis after extended jejunal resection. Although this operation caused severe
diarrhoea, all the additional constructive operations caused new problems, especially
stasis of the intestinal contents.
All the dogs that survived had an ileum that was 30 cm or longer. Recirculation of
bowel contents in the circular loop did not improve the situation. The dog that sur-
vived with the recirculating loop had an ileum of 50 cm long. We assume that this was
the reason for survival, not the recirculating loop.
Antiperistaltic segments and recirculating loops had some influence but the effects
were unpredictable.
The very good clinical and laboratory performance of the dog that underwent
extended resection of the jejunum compared to the one with 80% resection of the
ileum surprised us and emphasized the importance of preserving as much of the ileum
as possible. Apparently, the ileum is better able to take over the function of the
jejunum than vice versa.
CONCLUSION
On the basis of these studies in 1975, we have performed only end-to-end anastomosis
after bowel resection in children. No additional constructive surgery has been per-
formed since antiperistaltic segments and recirculating loops had unpredictable and
non-reproducible effects. To date, these conclusions are still valid.
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2.2 OVERVIEW OF PATIENTS AND SURGERY
RSVM Severijnen
University Medical Centre St Radboud, Nijmegen, The Netherlands
DEFINITION OF SHORT SMALL BOWEL
The length of the normal small bowel is variable. In adults, a length between 400 and
800 cm is given. Weaver and co-workers [1] combined data from eight studies based
on 1010 necropsies. They reported a mean small bowel length of 200 cm at 30 weeks
of pregnancy, a mean length of 275 cm at term, 380 cm at one year, 450 cm at five
years, 500 cm at 10 years, and 575 cm at 20 years of age.
Normal small intestinal length varies between 68 and 386 cm for newborns,
between 104 and 591 cm in children from one month to one year and between 232
and 485 cm between one and five years of age [2]. This makes a definition of a short
small bowel and the short bowel syndrome difficult. In addition, there are large dif-
ferences in intestinal adaptation in children. Even 20 cm of remaining small bowel in
some newborns may be sufficient to gain nutritional autonomy after an adaptation
period, whereas in others 100 cm of remaining small bowel is hardly enough to keep
intestinal nutritional autonomy. 
The American Gastroenterological Association states that a short bowel syndrome
is present when less than 200 cm of functional small bowel remains [3]. Touloukian
and Walker-Smith state that a short bowel syndrome is present when less than 30%
of functional small bowel remains [4]. In accordance with them, we consider 50 cm
for premature babies between 28 and 35 weeks, 75 cm for newborns and 100 cm of
remaining small bowel after 1 year sufficient to prevent the short bowel syndrome,
since we were seldom confronted with problems in neonates and young children
when more small intestine remained [5]. We use the term short small bowel if less
than 50, 75 or 100 cm for prematures, newborns or older children respectively,
remains and acknowledge that even some of these children, have few problems.
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SURGICAL THERAPY
Primary operation 
After resection of a diseased small bowel and careful assessment of the situation, the
paediatric surgeon will preferentially perform an end-to-end anastomosis. If an end-
to-end anastomosis is not possible, stomata have to be created. Care has to be taken
to preserve every piece of non-diseased tissue. Leaving non-functioning sclerotic
tissue behind, however, causes problems of stasis and/or diarrhoea. Stomata have to
be closed as soon as the condition of the child permits, usually after 3 to 4 weeks [6]. 
Secondary operations
Despite the paediatric surgeon's best efforts and judgement a stenosis of the remai-
ning intestines can occur. This will necessitate a second operation. Antiperistaltic
or valve operations have, in our opinion, no place in the surgical management of
these children. Dilated intestine with an acceptable transit time should be left alone.
When dilatation and delayed transit without an anatomical stenosis is present, it is
sometimes possible to perform tapering or infolding of part of the intestine [7].
Stasis without transit obviously requires corrective surgery. In such cases, we prefer
longitudinal bowel splitting and lengthening according to the technique described by
Bianchi [8]. Obstructive ileus that requires adhesiolysis is not unusual in children
with a short small bowel [9].
Vascular approach
In order to deliver nutrients parenterally, we initially prefer polyurethane catheters
put into a subclavian vein via the percutaneous route. Later, we use cuffed silicone
central venous catheters via the same route. We avoid, if possible, open placement by
venesection of these catheters, since the available sites for this technique are restricted.
In our opinion, there is no indication for subcutaneously implantable systems at an
early age, since these systems are more difficult to remove in case of infection or
occlusion.
If access to the circulation is or becomes problematic, direct arterio-venous shunts
or shunts with artificial material can help, but in small children it is difficult to
accomplish a usable shunt. Later, reoperation of such arterio-venous anastomoses is
sometimes necessary because of "steal-syndromes". Trombotic occlusion of the great
vessels, that scatters embolic particles, requires operative removal of the thrombus.
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Adjuvant intestinal operations 
When administration of nutrients via the enteral route is possible, we often perform
a Stamm gastrostomy for continous or nocturnal administration in order to prevent
the long-term use of nasogastric tubes. Where there is delayed gastric emptying
with gastro-oesophageal reflux a Witzel's jejunostomy is created for continous
administration of nutrients. Although parenteral administration of nutrients is asso-
ciated with gallbladder hypomobility and sludge formation, we have never had to
remove a gallbladder for gallstone disease in our children.
PATIENTS
In this chapter, the code numbers of patients with extensive problems described in the
different chapters of this thesis are presented. Patients IN 5, 6 and 7 are from former
articles and are changed into CH 5, 6 and 7. No higher IN numbers are used. The older
child from Chapter 4.5 where treatment was refused, evoking an ethical dilemma, is
not included here.
CH 1 is a girl, born at term in 1987. She was admitted on the first day post-partum
because of bilious vomiting and a distended abdomen, caused by malrotation and
acute volvulus. She underwent surgery and a large part of necrotic intestine was
resected, leaving 15 cm of proximal small bowel measured from the pylorus and 35
cm of the distal ileum, with the ileo-caecal valve in situ. Only the last 5 cm of the ileum
looked healthy. Since a primary anastomosis was not thought to be a good option,
stomata were created. These stomata were closed after 3 weeks. During closure of the
stomata, only the last 15 cm of the ileum were left in situ. One month later, however,
the child again required surgery since another 7 cm of the ileum were stenotic. In the
end she had only 22 cm of small bowel. Central venous catheter complications
occurred frequently and she developed thrombosis of the superior caval vein. After
seven months in hospital while on parenteral nutrition (PN) she developed a
meningo-encephalitis with a low-pressure hydrocephalus, probably related to
catheter infection. We therefore decided to construct an arterio-venous anastomosis
in the upper leg using a human venous graft. Unfortunately, this graft did not func-
tion well enough to be used. At the age of nine months she was finally discharged
from hospital on home PN. One month later, after another septic episode, an MRI was
performed and showed an occluded superior caval vein with flow via the azygos
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system. We then decided to keep her only on enteral feeding, initially through a gas-
trostomy and later orally. For many years she experienced abdominal pain, which
was assumed to be due to abdominal angina. Presently, she is doing fine, discharged
from paediatric surgical check-ups, but still under control of the paediatric gastroen-
terologist. Her height and weight are on the 50th percentile.
CH 2 is a girl, born at term in 1984. She was admitted because of bilious vomiting
shortly after birth. Acute volvulus with malrotation had caused gastrointestinal
obstruction with blood loss resulting in anaemia. On the second day of life, she under-
went an extensive resection of necrotic small bowel, leaving 15 cm of proximal small
bowel measured from the pylorus in place as well as 50 cm of the distal small bowel,
of which only 20 cm looked healthy. Stomata were constructed. At the age of one
month, an end-to-end anastomosis was constructed between the proximal 15 cm of
small intestine and 30 cm of the distal part. Two months later she was re-operated
because of ileus. Two cm of stenotic ileum was resected. For the same reason, another
15 cm of fibrotic ileum had to be resected at the age of four months. She ended up with
28 cm of remaining small bowel. For one year she was totally dependent of PN and
it took another year to provide all nutrition enterally. At the age of 21 months an
infected thrombotic mass in the heart was surgically removed. During that procedure,
a small part of the tricuspid valve was removed. At the age of two years parenteral
nutrition could be stopped. She remained short in stature and we tried to increase her
height using growth hormone. Unfortunately, she died at the age of six years during
a second cardiac operation for valvuloplasty after decompensation due to tricuspid
valve insufficiency.
CH 3 is a girl born in Austria in 1989. At the age of nine months, she developed an
ileo-colic intussusception necessitating resection of 15 cm ileum. Six months later a
strangulation ileus caused necrosis, necessitating resection of 220 cm small bowel,
including the ileo-caecal valve. Fifty cm of small intestine remained as well as the
colon. One year later, a third laparotomy was necessary to resolve an adhesion ileus.
Removal of small intestine was not necessary during this operation. Enteral feeding
was possible, but complete oral feeding could only be reached at the age of six years.
She suffered frequently from metabolic acidosis. Growth developed along the 25th
percentile.
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CH 4 is a girl born in 1990. She was healthy until the age of four years when she was
admitted with abdominal pain and fever caused by an acute intestinal ischaemic acci-
dent. After resection of the necrotic bowel, she was left with 60 cm of small intestine.
She had repeated surgery for abdominal abscesses and anastomosis leakages.
Eventually, 45 cm of small bowel remained, including the ileo-caecal valve. After a
hospital stay of six months, complicated by eight episodes of catheter related problems,
she was discharged while on PN. She received home PN for three years.
She participated in both the short- and long-term study on the effect of growth hor-
mone on bowel adaptation. In 1998 PN had to be stopped because of vascular access
problems. After this she failed to thrive. In 1999 PN was reinstituted initially via
central venous catheters, but this again caused frequent occlusion and infections. An
arteriovenous shunt was constructed in 2001 and several revision procedures were
necessary. Eventually, a second shunt had to be constructed and later the first one had
to be closed a steal-syndrome. In 2001 her last central venous catheter caused a
Candida guilliermondi infection with thrombosis in the heart. This problem was
solved by long-term antimycotic therapy. Gastrostomy feeding caused too many
abdominal complaints and so the gastrostomy was closed during a shunt revision in
2003. She is at present on home PN. She can manage to keep her weight constant for
several days without PN using Neocate®.
CH 5 (IN 5) is a boy born in 1996. We assume that he had an omphalocèle that closed
before birth. This resulted in the loss of most of the small bowel with a jejunal atresia
and both closed loops ending at the umbilicus. After surgery on the first day of life the
remaining small bowel tissue was 25 cm in length. He was re-operated five times
because of stasis of bowel contents in a non-functioning distended bowel and the ileo-
caecal valve was resected. In 1997, he underwent an intestinal lengthening procedure
according to Bianchi performed by professor Waag in Mannheim. During this proce-
dure his estimated bowel length was 43 cm of which 30 cm could be doubled. The
operation improved the passage of enteral feeding. He participated in both the short
and long term study on the effect of growth hormone on intestinal adaptation.
However, it was only after initiation of selective bowel decontamination that PN
could be diminished from daily to two times a week. At present PN is administered
for one or two nights  a week at home. He was proposed for small bowel transplanta-
tion because of venous access problems but was not accepted because of the ultimate
prospect of reaching intestinal autonomy.
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CH 6 (IN 6) is a boy born in 1996 with a gestational age of 31 weeks. At birth he
weighted 1185 grams. In the first week post-partum he suffered from bloody stools.
At week seven he became septic and necrotizing enterocolitis (NEC) was suspected
but at laparotomy no necrosis was detected. A second laparotomy at week 11 revealed
torsion of the intestine with necrosis of 70 cm of small intestine. After resection, 35
cm of jejunum distal to the ligament of Treitz and 5 cm of the distal ileum remained.
Stomata were created. After three additional laparotomies for abscess and fistula for-
mation, the stomata were closed at week 18 of life but had to be reconstructed two
days later. At week 23 during his 8th laparotomy the stomata were closed again over
a trans-anastomotic drain via a caecostomy. A gastrostomy for continuous feeding
was also performed. During this period a total of five central venous catheters had to
be inserted; complications were infections and trombosis of the subclavian vein. He
was treated with growth hormone and glutamine for nine weeks. After this treatment
period, PN could be stopped. He was discharged after 10 months in hospital. Since
this he is doing well despite an almost continuously distended abdomen.
CH 7 (IN 7) is a boy born in 1996 after a pregnancy of 33 weeks. At birth he
weighted 1510 grams. Perinatally, he was asphyctic leading to periventricular leu-
comalacia. Six days after discharge from the neonatal intensive care unit he was re-
admitted with NEC. After a difficult haemodynamic stabilisation period, a laparo-
tomy was necessary. At surgery 20 cm of necrotic ileum had to be resected.
Subsequently, a jejunostomy and a colostomy had to be constructed. Several weeks
later reconstructive surgery was performed leaving 50 cm of small bowel and 10
cm of colon. Although he is mentally retarded, blind and suffers from hearing loss,
he can manage pretty well. He participated for 18 weeks in the short- and for one
year and a half in the long-term study on the effect of growth hormone on bowel
adaptation.
CH 8 is a boy born at term in 2001. At birth his body weight was in the normal range.
Only two vessels were seen in the umbilical cord. Cryptorchidism was also found. In
the first weeks of his life he was treated for neonatal convulsions. Three weeks post-
partum he was admitted to hospital acutely because of a swollen abdomen and sepsis
due to malrotation and volvulus. A laparotomy was necessary and a necrotic part of
the small intestine had to be removed. Stomata were created. Three weeks later these
stomata were closed. During this period he developed cholestatic icterus while on PN.
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Two weeks after closure of the stomata, a further resection of 30 cm of fibrotic small
bowel was necessary with an end-to-end anastomosis. Finally, 40 cm of duodenum
and jejunum and 10 cm of ileum were left. He is nearly completely dependent of PN,
which is administered at home. Presently he has distended bowel loops but no signs
of relevant stasis. A colonoscopy, performed at the age of 16 months for anal blood
loss demonstrated a vulnerable atrophic mucosa with eosinophilic colitis at biopsy.
Central lines have had to be replaced several times because of occlusion and/or infec-
tious complications.
CH 9 is a girl born in 2001 after a pregnancy of 31 weeks. At birth her body weight
was 1740 grams. She was delivered because her intra-uterine condition deteriorated
caused by antenatal volvulus due to malrotation. Surgery was performed immediately
at birth. Part of the small bowel was removed and stomata were constructed. At the
age of two and a half weeks she suffered from candida sepsis. At week five the stoma-
ta were closed, leaving 45 cm of small bowel, including the ileo-caecal valve. After
this operation, she became septic and developed a complete wound dehiscence.
During this period she was continuously on artificial ventilation. It was not possible
to eradicate Morganella Morganii, causing the sepsis, probably because of an infect-
ed thrombus in the pulmonary vein. She also suffered from intrahepatic cholestasis.
She died at the age of two months.
IN 4 is an at term born girl (1994). At the age of two months she was admitted to hos-
pital because of vomiting and bloody stools. Volvulus and malrotation were diag-
nosed at laparotomy and a necrotic part of small intestine was removed. After resec-
tion with end-to-end anastomosis, 100 cm of small intestine remained. At four months
she was readmitted because of bilious vomiting. This was caused by stenosis of the
anastomosis. The stenotic part, including the ileo-caecal valve, was removed leaving
80 cm of proximal small intestine. She suffered from a short bowel syndrome and was
admitted for nine months until complete enteral feeding became possible.
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ABSTRACT
Background: Volvulus of the small bowel is a life-threatening event and in most cases
malrotation is the cause. Recognition of malrotation is difficult for general or gastro-
enterological surgeons and infrequently diagnosed in adults. As children with con-
genital anomalies become adult, the possibility of malrotation should be considered
if they present with abdominal problems.
Methods: Thirty-three children, diagnosed with a malrotation in 2001 were examined
as regards diagnosis, treatment and results. Thirty-two of them were operated.
Results: The diagnosis was missed in two older children at the first operation. Surgery
cured 24 of the 32 operated children of their abdominal problem. In two children
resection resulted in a short small bowel. Two children died, one infant with a short
small bowel and intractable sepsis, and one from severe untreatable congenital heart
disease. In five children with constipation or motility problems, intestinal passage did
not improve after surgery.
Conclusion: The indications for surgery in the neonatal period and in the case of an
acute abdomen are undisputed. In other cases once the diagnosis is confirmed, sur-
gery should be performed to prevent a life-threatening volvulus. A wait-and-see
policy is only acceptable if there are severe contraindications to surgery and the
parents warned of the possible dangers of an acute volvulus.
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INTRODUCTION
Volvulus of the small intestine is a life-threatening event as it may lead to a short
small bowel (SSB). In most cases it is due to an abnormal rotation and fixation of the
small bowel. For many gastrointestinal surgeons who operate mainly on adults, mal-
rotation is an uncommon finding occurring in 1:6000 patients [1]. It is also difficult
to recognise [2]. In paediatric surgery it is seen more often and a figure of 1:500 live
births has been reported [3]. 
The intestines grow so fast in the first weeks of pregnancy, that they are temporarily
located outside the abdomen. This physiological omphalocèle disappears in the 10th
week when the intestines take their proper place, i.e. the first jejunal coil lies behind
the mesenteric vessels at the ligament of Treitz, and the caecum becomes fixed in the
right lower part of the abdomen [4]. The mesentery is broadly attached from the liga-
ment of Treitz to the ileo-caecal valve of Bauhin, making a volvulus of the complete
small bowel unusual. If there is an abnormal re-entry of the intestines in the abdomen,
the normal fixation of the mesentery may be absent. The narrow stalk of the attach-
ment of the entire intestine may constitute the basis for a volvulus from the duode-
num to the middle of the transverse colon - the part of the bowel supplied by the
upper mesenteric artery. Volvulus may occur in children and adults and may even
present antenatally.
A clear and extensive description by NM Dott about the anomalies of intestinal rota-
tion was written in 1923 [5]. He considered the abnormally situated appendix, the
problems of recognition of the malrotation during laparotomy and cases of secondary
volvulus in the newborn. He suggested fixation of the caecum in the right lower
abdomen, but left the possibility open of putting the intestine back in a position of
non-rotation.
Waugh in 1928 described "indigestion" with attacks of pain in childhood, diagnosed
as "chronic appendicitis" caused by a congenital malformation of the mesentery. He
noted a high-positioned caecum on an X-ray enema and suggested a barium meal
would be better for diagnosis [6].
Since then few publications have been written outside the paediatric surgical litera-
ture and few cases have been described in adults [2]. Von Flüe and co-workers in 1994
found 40 adult patients in German and English literature and added nine cases [7].
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Table 1. Some syndromes with malrotation as a feature.
Malrotation commonly accompanies other congenital abnormalities, like duodenal
atresia, abdominal wall defects or diaphragmatic hernia. Its presence is described in
nearly 100 different combinations and syndromes [8]. Some of the more common are
listed in Table 1. We studied the symptoms at diagnosis and the outcome of surgery
in children with a malrotation referred to us in one year, both typical and atypical
cases in neonates and older children.
Syndrome Some features Inheritance   Locus/Gene
Beckwith-Wiedemann Omphalocèle, macroglossia, gigantism,
hypoglycaemia AD/imprinting p15.5
Cornelia de Lange Pre- and postnatal growth deficiency, facial 
dysmorphisms, mental retardation Sporadic --
Fraser cryptophthalmus Cryptophthalmus, genital anomaly, ear anomalies AR FRAS1
Fryns Diaphragmatic defects, coarse facies, distal digital
hypoplasia AR --
Focal dermal hypoplasia Poikiloderma with focal hypoplasia, syndactyly,
(Goltz) dental anomalies XLD Xp
Ivemark Situs inversus, a/polysplenia, heart defect AR/multifactorial --
McKusick-Kaufman Polydactyly, hydrometrocolpos, heart defect AR MKKS
Marfan Ectopia lentis, aortic dilatation, long stature,
pectus excavatum/carinatum AD FBN-1
OEIS Omphalocèle, Exstrophy, Imperforate anus,
Spinal deformities Sporadic --
Simpson-Golabi-Behmel Macrocephaly, coarse facies, overgrowth,
poly/syndactyly XLR GPC3
Smith-Lemli-Opitz Facial dysmorphisms, syndactyly, hypospadias,
mental retardation AR DHCR7
Total colonic aganglionosis Aganglionosis of the entire colon Multifactorial --
VACTERL Vertebral defects, Anal atresia, Cardiac defects,
Tracheo-Esophageal fistula, Renal defects,
Limb anomalies Multifactorial --
X-linked heterotaxia Situs inversus XLR ZIC3
Legend: AD: autosomal dominant; AR: autosomal recessive; XLD: X-linked dominant; XLR: X-linked recessive.
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METHODS AND PATIENTS
Diagnosis
Since it is difficult even for experienced paediatric surgeons to discern all the different
forms of malrotation, nonrotation or fixation disorders, we prefer to speak of a mal-
rotation, when the first jejunal loop does not cross behind the superior mesenteric
artery and vein.
Clinically, green vomiting with cramping abdominal pain is the cornerstone of the
diagnosis of malrotation in neonates. In older children a story of intermittent or recur-
rent abdominal pain and vomiting may suggest the diagnosis. In patients with failure
to thrive or even chronic constipation, a malrotation may also be considered. In cases
of bilious vomiting in an older child, malrotation must be excluded. Acute volvulus
presents as an acute abdomen and this is the indication for surgery.
Upper gastrointestinal X-rays may show the typical corkscrew appearance of the
first part of the jejunum with no crossing of the spine of the duodeno-jejunal junction
at the Treitz ligament [9]. It can be difficult for a radiologist, who is not familiar with
this picture, to recognise it. Barium enema may show the caecum to be localised in
the upper right part of the abdomen. However a normal position of the caecum does
not rule out an abnormal position of the small bowel and on the other hand, a mobile
caecum may exist without malrotation. 
Echography as a diagnostic method is described [10], but may not be reliable enough
to indicate the need for surgical intervention in cases of malrotation. Most surgeons
will ask for an upper gastrointestinal X-ray to confirm the suspected diagnosis.
CT-scanning for unclear abdominal complaints may suggest an abnormal course of
the mesenteric vessels and a "whirl like" arrangement [11]. Chronic volvulus with
superior mesenteric vein thrombosis diagnosed by CT or MR angiography is also
described [12]. 
Antenatal diagnosis of malrotation is mostly impossible. In cases of duodenal atresia,
omphalocèle, gastroschisis and diaphragmatic hernia concomitant malrotation can be
expected. Volvulus in utero may lead to intestinal atresia with congenital short bowel.
Operation
Operative diagnosis is based on the typical absence of the ligament of Treitz and
the jejunum not crossing behind the mesenteric vessels. Ladd's bands between the
lateral abdominal wall and the caecum may be present in neonates and compress
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the duodenum but are not always present in older patients. In the case of an abnor-
mal position in the abdomen of the caecum or appendix at emergency appendectomy
a mobile caecum must be distinguished from a typical malrotation. 
If the ascending colon is fixed on the right lateral side it should be cut loose from the
right abdominal wall and the first jejunal loop must be completely freed. This can be
quite difficult at the deepest point at the duodeno-jejunal flexure. If there are Ladd's
bands between the right upper abdominal wall and the caecum, compressing the duo-
denum [13], usually in neonates, they should be divided to free the duodenum com-
pletely. The mesentery stalk, thickened in cases of chronic volvulus, can be broadened
by cutting the overlying peritoneum to prevent a volvulus. The intestine is placed back
in a non-rotated position in the abdomen, i.e. the small intestine to the right, to assure
a free passage from the duodenum to the jejunum and the colon to the left side of the
abdomen. The appendix is removed in most cases as it lies somewhere in the middle
or the left upper abdomen. We never fix both parts of the colon as described by some
authors [2], and neither place nor fix the caecum in its "proper" place. 
PATIENTS
In 2001, thirty-three cases of malrotation were diagnosed, aged from one day to fif-
teen years. Thirty-two of them were operated and are listed and numbered according
to age at surgery in Table 2. 
Nine children underwent surgery in the first week of life, six were male. Of the 23
children operated in the first year, 16 were male. Of the nine children operated after
the first year three were male. 
Malrotation was the only diagnosis (besides prematurity or a single umbilical
artery), in 7 of 13 neonates, 4 of 9 infants and 2 of 9 children above one year.
The only child not operated was a boy with Down's syndrome and Hirschsprung's
disease. The malrotation was diagnosed on X-ray at two years of age, when he was
investigated for vomiting. However, no operation for the malrotation was performed
as his passage problems disappeared on laxative treatment. As the malrotation was
not diagnosed at three previous laparotomies to correct his Hirschsprung's disease, (a
colostomy, a low anterior resection and closure of the colostomy), we concluded that
the chance of developing a volvulus was low. 
In one neonate - not included in Table 2 - the diagnosis was made on a typical X-
ray appearance, but could not be confirmed at operation. 
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Table 2. Thirty two children with malrotation, operated in 2001
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No Malrotation Gender Presentation Concomitant diagnosis Abdominal problem 
operation solved? 
1 1 day F Antenatal volvulus Premature, 31 weeks 1780 g. Short small bowel,
died at 2 months
2 2 days M Pulmonary problems Diaphragmatic hernia Cured
3 2 days M Antenatally Duodenal atresia, Down's
Syndrome Cured
4 2 days F Gastric bleeding Duodenal atresia Cured
5 3 days M Bilious vomiting, 
acute volvulus - Cured
6 4 days M Bilious vomiting - Cured
7 6 days M Bilious vomiting Convulsions, colonic perforation
(NEC?), Meckel Cured
8 6 days F Vomiting Duodenal stenosis Cured
9 6 days M Bilious vomiting Pseudo-obstruction syndrome Motility problems
10 12 days F Bilious vomiting - Chyloperitoneum 
Cured
11 13 days M Bilious vomiting - Cured
12 15 days M Bilious vomiting - Cured
13 24 days M Bilious retentions
acute volvulus Single umbilical artery Short small bowel, 
home PN 
14 1 month M Abdominal distension Hypoplastic left heart Cured
15 1 month M Vomiting - Cured
16 1 month F Bilious vomiting Premature 31 weeks, 1120 g Cured
17 2 months F Ileus after heart Hypoplastic left heart, Died after 1 day,
operation duodenal stenosis multiorgan failure,
and septic shock
18 2 months M Abdominal pain, Oesophageal and anal atresia,
vomiting, gastro- left radius aplasia, floating thumbs, Cured,
oesophageal reflux pylorus hypertrophia Fundoplication later
19 2 months M Strangulation ileus
with volvulus Diaphragmatic hernia Cured
20 4 months M Oesophageal stenosis Oesophageal atresia Chyloperitoneum
Cured
21 5 months M Feeding problems Cured
22 5 months M Feeding problems and Motility problems 
Gastro-Oesophageal Reflux solved after 6 months
23 6 months F Abdominal pain Hypoplastic left heart, cholelithiasis Cured
24 1 year M Vomiting Urethral valves, hydronephrosis,
renal insufficiency Cured
25 1 year F Adhesion ileus Diaphragmatic hernia Cured 
26 2 years F Vomiting and Gastro-
Oesophageal Reflux Sliding gastric hernia Fundoplication later 
27 2 years F Failure to thrive, constipation Motility problems
28 5 years M Ileus, acute abdomen Diaphragmatic hernia + recidive, Meckel Cured
29 7 years F Failure to thrive Pseudo-obstruction syndrome Motility problems
30 8 years F Constipation Situs inversus solitus Motility problems
31 9 years M Bilious vomiting acute volvulus - Cured
32 15 years F Acute volvulus - Cured, adhesion ileus
RESULTS
Table 2 shows the heterogeneity of the patients with isolated malrotation, other con-
genital abnormalities and motility problems.
Acute volvulus was observed in six children. Resection of necrotic bowel in two of
the infants resulted in SSB. The two older children were operated in another hospital
where the malrotation was not recognised. A nine-year-old boy was transferred after
surgery after untwisting of a volvulus to our paediatric intensive care unit. Repeat
laparotomy was performed with treatment of the malrotation by us the next day. 
A fifteen-year-old girl first underwent an untwisting of a volvulus, but her malro-
tation was unrecognised because of the normal fixation of the ascending colon. A
second laparotomy showed improvement of the colour of the intestine. At her third
laparotomy, because of intestinal transit problems, the malrotation was recognised
and treated. The girl recovered without intestinal resection, but had to be operated
for a strangulation ileus two years later. 
Bilious vomiting or green gastric retentions were seen in nearly all neonates, but
only twice in the group of infants and older children. 
Duodenal stenosis or atresia was diagnosed in four children, one had also a heart
problem and another Down's syndrome. 
Oesophageal atresia was seen twice, anal atresia in one of these two with a VAC-
TERL association (Table 1). 
One child presented with acute gastric bleeding, for which no satisfying explanation
could be found, as there was no acute volvulus combined with her duodenal atresia.
Five children presenting with feeding problems, failure to thrive or severe consti-
pation, were diagnosed and referred by the paediatric gastroenterologist. One of them
also had an abdominal situs inversus. One boy and a girl showed a pseudo-obstruc-
tion syndrome.
Diaphragmatic hernia was the primary diagnosis in four children. The malrotation
was corrected in one at the first operation and in the other three at a secondary ope-
ration. Two of these children had an acute ileus, and one presented with a recurrent
hernia.
There were three children with a hypoplastic left heart syndrome. In two, with a
low flow state after Norwood surgery, an acute abdomen led to an acute abdominal
operation. The girl who died also had a duodenal stenosis and an absent gallbladder.
The third child had severe abdominal complaints after major heart surgery. She
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underwent cholecystectomy for proven cholecystolithiasis at the age of three months
but the severe abdominal complaints continued. After suspecting a gastric volvulus
and diagnosing the abnormal intestinal fixation, a malrotation operation was per-
formed with a side-to-side duodeno-jejunostomy. This cured her cramping abdominal
pain as proven by ending her inconsolable crying. A combination with a renal prob-
lem was seen once.
Outcome
In 24 of the 32 operated patients surgery was successful in relieving the abdominal
complaints. Two children died, a girl from untreatable abdominal infection after an
extensive bowel resection, the other girl from complications of her hypoplastic left
heart syndrome. The boy with SSB who survived is still on home parenteral nutrition. 
Three children experienced continuing motility problems, two of them showed high
passage problems after three to six weeks, requiring a reoperation with a duodeno-
jejunostomy, as the fixation to the rear wall at that point could not be completely
freed. In fact surgery caused more problems after the malrotation correction as
passage before surgery was not completely obstructed. The third one is a boy with
an intestinal pseudoobstruction syndrome. 
Two of the three children with gastro-oesophageal reflux underwent at first a mal-
rotation correction, but this did not solve the reflux and later a fundoplication opera-
tion was necessary. 
Chyloperitoneum as a complication of the operation was seen twice, requiring one
month of total parenteral nutrition and two months of a medium chain triglyceride
diet afterwards in one and six months of this diet in the other child.
DISCUSSION
The diagnosis of malrotation was missed in several children especially the older ones.
Surgeons who treat non-neonatal cases or older children should be aware of the pos-
sibility of a malrotation and how to recognise the failing crossing of the jejunum
behind the mesenteric vessels. Recognition is especially difficult in cases of a normal
fixation of the ascending colon and caecum, because the surgeon may not realise the
possibility of a malrotation. The observation of a first jejunal loop not passing behind
the superior mesenteric vessels is proof of the abnormality. If there is a chronic
incomplete volvulus, there are many thickened glands in the mesentery. To prevent a
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chyloperitoneum we consider the necessity of broadening of the mesenterial stalk.
This should be restricted to the peritoneum only.
Fortunately many neonates with a malrotation have Ladd's bands obstructing the
second part of the duodenum and this allows fast recognition of the condition. In
older children, adolescents or adults volvulus as a result of the malrotation may be the
first sign. There may exist a long history of abdominal complaints, resulting in
unsuccessful psychological or psychiatric consultation and treatment. 
In cases of an acute abdomen or adhesion ileus after previous paediatric surgery like
diaphragmatic hernia, oesophageal atresia, anal atresia or Hirschsprung's disease, the
surgeon should consider the possibility of a malrotation contributing to the com-
plaints instead of only operating on adhesions from fibrous bands. 
We re-operated three children (9%). This is a higher figure than described by Festen
as a number of 2.2% postoperative small bowel obstructions in 1476 laparotomies
[14], but more resembling the 15% Wilkins gives for re-operation in cases of malro-
tation in neonates, compared to 8.3% for all neonatal abdominal operations [15].
Conservative treatment in cases of mechanical obstruction causes unnecessary delay
and should be avoided.
For surgeons experienced in laparoscopy, who are familiar with the clinical and
operative picture, the malrotation operation can be performed completely by laparo-
scope [16]. Maziotti suggests in unclear cases of malrotation to decide after
laparoscopy if a correction to prevent volvulus is necessary, depending on the width
of the mesenterial stalk [17].
Malrotation is associated with a large variety of other congenital malformations, in
particular of the gastro-intestinal tract, e.g. oesophageal [18], pyloric, duodenal,
applepeel small bowel and anal atresia [19], congenital short bowel, Hirschsprung's
disease [20] and biliary atresia. It is seen in congenital hernia diaphragmatica, situs
inversus, omphalocèle and gastroschisis and also in congenital heart disease and uro-
genital tract anomalies [8]. The recurrence risk in a family in case of an isolated, non-
syndromal malrotation is 1% or less for a sibling and for offspring.
A special problem nowadays are the children with complicated heart disease like a
hypoplastic left heart syndrome. When, between the necessary cardiac corrections,
can surgery for the malrotation be planned? This also is dependent on the haemody-
namic situation at the time.
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We do not correct malrotation in children while on ECMO (Extra Corporal
Membrane Oxygenation) at the time of repairing the diaphragmal defect, which we
do during ECMO treatment, because we fear the possibility of bleeding. Later two of
these children were operated on their malrotation when another procedure like fun-
doplication or a laparotomy for a strangulation ileus was needed. In motility disorders
like pseudo-obstruction cases or children with severe constipation where a malrotation
is found on work-up, the paediatric surgeon should warn the parents that operation
only prevents a volvulus, and may not improve intestinal passage and constipation.
In cases of documented gastro-oesophageal reflux we perform the malrotation
correction and antireflux procedure simultaneously [21].
When at an emergency appendectomy with abnormal presentation of the caecum, a
malrotation correction is contraindicated at that time because of the appendicitis, a
corrective operation should be performed later. 
As operation results are good in general, surgery should not be dependent upon the
age of the patient, every patient with a malrotation merits surgery to prevent a life-
threatening volvulus [22]. With nearly 50.000 births in our region a number between
8, when the number of 1:6000 is correct [1] and 100 cases with malrotation, when
1:500 is used [3], may be expected each year. Thirty-three cases were referred in
2001, 6 of them presented with an acute volvulus. This supports our recommendation
for surgery in asymptomatic cases. 
CONCLUSION
Emergency operation is indicated in all infants and in cases of acute volvulus and
non-acute operation in symptomatic children without signs of a vascular intestinal
problem [23,24]. In completely asymptomatic cases in older children also an opera-
tion should be performed. If after extensive consultation with the patient and parents
a wait-and-see policy is adopted for acceptable reasons, they should be warned of the
possible dangers of an acute volvulus. 
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3.1 INTESTINAL MICROBIAL ACTIVITY
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INTESTINAL MICROBIAL ACTIVITY
Development of a stable microflora ecosystem in the gut is a slow process that takes
several years from birth. Once formed, it remains remarkably constant throughout
life. Gut flora is an important factor in certain pathological disorders, but bacteria and
other bowel inhabitants may also contribute to human health [1].  
After vaginal birth, the first micro-organisms in the bowel are facultative anaerobic
bacteria, mainly streptococci, enterobacteria and to a minor extent staphylococci,
depending on the mother's vaginal and rectal flora. After 48 hours, the number reach-
es 104-106 colony-forming units (cfu) per gram faeces. Caesarean section may alter
the flora for up to 6 months. 
Premature babies in an incubator have a much lower developmental rate of anaero-
bic flora, possibly due to antibiotics and nursing care. This may lead to an increase in
harmful bacteria such as clostridia or Klebsiella, Citrobacter and Enterobacter spp,
and nosocomial infections [2].
On day 10, bifidobacteria and lactobacilli reach stable concentrations of 109 cfu/g
faeces. This colonisation is associated with increases in Escherichia coli, Bacteroides
spp and clostridia and decreases in staphylococci. 
In breast-fed children, nearly all faecal microbes are bifidobacteria, whereas in
bottle-fed children, they form only 30-40% of all bacteria. The growth of these bifi-
dobacteria is enhanced by the low protein and low phosphorus content combined
with high lactose concentration in human milk, and is not due to bifidogenic growth
factors alone, such as glycoproteins and mono- or oligosaccharides [3].
With dietary supplementation, differences between bottle-fed and breast-fed
children disappear. Enterobacteria, streptococci and clostridia increase and diverse
anaerobic flora with fusobacteria and eubacteria develop.
42
Chapter 3
NORMAL ADULT INTESTINAL MICROFLORA IN THE INTESTINAL
TRACT
In the human adult, the intestinal microflora is a complex system that contains about
400 different species. Anaerobes are 100 to 1000 times more prevalent than aerobic
or facultative aerobic bacteria, but nearly all are restricted to the colon [2].
The gastric pH of below 3.5 is normally too low to permit the growth of human
bacteria. Most bacteria present in the food are killed in the stomach. Only a few
acid-tolerant micro-organisms survive the stomach and will enter the small bowel. 
In the duodenum, the first bacteria encountered are lactobacilli. Later in the small
bowel at a pH of 4.5 to 5.5, the enterococci emerge and at a pH of 5.5 to 7, especially
the enterobacteria, such as E. coli. At the end of the small bowel, the food mass has
become completely anaerobic. In the colon the food mass is infused with many kinds
of strictly anaerobic bacteria, such as pepto(strepto)cocci, eubacteria, propionibacte-
ria, fusobacteria and Bacteroides spp.
In the proximal part of the small bowel, the resident flora concentration amounts to
about 103 cfu/g food mass, while distally it may rise to 107 cfu/g [1]. In the colon the
bacterial count increases to 1011- 1012 cfu/g faeces [4]. 
Microbial intestinal activity
The activity of microbes in the intestinal tract depends on the food consumed, intes-
tinal location and type and amount of bacteria. There is only limited microbial
activity in the small bowel due to the relatively small number of bacteria. In the
colon different bacteria and different biochemical reactions give rise to short chain
fatty acids (SCFA), such as acetic acid, butyric acid and propionic acid [5]. They are
reabsorbed, used as fuel to produce energy for the colonocytes, and excreted in the
faeces [6]. They also have important effects on gastrointestinal motility via the pep-
tide YY pathway [7].
H2 and CO2 are also products of colonic bacterial fermentation of glucose, in con-
trast to CH4, which is a waste product of intestinal methanogenous bacteria, that
arises from the anaerobic oxidation of H2 in the presence of CO2; all are released as
flatus. The bad smell is related to butyric acid (produced from indigestible carbohy-
drates), amines, H2S and indol. The latter three compounds are produced from
aminoacids and proteins. 
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The most important advantage of intestinal CH4 production is that it reduces the intes-
tinal gas volume. As the molar gas volume is identical for all gases, a volume of 1
mol gaseous CO2 and 4 mol gaseous H2 are reduced, in the presence of the necessary
bacteria, to a volume of 1 mol gaseous CH4 and a negligible volume (2 mol) of liquid
H2O. This means reduction in intestinal gas volume up to maximally 80%.
The intestinal microflora also plays a role in the gut immune system, including the
development of oral tolerance to harmless antigens, such as food proteins. 
We studied the microbiological and biochemical consequences of the overwhelmingly
high concentration of lactobacilli we discovered in the faeces of children and adults
with a short small bowel. In the following parts of this chapter we present some of
our results.
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ABSTRACT
Background: In patients with a short small bowel, D-lactic acidemia and D-lactic
aciduria are caused by intestinal lactobacilli. The purpose of this study was to obtain
a detailed picture of the metabolic acidosis in young children with short small bowel. 
Methods: Feces, blood, and urine of children with short small bowel and acidosis
were studied microbiologically and/or biochemically. 
Results: Previous findings were confirmed that more than 60% of the fecal flora of
patients with short small bowel, who are not receiving antibiotics, consists of lactic
acid-producing lactobacilli. In blood, D-lactic acid was the most prominent metabo-
lite: the highest serum D-lactate (15.5 mmol/l) was observed in a sample taken imme-
diately after the onset of hyperventilation. The highest D-lactate excretion was in urine
collected some hours after the onset of hyperventilation, and amounted to 59 mol/mol
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creatinine. Acidosis in the patients with short small bowel was related to strongly
increased serum D-lactate and anion gap, and to strongly decreased serum bicarbonate
and pH. 
Conclusion: In children with short small bowel and acidosis, the common intestinal
flora of mainly lactobacilli abundantly produces D-lactic acid from easily fermentable
carbohydrates. Thus, these bacteria directly cause shifts of bicarbonate, pH, and base
excess, and indirectly cause shifts of the anion gap, as well as hyperventilation. These
kinetic parameters are strongly associated. 
INTRODUCTION
In patients with a short small bowel (SSB), intestinal uptake capacity is strongly
reduced, and therefore these patients have malabsorption. Absorption of food com-
ponents is too slow, and because of the prolonged presence of nutrients in the acidic
proximal bowel lumen, an overgrowth of lactobacilli emerges within a very short
time. These bacteria produce massive amounts of D- and L-lactic acid, and thus prevent
other bacteria from increasing [1]. Both D- and L-lactic acid are intestinally absorbed.
Consequently, D-lactic acidemia and aciduria will arise daily, but D-lactic acidosis
also may be seen, and less frequently, D-lactic acidosis-associated encephalopathy.
Often, these patients have a complex of symptoms and metabolic alterations, that all
may be part of the short small bowel syndrome (SSBS) [2-7]. This report demon-
strates both the causal factors and the time-related consequences of the abundant lac-
tic acid production in the SSB. With data collected from a large number of samples
of mostly feces and urine, and occasionally blood, we constructed a detailed picture
of the pathogenesis of D-lactic acidosis. 
MATERIALS AND METHODS 
Definition. 
In this study a short small bowel (SSB) was defined as either a small bowel from
which more than 70% has been resected, or, as in neonates, one with a length of less
than 50 cm.
46
Chapter 3
Patients
This study included seven patients with SBB, three children (CH) and four infants
(IN); their clinical data are listed in Table 1. CH 1, CH 2 and IN 4 have been
described previously [1]. All patients were consuming a lactose-free diet. At the time
of study IN 4 and CH 3 had a full oral diet, whereas IN 5, -6, -7 were partially
dependent on parenteral nutrition. All children with SSB received dextrin-maltose-
based food as their main carbohydrate source. During enteral nutrition by gastros-
toma or by nasogastric drip feeding, and also during oral nutrition, the infants and
children had daily D-lactic acidemia and had regular occurrence of metabolic acido-
sis. This study was performed in accordance with the Helsinki Declaration of 1975,
as revised in 1983. It was approved by the Ethics Committee of the University
Hospital Nijmegen. 
Table 1. Clinical data of study patients with short small bowel
Methods
Bacteriological analysis was performed as previously described [1]. Capacity of fecal
samples to produce lactic acid was measured after a 3-hour anaerobic incubation of
one part feces to nine parts 3.7% brain heart infusion-0.6% yeast extract broth with
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Patient/ Sex Cause of Year of Length of Ileocaecal Colon
(yr of birth) small short resection small valve presenta
bowelb intestinec presenta
CH 1 ('87) F V 1987 22 + +
CH 2 ('84) F V 1984 28 + +
CH 3 ('89) F ICI 1990 50 - +
IN 4 ('94) F V 1995 80 - +
IN 5 ('96) M CSB -- 25 - +
IN 6 ('96) M V 1996 40 + +
IN 7 ('96) M NEC 1996 50 - 10 cm
a +. present; -. absent.
b V, resection due to volvulus of small intestine; ICI, ileocolic invagination;
NEC, necrotizing enterocolitis; CSB, congenital short bowel (without resection). 
c Length of small intestine (immediately after intestinal surgery) in cm.
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10 mg vitamin K3/l, 1% (filter-sterilized) glucose, 5 mg hemin/l (comprising
BHI/YE-glucose broth) with initial pH of 5.0. The D- and L-lactic acid were quanti-
fied by enzymatic assay [8]. Serum and urine were studied qualitatively and quanti-
tatively by use of both capillary gas chromatography-mass spectrometry; (GC-MS),
especially for determining organic acids [8,9], and nuclear magnetic resonance spec-
troscopy according to Wevers et al [10]. Minerals (sodium, chloride, bicarbonate)
were determined with a fully automated analyzer for measurements of clinical
chemical parameters (Hitachi 747; Roche Diagnostics, Almere, The Netherlands)
using standard procedures. The pH and base excess were determined and calculated,
respectively, with a fully automated blood gas analyzer (Corning 288; Bayer
Diagnostics Division, Mijdrecht, The Netherlands). The anion gap was defined as
[Na+]-{[HCO3-]+[Cl-]} in serum. 
RESULTS
Fecal Short Small Bowel Syndrome flora 
During a 10-year period, we examined about 200 SSB fecal samples. In the past 5
years we confirmed in all fecal samples of new, orally fed patients with SSB, who
were receiving no antibiotic therapy, the previously reported rather constant and
characteristic flora with more than 60% gram-positive rods, mainly lactobacilli [1].
After inoculation in BHI/YE-glucose broth (pH 5.0), fresh fecal samples had a
marked capacity to ferment glucose completely in a rather short time, with D- and L-
lactic acid as main fermentation products. Nevertheless, we found that in fecal sam-
ples of patients without acidosis, who had SSB the D- and L-lactic acid concentrations
were low (i.e., not higher than in healthy control subjects without SSB). The pH of
most samples usually ranged between 5.0 and 5.5, but the lowest pH observed was
3.9. A relation between the fecal content of gram-positive rods and the presence of
the ileocaecal valve was not observed. 
Serum D-Lactic Acid During Short Small Bowel Syndrome Acidosis 
D-lactic acid is usually unmeasurable in healthy persons; the reference value for
serum L- and thus also for total lactic acid is 2.0 mmol/l or less. Serum D-lactate
values of acidosis in children with SSBS generally were less than 6.8 mmol/l [8].
However, in the blood of CH 3 in the hospital, sampled during critical phases of seven
acidotic episodes, total lactic acid ranged between 3.1 and 14.9 mmol/l (median
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value, 10.5 mmol/l). During the next episode of acidosis of this patient, we specifi-
cally measured serum D- and L-lactic acid to be 15.5 mmol/l and 1.55 mmol/l, respec-
tively. Blood sampling of the various patients mostly occurred several hours after the
onset of hyperventilation. However, in the case of CH 3, who was in the hospital,
blood was immediately, sampled as soon as hyperventilation began. 
In serum of infants and children with SSB acidosis, lactic acid was always present
in clearly elevated concentrations. Sometimes, increased concentrations of other
organic acids (mainly 3-OH-propionic acid, p-OH-phenyl-acetic acid, p-OH-phenyl-
lactic acid, phenyl-lactic acid, oxalic acid, glycolic acid and glutaric acid) were
observed in blood and urine of our patients [11].
Urinary D-Lactic Acid During Short Small Bowel Syndrome Acidosis
Urinary D-lactic acid excretion is usually not detected in healthy persons; the reference
value of L-lactic acid and thus also for total lactic acid, is 60 mmol/mol creatinine or
less. In a urine sample of CH 1 collected at night, after an emergency admission to
the hospital, the D-lactic acid excretion was measured at 40 mol/mol creatinine; in a
sample of IN 4 it was as high as 59 mol/mol creatinine (concomitant L-lactic acid
excretion was 95 mmol/mol creatinine); and in two samples of CH 3, collected during
two acidotic episodes, it was 34 and 19 mol/mol creatinine, respectively. The mentioned
urine sample of CH 3 (with D-lactic acid at 34 mol/mol creatinine) was also studied for
organic acids both by GC-MS and by nuclear magnetic resonance spectroscopy. Lactic
acid was the most important metabolite excreted, as detected by both techniques.
Several other organic acids (e.g. formic acid) were detected, but only in extremely small
amounts.
Relation Between Lactic Acid and Other Acid-Base Parameters During
Untreated Acidosis
In spite of the long period of 10 years, available data concerning serum D-lactic acid,
L-lactic acid, total lactic acid, bicarbonate, pH and/or anion gap, in untreated patients
with SSBS acidosis, were limited. Still, the data collected from our patients made
clear that the acidosis was always related to decreased serum bicarbonate (reduced to
4 mmol/l; reference range in healthy control subjects, 22-26 mmol/l) and pH (reduced
to 7.05; reference range, 7.38-7.43) and to increased total serum lactic acid (increased
to 17 mmol/l) and anion gap (increased to 26 mmol/l; reference range: 4-12 mmol/l).
Of the anion gap parameters (defined in Materials and Methods) serum sodium was
49
Lactobacilli and acidosis
constant, whereas serum bicarbonate (as mentioned) and chloride were much more
variable. 
DISCUSSION
Just as in the previously described patients with a SSB, the new entries in our study
had acquired a characteristic intestinal flora mainly consisting of lactobacilli.
Because these bacteria are regarded as benign, the standard arsenal of media used in
clinical diagnostic bacteriological laboratories for the isolation of bacteria is not ade-
quate for convenient isolation and quantification of these bacteria. Especially, the
tomatojuice- and the Man-Rogosa-Sharp-media facilitate these assays. Also,
microscopy according to Gram's technique conveniently reveals the abundant pre-
sence of gram-positive rods, which have been shown in these patients to be mainly
lactobacilli [1]. 
Lactobacilli can be divided in two major groups: homolactic and heterolactic. The
homolactic ones produce lactic acid(s) only from fermentable sugars (not lactulose),
and the heterolactic ones produce lactic acid(s), ethanol and CO2. Because sugar
hydrogen breath tests are based on bacterial fermentative production of molecular
hydrogen from the sugar, whereas this type of bacteria cannot do so, it is useless to
examine overgrowth of lactobacilli or malabsorption of sugars by means of a sugar
breath test. During a glucose loading experiment in an adult with SSB, we confirmed
that molecular hydrogen was not detectable in a breath test (unpublished data). 
In our studies, all patients with SSB had abundant lactobacilli in the intestinal flora,
and all had episodes of hyperventilation and, simultaneously, of acidosis. In general,
the shorter the small bowel, the more the patient is affected by malabsorption, the
more and the longer any food is available in an acidic environment for acidophilic
bacteria (especially the lactobacilli), and the sooner the overgrowth of lactobacilli
emerges. 
The massive amounts of lactobacilli (1010-1012 colony-forming units/g wet feces)
affect the intestinal environment and subsequently also the patient. Because of their
fermentative activity in all orally or enterally fed, symptom-free patients with SSB,
who are not receiving antibiotic therapy (1), D- and L-lactic acid clearly emerge
daily, first in the intestinal lumen, next in serum and finally in urine [8,11].
Production of D-lactic acid may be so massive, that acute SSB-associated metabolic
acidosis, also called D-lactic acidosis, may arise [2-5]. 
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Lactic acidosis is generally defined as metabolic acidosis, in which serum lactic acid
is a major factor in the decrease of serum bicarbonate. Often, in patients with lactic
acidosis, serum lactic acid may transiently reach concentrations as high as 20-25
mmol/l, with systemic pH declining to 6.80 [12]. The literature on SSB contains
many reports on D-lactic acidosis with hyperventilation, and the presence of serum
D-lactic acid, but at concentrations of only 2 to 6 mmol/l, with near normal pH [12].
In the current study, we report that during D-lactic acidosis, serum total lactic acid
transiently reached high concentrations (17.5 mmol/l) and that, consequently, sys-
temic pH may fall to low values (e.g., 7.05) as in general (L-)lactic acidosis. 
D-lactic acid was demonstrated to be the most prominent acid in serum and urine in
the presence of SSB. Serum D-lactic acid was highest (up to 15.5 mmol/l) in samples
that had been obtained very soon after the onset of hyperventilation. Strongly eleva-
ted D-lactic acid excretion (up to 59 mol/mol creatinine) was measured in urine that
had been collected several hours after the onset of hyperventilation. It is hypothesized
that in patients with SSB-induced hyperventilation who come to the hospital, a major
part of the serum D-lactate has already been cleared from blood into urine by the time
they reach the hospital. 
Acidosis associated with SSB was mostly acute, unpredictable, and short-lasting.
The onset of acidosis was especially signalled by hyperventilation. Although organic
acids other than (D-)lactic acid may be increased, it is mainly the D-lactic acid load in
blood and tissues that strongly affects serum pH and thus contributes to SSBS acidosis. 
An increase of serum lactic acid means merely an increase of serum organic anions.
The emergence of SSBS acidosis is strongly related to decrease of bicarbonate and
increase of the anion gap. This may imply that during the emergence of acidosis,
the serum mineral concentrations and blood gases also may change, as well as the
related base excess. Anion gaps of more than 12 mmol/l have only been observed
early in the acidosis. 
As soon as lactic acid enters serum, the total organic anion concentration increases,
whereas the protons are spread over the buffering substances: serum proteins, phos-
phate and bicarbonate. Thus, bicarbonate neutralizes the protons, and consequently
the bicarbonate concentration decreases, and the (undissociated) carbonic acid
increases. As intestinal organic acid supply continues, the buffering capacity
decreases, causing neutralization to fail and, consequently, the pH to decrease [13]. 
As might be expected, our data confirm the compensatory mechanisms based on the
chloride shift. If the increase of D-lactic acid is extremely high, the influx of its anion
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is increasingly compensated by the neutralization-mediated disappearance of bicar-
bonate and an efflux of chloride, sometimes leading to hypochloremia [14]. Both the
organic anions and equimolar amounts of protons (as bound to buffering substances)
are cleared by the kidneys. The result may be an abundant excretion of a mixture of
organic anions (especially D-lactate), proton-bearing phosphate and sodium and a
decrease in urine pH down to 4.0. If the body is not able to restore sufficiently the
efflux of organic anions by adequate production of new bicarbonate, chloride will
replace these anions. This may often lead to hyperchloremia [2,4,5,15-20].
Hyperchloremia does not mask (through a lower anion gap) the serum D-lactate
whatsoever [15]. Rather, it indicates that the maximal D-lactic anion level in serum
has passed and that these anions are increasingly be found in urine. At sufficient
supply of bicarbonate by the human metabolism, chloride decreases to normal. 
The frequent neutralization in acidotic SSBS-patients by use of sodium bicarbonate
solutions is meant to restore the serum pH. In these patients H2CO3 arises massively
from the bicarbonate-mediated neutralization of organic acids in serum and tissues
and is decomposed in the lungs. An increased amount of CO2 is expired, and activates
the respiratory center to ventilate at a higher rate (hyperventilation). This process
stops as soon as the CO2 release is reduced to normal. Consequently, hyperventila-
tion is a marker of both the increase of organic anions in blood and simultaneous
neutralization. As continuous organic acid supply goes on with a simultaneous, too
slow release of CO2 (due to strongly decreased bicarbonate concentration), hyper-
ventilation stops, and a dangerous condition may result, because the progressive
acidification of the body cannot be recognized anymore. 
We wonder whether some of the mentioned parameters other than organic acids
might be useful in monitoring and managing patients with SSBS. For example, the
base excess together with the pH seem best to represent the state of the neutralisation.
As long as one or both are below the lower reference value, the acidosis has not yet
completely disappeared. 
For a better understanding of the D-lactic acidosis in pediatric patients with SSB the
essential microbiological and physiological aspects are illustrated in the following
description [1,8]. Overgrowth of lactobacilli gradually emerges within 2 to 3 weeks
after the introduction of oral feeding that contains fermentable carbohydrates. Just
after the stomach in the resected small bowel, the pH is rather low due to the not yet
neutralized gastric acid, and thus it creates an optimal environment for the lacto-
bacilli. In contrast to controls, in these patients (because of the malabsorption), more
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food is available for the lactobacilli, thus permitting them to increase. Soon, the
resultant massive bacterial production of lactic acid overwhelms the buffering
capacity of the pancreatic juice, transforms the whole intestine into an optimal
environment, and inhibits the increase of other bacteria, thus warranting a massive
production of merely lactic acid.
In all orally fed children with SSB who receive normal amounts of dietary carbo-
hydrates, without antibiotic therapy and with normal gastric acid production, the
same characteristic flora develops, comprising more than 50% (up to nearly 100%)
lactobacilli. During acidosis and hyperventilation the bacterial composition of stool
samples is the same as before, but the lactic acid concentration increases and the
pH decreases, sometimes from approximately 6 to 7 to approximately 4.0. The dif-
ferences in the colonic pH are merely temporarily fermentative effects of lactobacilli
on a large amount of fermentable sugars. After the lactic acid has been resorbed from
the bowel, the pH increases again, but the lactobacilli remain present. Because of the
characteristic acidogenic SSB flora, which often contains an abundance of D-lactic
acid-producing lactobacilli, all young pediatric SSB-patients are at high risk for
excessive levels of total serum lactic acid, and thus the occurrence of acidosis may be
predicted. Determination of serum pH and base excess is therefore useful in the
managing of the neutralization process. In these patients, abundant amounts of lacto-
bacilli are continuously present, even in the absence of acidosis. In the total absence of
oral feeding, the lactobacilli starve, and soon die. In orally fed patients D-lactic
acidemia occurs daily soon after consumption of carbohydrates, whereas D-lactic aci-
dosis with hyperventilation occurs only as the amount of D-lactic acid in serum and
tissues becomes too high. Subclinical (D-)-lactic acidosis (without hyperventilation)
occurs only as the amount of serum and tissue bicarbonate becomes too low. To reach
the subclinical stage, patient must pass the clinical stage, during which lactic acid is
normally neutralized with bicarbonate, and oral feeding is stopped. Consequently, the
subclinical stage seldom emerges. 
Lactobacilli produce lactic acid, as long as suitable substrate is present. They begin
as soon as the first substrate of the day enters the bowel (after breakfast) and stop in
the evening after the last substrate has disappeared. Most of the bacterial L-lactic
acid is catabolized for energy generation, whereas most D-lactic acid is accumula-
ted during the day. The consequent peak concentrations in blood and urine are found
early in the evening. During the whole day, D-lactic acid is renally cleared, but the
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effect is most obvious during the night when no D-lactic acid is produced. Every day,
the serum D-lactic acid is minimal at the first meal, increases again until peak con-
centration is reached after the last meal, and decreases again during the night (circa-
dian rhythm). If the nightly clearing is prevented by nightly tube feeding, instead of
decreasing, the acid and the risk of acidosis increases. 
The endurance of an acidosis episode depends on the level of lactic acid accumula-
tion in blood and tissues. At a low level of accumulation the episode lasts only a few
hours, but at a high level it may last several days. Often the acidosis is neutralized
with bicarbonate, and thus the episode may substantially be shortened. Normally, the
moment at which the accumulation of D-lactic acid reaches the level at which pH
decreases causing the onset of hyperventilation is unpredictable. Many factors may
affect this process, but the most important factor is the oral consumption of low
molecular weight, easily fermentable carbohydrates (as in sweets). In many cases,
high serum lactate seems to represent a high-carbohydrate food, but in some cases it
seems to represent a quite different phenomenon (in study). Patients who have aci-
dosis should alter their diet to consume less easily fermentable, long-chain carbohy-
drates; should have a higher meal frequency, perhaps with smaller quantities, to pre-
vent high lactate peaks, and thus lactic acidosis; and should permit nightly D-lactic
acid clearing. 
The primary prerequisite to the development of acidosis is the absence of a major
part of the small bowel. The overproduction of lactate is merely the massive response
of the lactobacilli to excessive consumption of fermentable sugars. The secondary
prerequisite is an insufficient D-2-OH acid dehydrogenase activity [2,21] in neonates,
infants and young children (until approximately 5-7 years). This enzymes oxidizes
the D-2-OH acids, D-lactic acid included, and thus converts a major part of D-lactic
acid to the easily metabolizable pyruvic acid. The low serum D-lactate and the low
urinary D-lactate excretion in the bodies of older children and adults are fully
explained by sufficient activity of this enzyme. 
The short chain fatty acids in the human intestines are mainly produced (with lac-
tate as the intermediate) in the colon by anaerobic bacteria other than the lacto-
bacilli. Because the SSB flora contains up to 100% lactobacilli, short-chain fatty
acids are produced in only small or even negligible amounts in stool. 
In patients with SSB, lactic acidosis is primarily related to massive resection of the
small bowel. Nevertheless, all other factors (e.g. sepsis and thiamine insufficiency
due to the continuous malabsorption) that per se may cause lactic acid production,
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may also contribute to the accumulation of total lactic acid, and thus may help induce
lactic acidosis in patients with SSB. 
CONCLUSION
Because of (iatrogenic) malabsorption, strong predomination of lactobacilli in the
intestinal flora is inherent in all pediatric patients, and consequently acidification
may occur, depending on the amount of available fermentable carbohydrates. Many
symptoms and aberrant parameters may be seen during the acidification, but the
fundamental ones, which have been mentioned above (e.g. serum pH and base
excess), always show the same characteristic pattern. 
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INTRODUCTION
As early as 1986 Ohkohchi et al. [1] reported on the nutritional condition and the
absorptive capacity of infants with a short small bowel (SSB), especially with respect
to severe steatorrhea, disrupted absorption of bile acids, and subnormal concentra-
tions of serum vitamin D and of total cholesterol, with the intake of normal meals. In
1997 the same group [2] specifically reported on the disturbed bile acid metabolism
in children with SSB. In children without diarrhea, no severe fat malabsorption was
recognized, and the content of total bile acids in the feces was normal to slightly
increased [2]. In patients with intractable diarrhea, fat malabsorption was observed,
and the fecal content of total bile acids in these patients exceeded by more than ten-
fold that of controls [2]. In healthy persons the primary bile acids, cholic acid and
chenodeoxycholic acid, account for 60%-70% of the total serum bile acids, but in
SSB-children with intractable diarrhea, they account for more than 95%. In these
children the (taurine- and glycine-) conjugated bile acids accounted for only 10% of
the total serum bile acids. Some children with and without diarrhea had hyperbile
acidemia [2]. 
In the same year, 1997, we published our findings on the intestinal flora in patients
with a SSB[3]. Most remarkable was the intestinal predominance of lactobacilli (up
to 95%) in the fecal flora of orally fed SSB patients without antibiotic therapy [3].
Ohkohchi et al.[2] assumed that unconjugated bile acids from an indistinct origin
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affected the growth of intestinal bacteria such as lactobacilli. It is clear now that the
contrary is true: the intestinal lactobacilli are bile acid-resistant, and they deconjugate
the bile acids [4,5], thus strongly disturbing bile acid and lipid metabolism. An essen-
tial factor in the reporteddisorder of patients with SSB is bacterial bile salt hydrolase
(BSH) activity [6,7], a specific property of many Lactobacillus spp, especially the
intestinal ones.
INTESTINAL BACTERIA AND BILE ACIDS
In the liver, the primary bile acids, cholic acid and chenodeoxycholic acid, are pro-
duced from cholesterol, and are next conjugated with glycine or taurine. As bile
constituents, the conjugated bile acids enter the gastrointestinal tract in the duodenum
(see Fig. 1a.), and are important in the emulsification, digestion, and absorption of
dietary lipid that occurs in the small bowel. More than 95% of the conjugated bile
acids are reabsorbed in the small intestine, mostly in the terminal ileum (enterohe-
patic cycle [8]). The bile acids that escape absorption in the ileum (2-3% per cycle),
are metabolized by colonic bacteria (mainly bacteroids [9]). Deconjugation and sub-
sequent dehydroxylation of the conjugated primary bile acids results in the formation
of the secondary bile acids, deoxycholic acid and lithocholic acid. Part of these
secundary bile acids (about 30%) is absorbed in the proximal colon and enters the
enterohepatic circulation, and part (about 70%) is excreted in feces. The latter loss of
secondary bile acids is compensated by the liver-controlled synthesis of primary bile
acids from cholesterol. Increased concentrations of unconjugated bile acids in serum
are thought to arise from intestinal bacterial activity, and are therefore markers for
small-intestinal bacterial overgrowth [10]. 
Lactobacilli in the (short) small bowel
During some parts of the day the proximal part of the intact small bowel, i.e. the duo-
denum and the proximal part of the jejunum, presents an optimal "ecosystem" for
intestinal lactobacilli with, on one hand, a low pH, absence of oxygen and abundance
of sugars, and on the other, the bile resistance of the lactobacilli [4,5]. However, this
combination of optimal conditions is limited in time. The intestinal concentrations of
sugars, especially glucose, sucrose and lactose, i.e. the energy-rich substrates for lac-
tobacilli, and of aminoacids strongly decrease due to the luminal uptake, whereas
pancreatic juice effects intestinal neutralization. Therefore, the optimal "ecosystem"
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exists only during a rather short time after food intake. Consequently, after this
optimal "ecosystem" period the growth rate of lactobacilli strongly decreases, and
for this reason, (i) the final ileal concentration of lactobacilli will not exceed 107 cfu/g
wet intestinal mass, and (ii) the effects of lactobacilli are limited.
In SSB patients, however, the extensive resection has strongly reduced the uptake
capacity regarding sugars and other nutrients by the luminal wall. Consequently, soon
after the onset of oral feeding these patients will suffer from malabsorption.
Therefore, appreciably more suitable mono- and disaccharides are available for the
lactobacilli [3], which fermentatively produce lactic acid and, thus, acidify the bowel
lumen [11]. In this way the initial acidity is strongly extended, and, consequently, the
pancreatic juice-mediated neutralization of the acidic food mass in the duodenum and
jejunum is slowed down. The prolonged acidity stimulates growth of lactobacilli, and
simultaneously inhibits growth of most other bacteria [3]. Thus, a considerable por-
tion of the fermentable sugars is consumed by lactobacilli. Consequently, an abundant
characteristic flora emerges, which consists mainly of lactobacilli (1010-1012 cfu/g
feces) and Escherichia coli (108-1010 cfu/g feces [3]). 
Effect of lactobacilli in SBB patients
Previously it has been shown that the lactobacilli, but not the coliforms, are able to
deconjugate bile acids [4,5], probably in order to resist the solubilizing effect of con-
jugated bile acids on bacterial membranes, and thus to resist the bactericidal and cyto-
toxic effect of the conjugated bile acids [12,13]. Because of the massive amount of
lactobacilli in the intestines of SSB-patients, the conjugated bile acids present will be
rapidly deconjugated [2,14]. The fate of the bile acid molecules depends on the length
of the non-resected part of both the small bowel and the colon, as well as on the intes-
tinal passage time. With decreasing length of the ileal part of the SSB, the ileal
resorption of conjugated bile acid will decrease, and the flow of deconjugated bile
acid to the colon will increase, due to the increased lactobacilli-mediated deconjugation.
The longer the colonic part that has additionally been resected, the less the deconju-
gated bile acid molecules will be resorbed from the colon. 
The changes expected in the case of either a long or a short fecal passage time are
presented in Fig. 1b and 1c, respectively. In both cases, the flow of deconjugated bile
acid to the colon will be strongly increased. During fecal stasis, with a long passage
time, colonic resorption of (deconjugated) bile acid will be strongly increased,
whereas fecal excretion will fully disappear. 
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Figure 1. Causes of Short Bowel Syndrome in neonates and children in %
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Representation of the enterohepatic circulation of bile acids in a healthy adults and b and c in extreme
situations in patients with a short small bowel (SSB-) with either a very long fecal passage time (b), a
situation which is nearly comparable with fecal stasis, or a very short fecal passage time (c), as in
intractable diarrhea. The effect of both the lactobacilli-mediated deconjugation and massive short bowel
resection on the total flow of all (i.e. conjugated plus de/unconjugated, and primary plus secondary) bile
acids is compared with the identical flow in healthy controls. The effects are presented relatively as:
equal sign, No change; upward arrows, increasing levels; downward arrows, decreasing levels. Hepatic
neosynthesis of primary bile acids from cholesterol precedes the conjugation, and is suggested to equal
the fecal loss of the various bile acids together. The site of conjugation (in the liver) is marked C, and
of lactobacilli-mediated deconjugation (in the SSB) is marked D. For SSB-patients without fecal stasis
or intractable diarrhea, intermediate bile acid flows may be derived. For a more detailed explanation,
also see text.
During intractable diarrhea with a continuous short passage time, colonic resorption
will be less, and fecal excretion will be strongly increased [2]. The deconjugative
activity of the intestinal lactobacilli in SSB-patients, especially those with
intractable diarrhea, also suggests that steatorrhoeal loss of nutritional energy may
strongly contribute to the growth failure of these children. 
Normally, the primary bile acids are enzymatically transformed (by chemical
reduction) to secondary bile acids during intestinal bacterial fermentation of sugars.
In patients with diarrhea, this process is limited, because of the limited contact time
between the primary bile acids and bacteria, resulting in an extremely high percen-
tage of unconjugated primary bile acids (95% of all bile acids) in the feces of these
patients. SSB-patients without diarrhea have a rather high percentage of secundary
bile acids in their feces [2]. 
Significance of bile acid deconjugation in SSB patients
The significance of the rapid lactobacilli-mediated deconjugation is that, in SSB-
patients, only a very small amount of conjugated bile acids is available to facilitate
the intestinal micellar uptake of triglycerides, fatty acids, cholesterol and lipophilic
vitamins. This corresponds with our finding that, in SSB sera, the concentrations of
cholesterol, triglycerides and lipophilic compounds, e.g., the vitamins A, D and E,
were often low to low-normal: e.g., cholesterol concentration was 1.4 mM (normal
range [NR]: 2.6-5.2 mM), the concentration of triglycerides was 0.8 mM (NR, 0.8-
2.0 mM), the concentration of vitamin A was 0.5 µM (NR, 0.7-3.0 µM), the concen-
tration of vitamin D was 11 nM (NR, 10-40 nM) and the concentration of vitamin E
was 7.7 µM (NR, 7-33 µM). Thus, it is clear that a rather large amount of the
lipophilic nutrients will not be resorbed, and will be present in the feces (sometimes
observed as steatorrhea). Additional factors which contribute to fat malabsorption,
steatorrhea and insufficient serum concentrations of lipophilic vitamins are: the length
of the resected SSB (and colon), the absence of the ileocecal valve, and diarrhea. The
larger the resected ileum, i.e., the smaller the intestinal site for conjugated bile acid-
facilitated lipid uptake, the less the intact conjugated bile acid molecules will be
resorbed in the enterohepatic cycle, and the more (deconjugated) bile acid molecules
will arrive in the colon (Fig. 1b,c). Absence of the ileocecal valve will speed up the
flow to the colon, decrease the resorption from the ileal part of the SSB, and con-
tribute to diarrhea. In particular, because of the short contact with the bowel wall, a
considerable portion of the bile acids may be lost from the enterohepatic cycle (see
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Fig. 1c) during periods of frequent diarrhea. To compensate for this loss, it is
suggested that, in agreement with the observed low serum cholesterol, high-density
lipoprotein (HDL)-cholesterol, and low density lipoprotein (LDL)-cholesterol
(unpublished data, [13]), the systemic pool of cholesterol is depleted [6,7,15,16].
Thus, the mechanism presented by De Smet et al. [7] to explain the lowering of serum
cholesterol in mice intestinally treated with Lactobacillus plantarum, seems to be
confirmed now in human SSB-patients. Theoretically speaking, probiotic lactobacilli
may indeed lower the cholesterol pool in healthy people to some extent, but for a sig-
nificant effect, other supporting conditions seem to be necessary. 
In bile of an antibiotic therapy-free SSB patient we observed that the unconjugated
bile acid had increased up to 25% of the total bile acid content, whereas in plasma of
similar patients the percentage of unconjugated bile acids increased up to 73%. The
hyperbile acidemia in SSB-children with and without diarrhea refects an aspect close-
ly associated with the enterohepatic cycle: the extraction of bile acids from portal
blood is much higher for conjugated than for unconjugated bile acids [17,18]. The
hyperbile acidemia is explained by a higher than normal load of unconjugated bile
acids to the liver, resulting in elevated levels of unconjugated bile acids in the sys-
temic circulation. 
Management of bile acid deconjugation in SSB patients
How to manage the lactobacilli-mediated deconjugation of bile acids? Every attempt
must be made in coherence with the therapeutic management of D-lactic acidosis
[3,19-21]. In spite of the mentioned deconjugation effects, lactobacilli remain rather
innocent bacteria; antibiotic-mediated replacement of lactobacilli by other more
pathogenic bacteria will probably create greater, especially infectious, problems.
Bicarbonate meant to neutralize a too low intestinal pH will stop the overgrowth of
lactobacilli, but will also stimulate the overgrowth of other bacteria. Theoretically,
replacement of the lactobacilli in SSB intestines by probiotic, L-lactic acid-producing
and facultatively heterolactic lactobacilli, such as Lactobacillus casei, may be suitable
for combating D-lactic acidosis [22], and for reducing diarrhea, but not for stopping
deconjugation. A disadvantage of probiotic, non-acidophilic yeasts, e.g.,
Saccharomyces boulardii, is the production of 2 mol carbondioxide from 1 mol glu-
cose during simultaneous production of 2 mol ethanol from the same glucose molecule.
Because of its gaseous character, carbon dioxide may increase diarrhea and thus con-
tribute to loss of nutritional fat and bile acids. We hypothesize that parenteral feeding
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(to prevent fecal loss) enriched with essential lipophilic compounds and with
mevalonic acid, a well-known precursor of cholesterol and thus of bile acids, would
be a suitable therapy to restore both the level of essential lipophilic compounds and
the depleted cholesterol pool, preferrably combined with oral feeding enriched with
probiotic L. casei.
CONCLUSIONS
Whereas lactobacilli are rather innocent bacteria, it is clear now that their permanent
massive presence in the bowel of orally fed SSB-patients has important effects on
the physiology and the metabolism of lipophilic substrates. These effects may,
additionally, contribute to the very vulnerable condition of the SSB-patient. 
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ABSTRACT
Stool analysis in patients with a short small bowel showed an intestinal flora with
90% lactobacilli. Sugar fermentation by CO2-producing lactobacilli may be the cause
of abdominal pain, diarrhoea and flatulence. 
In the faeces of a child the heterolactic CO2-producing Lactobacillus fermentum
was dominant. The only gas the bubbling faeces and L. fermentum produced was
CO2. With oral feeding, a parenterally fed girl suffered from a distended abdomen,
flatulence, diarrhoea and abdominal pain, and without oral feeding she did not. After
glucose loading in an adult woman, D-lactic acidaemia developed as well as massive
intestinal CO2 production; there was no hydrogen gas present in the expelled air. The
patient became increasingly flatulent and ill. After passing flatus and diarrhoea all
symptoms disappeared. 
Conclusion: Oral consumption of easily fermentable carbohydrates in short small
bowel patients, will give rise to production of CO2 from lactobacilli, causing flatu-
lence, diarrhoea and abdominal pain. 
INTRODUCTION
The American Gastroenterological Assocation in its publication "Short bowel syn-
drome and intestinal transplantation" states that less than 200 cm. of functional small
intestine is its definition of short bowel syndrome [1]. We count 75 cm remaining
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jejuno-ileal segment for an infant born at term, and 50 cm for infants born between
28 and 35 weeks gestational age as our limits for a short small bowel (SSB) in accor-
dance with 30% remaining intestinal length according to the measurements of
Touloukian and Walker Smith [2]. For children above one year we keep 100 cm as
the limit of an SSB.
Common characteristics of the most SSB-patients are: diarrhoea, increased flatu-
lence and abdominal pain. The diarrhoea is caused by a combination of factors as
rapid intestinal transit time and loss of absorptive capacity, but abnormal bacterial
growth may also occur. Steatorrhoea from inadequate fat absorption is often present
[3]. Because of nutrient malabsorption in the small intestine these patients develop a
characteristic intestinal flora consisting mainly of lactobacilli [4,5]. With massive lac-
tic acid production and subsequent low pH, the lactobacilli inhibit the growth of other
bacteria in the intestine [6]. This particular flora causes daily D-lactic acidaemia and
aciduria in many patients [5,6], less frequent acute D-lactic acidosis [6] and proba-
bly also sporadic D-lactic acidosis-associated encephalopathy [4]. 
Over the years we have studied SSB-patients, and some characteristic diarrhoea-
related features are seen. Most SSB-patients suffer frequently from audible intestinal
bubbling, visibly distended abdomen, flatulence, painful abdominal cramps and
diarrhoea. Abdominal cramps are decreased by flatulence and diarrhoea. These symp-
toms are strongly related to food consumption. Apple juice and lactose-containing
dairy products are diarrhoeagenic and cause abdominal complaints in our patients and
have to be avoided. The frequency of bowel movements in SSB-patients varies
markedly (up to 20 times/day), but normally ranges between 4 and 10 times per day. 
The total bacterial concentration in the faeces of SSB-patients (1010-1012 cfu/g wet
faeces) is the same or slightly higher than that of healthy people (1010-1011 cfu/g wet
faeces). However 85-90% of the faecal flora of the SSB-patients studied, are Gram-
positive and mainly lactobacilli [4]. Homolactic lactobacilli species (e.g.
Lactobacillus acidophilus) produce only 2 mol lactate from fermentable mono-
saccharides (such as glucose or galactose) and no gas, whereas heterolactic species
(e.g. Lactobacillus fermentum) produce 1 mol lactate, 1 mol ethanol, and 1 mol of the
gaseous CO2. Since lactobacilli are predominantly present in the intestine of SSB-
patients, we postulate that the occurrence of diarrhoea in SSB-patients is mainly
determined by the fermentative activity of the present heterolactic lactobacilli on fer-
mentable sugars such as glucose, fructose, sucrose and lactose. 
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We collected data to confirm that CO2 gas in particular may be the main cause of the
abdominal complaints in SSB-patients.
METHODS
Patients
The clinical data of three SSB-patients, CH 2, CH 4 and AD 7, have been studied in
more detail. They have been previously described by us [4] and are listed in Table 1.
The small bowel of the girl CH 2 had been resected on the second day after her birth.
Presented observations and experimental data were obtained, when she was between
4 and 6 years old.
Table 1. Clinical data of the patients with a short small bowel
The length of the remaining small bowel of the girl CH 4 was 45 cm after a second
resection. Parenteral feeding was gradually replaced by enteral feeding, consisting of
both oral nutrition and enteral drip-feeding by a gastrostomy.  The presented obser-
vations and experimental data were obtained when she was 7 years of age. 
The SSB-children, CH 2 and CH 4, were on an essentially lactose-free oral diet,
with soy milk replacing dairy products, and with micronutrient supplementation; they
received dextrin-maltose-based food as the main carbohydrate source. With oral
feeding the patients suffered daily from D-lactic acidaemia and aciduria, and very
often from flatulence, abdominal pain and diarrhoea. Other common features were
a characteristic Gram-positive faecal flora consisting mainly of lactobacilli [4] and
an excessively distended abdomen especially after meals. 
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Patients CH 2 CH 4 AD 7
Year of birth 1984 1990 1950
Cause of resection volvulus ischaemic mesenteric 
incident thrombosis
Length of small bowel (cm) 28 45 50
Ileocoecal valve present + + -
Colon present + + 85%
The small bowel of the adult female patient AD 7 was resected in 1991. The reported
glucose loading tests were performed five years after resection. The patient was on an
essentially lactose-free, but otherwise normal caloric diet enriched with carbohy-
drates and proteins. She also received additional parenteral nutrition. With normal
oral feeding she suffered daily not only from slight D-lactic acidaemia and aciduria,
but also from diarrhoea. Other common features were a characteristic Gram-positive
faecal flora with mainly lactobacilli [4] and an excessively distended abdomen, espe-
cially after each meal. The mean defecation frequency of AD 7 was about 16 times a
day, and sometimes this increased up to 20 times a day. She used loperamide as anti-
diarrhoea medication.
This study was performed in accordance with the Helsinki Declaration of 1975, as
revised in 1983, and approved by the Ethics Committee of the University Hospital
Nijmegen.
Bacteriological analysis 
Bacteriological analysis was performed as previously described [4]. For microscopy,
smears of faecal samples were studied after Gram-staining. For total counts of non-
acidophilics, faecal samples were plated on both aerobic blood agar and anaerobic
Brucella blood agar. To count the total number of the acidophilic lactobacilli the same
samples were cultured anaerobically on De Man-Rogosa-Sharpe agar (Oxoid CM-
361) and on Tomato Juice agar (Oxoid CM-113). The capacity of either faeces or lac-
tobacilli to produce gas was tested in a test tube equipped with a reversed Durham
test tube in filter-sterilised 5% glucose solution. 
Biochemical analysis 
The only gas accumulated under the reversed Durham test tube that is fully absorbed
by the growth medium after the addition of NaOH pellets, is CO2 (chemical conver-
sion to non-gaseous soluble bicarbonate). For quantification of L-lactate in blood and
urine, an enzymatic assay with L-LDH was performed, and for quantification of D-
lactate L-LDH was replaced by D-LDH [4]. Quantitative analysis of organic acids
was performed by capillary gas chromatography-mass spectrometry [7]. Urine was
also studied by nuclear magnetic resonance (1H-NMR) spectroscopy according to
Wevers et al [8]. 
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RESULTS
The diarrhoeal stools of CH 2 were often bubbling. In her faeces the resident L. fer-
mentum (1011-1012 cfu/g wet faeces) predominated. This is almost 100 fold more than
the resident L. acidophilus and the other, transient intestinal bacteria [4]. The capac-
ity of the isolated L. fermentum to produce merely CO2 was confirmed. The bubbling
faeces (with 90% Gram-positive rods identified as lactobacilli; 1012 cfu/g wet faeces
and 10% Gram-negative rods) have also been found to produce massively CO2; pro-
duction of hydrogen or methane gas could not be demonstrated. 
Patient CH 4 suffered from a distended abdomen and intense abdominal pain with
increasing frequency. At the age of seven years her body weight fell from 19.5 kg to
17.5 kg in three months. From the moment she was hospitalised, she received both
parenteral and oral feeding. At this point her faecal flora contained 85% Gram-posi-
tive rods (identified as lactobacilli; 1012 cfu/g wet faeces), 10% Gram-negative rods
and 5% yeast. During incubation of her faeces with glucose, CO2 was produced. After
four days of parenteral feeding in combination with some oral feeding the composition
of the faecal flora had not changed, and she still had severe abdominal pain and a dis-
tended abdomen. In the next three days of merely parenteral feeding, abdominal pain
and distension disappeared completely and so did the lactobacilli in the faeces.
In patient AD 7 the diarrhoeagenic effect of glucose in SSB was studied twice with
an interval of four months during 3 hours after loading with 50 g glucose dissolved
in 200 ml water. Her faecal flora consisted of 90% Gram-positive rods (among
others CO2-producing lactobacilli), 5% Gram-positive cocci, 5% Gram-negative
rods, les than 1% Gram-negative cocci and sporadically yeast. The glucose intake
lasted five minutes. Immediately after ingestion, intestinal fermentation started and a
bubbling sound was heard. During the test large amounts of intestinal gas were pro-
duced. The patient felt bloated, first in the upper, later in the lower abdomen, and the
whole abdomen became visibly distended. After 15 minutes nausea started, and after
20 minutes abdominal pain and cramps started. At 30 minutes she became flatulent,
and slowly felt the urge to defecate. After 45 min she felt ill and had to lie down. After
75 minutes she suffered from severe diarrhoea for about 15 minutes. After 90 minutes
all the symptoms mentioned above had gone. During the whole experiment H2 in
expired air was constantly 3 parts per million. Serum glucose increased from 4.5 to a
maximum of 8.0 mM, D-lactate from 150 µM to a maximum of 400 µM, and L-lac-
tate from 1000 µM to a maximum of 1600 µM. In addition, by NMR investigation a
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slight increase of serum acetate was observed, but not of other organic compounds.
Serum pH was continuously 7.33. Urinary excretions of total lactic acid just before and
after the experiment were low: 30 mmol/mol creatinine. The gas produced after incu-
bation of a small sample of faeces in a glucose solution, was confirmed to be CO2.
DISCUSSION
Flatulence is a common event in most people and is generally ascribed to intestinal
production of gas, mainly H2, but in many people also CH4. Strict anaerobes are nor-
mally absent in SSB-patients, and therefore bacterial methane production is not
expected to occur. The collected data concerning patients CH2 and CH4 indicate that
in SSB-patients without antimicrobial therapy or neutralization of gastric acid and
with a normal gastric acid production, flatulence, abdominal pain and diarrhoea are
strongly associated with the lactobacilli-mediated production of CO2 gas. As far as we
know this is the first time that an intestinal flora is reported to produce up to about
100% CO2 as gaseous metabolic product.
In order to elucidate in more detail the relation between flatulence, diarrhoea and
abdominal pain, the intestinal flora of AD 7 was manipulated by use of glucose
loading. The data of this study confirmed that after glucose loading in the breath test
the H2-production is negligible, and after incubation of the faeces with glucose the
only gas produced was CO2. If in the loading experiment only 5 g (10% of the load)
of the glucose (Molecular Weight = 180) is not absorbed but fermented by heterolac-
tic lactobacilli, then 600 ml CO2 gas should be produced (molar gas volume: about
22.4 L). With increasing CO2 production intra-intestinal gas-pressure and volume
increase and this is seen as abdominal distension. In turn, the intra-intestinal pressure
may be diminished by deflation. If the intestines become too distended, and deflating
activity is not in relation to the production, abdominal pain is thought to arise. 
Four related factors are causative for the massive CO2 production: the diet, malab-
sorption as a consequence of massive resection, heterolactic bacterial activity and the
subsequent low intestinal pH due to fermentative lactic acid production [5]. During
intestinal heterolactic bacterial fermentation in acidic watery solution gaseous CO2
will increase massively because of its limited solubility. Consequently, the intestinal
lumen will be filled with gas and become distended. The diarrhoeagenic character of
apple juice (containing mainly glucose and fructose) and of dairy produce (containing
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lactose) in these patients is thought based on the suitability of these sugars for intes-
tinal lactobacilli-mediated fermentation. 
Polymeric carbohydrates from ingested food are mixed in the intestine with fer-
mentative SSB-flora, and fermented after depolymerisation by human amylase. Just
as of fermenting dough the volume of the intestinal, fermenting food mass increases
markedly due to the gaseous CO2 inside. As this gas-pressure passes a threshold, it is
thought to create a rather strong neurophysiological stimulus that forces the lumen
muscles to contract and the anal sphincter to relax and expel the intestinal contents
[9], before all normal digestive processes have been completed, resulting in diar-
rhoea. If peristalsis is reduced, as in stasis of intestinal contents, bacterial metabolites,
e.g., D-lactic acid, can accumulate and contribute to acidosis and/or encephalopathy. 
Antimicrobial therapy, neutralization of gastric acid or therapeutically reduced gas-
tric acid production may favour uncontrolled intestinal overgrowth of various fer-
mentative micro-organisms [4] and the final effect is unpredictable. Since yeasts pro-
duce nearly 2 mol CO2 per mol glucose, they may also increase flatulence, pain and
diarrhoea. Heterofermentative microorganisms, like Escherichia coli, produce both
CO2 and H2. If in SSB-patients H2 is produced, it is done only by E. coli and some
transient facultative or strict anaerobes, and not by either lactobacilli or yeast. Since
obligatory homolactic lactobacilli do not produce CO2 or any other gas, we postulate
that they not only prevent diarrhoea, but also may even contribute to intestinal stasis
in the absence of heterolactic lactobacilli or yeasts. The presence of the facultative
heterolactic Lactobacillus casei as probiotic with limited CO2 production theoretically
seems to be preferable above the naturally present lactobacilli, such as the obligatory
heterolactic L. fermentum and the obligatory homolactic L. acidophilus.
The mentioned data indicate that after the glucose loading intestinally a massive
bacterial fermentation with concomitant gaseous CO2-production had occurred,
which caused a short transit time, and resulted in diarrhoea, flatulence and pain. To
avoid such a massive intestinal gas production one may choose for sugar-free poly-
meric carbohydrate diet or probiotic L.casei as food supplement, but this study makes
clear that for SSB-patients especially high fat, low fermentable carbohydrate diets are
very interesting [10]. The absence of fermentable carbohydrates inhibits outgrowth of
lactobacilli, and thus massive intestinal gas production will be limited. This agrees
with our finding that in the absence of oral feeding, i.e., in the absence of intestinal
carbohydrates the faecal lactobacilli of CH 4 completely disappeared. This study may
also explain the fact that others have not found the uniform overwhelming predomi-
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nance of lactobacilli in intestinal overgrowth [11]: the intestinal presence of dietary,
fermentable carbohydrates strongly affects the outgrowth of lactobacilli and their
consecutive effects in patients with a short small bowel and in the study of Bouhnik
[11] only two of the 63 patients had a short small bowel. 
An important consequence may be that a smaller percentage of primary cholic acids
will be deconjugated, and thus fat and lipophilic vitamins will be taken up more effi-
ciently [3]. 
CONCLUSION
Due to malabsorption in SSB patients, a part of the ingested carbohydrates is
available for heterolactic fermentation. This leads to massive CO2 production, which
is mainly responsible for the flatulence, abdominal discomfort and diarrhoea. Not
only the use of probiotic L. casei in the diet is thought to reduce the massive CO2 pro-
duction, but also the use of high fat, low fermentable carbohydrate diet.
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ABSTRACT
During acidotic periods in a girl with a short small bowel very high D-lactate con-
centrations were measured in blood and urine. Initially the characteristic faecal flora
contained many lactobacilli. After treatment with antibiotic cocktails had started, also
many yeasts were cultured. Antibiotic cocktail therapy soon reduced both the acido-
sis-assisted symptoms and the lactobacilli-mediated D-lactate production, but it
increased strongly the percentage of yeast in the faecal flora. In 4-6 weeks after each
antibiotic cocktail course the percentage of yeast decreased, whereas the percentage
of intestinal lactobacilli increased; simultaneously also D-lactate increased in blood
and urine. Patient felt very well with high percentages of intestinal yeast, but with
high percentages of lactobacilli she suffered from acidosis. The yeast was identified
as the potentially pathogenic Candida glabrata. The mentioned data together with
data from literature were explained as follows: during several weeks the selected
yeast acted as a metabolic and microbiological buffer. In an ecological competition
for glucose the intestinal yeast cells prevented both abundant bacterial D-lactic acid
production and thus D-lactid acid-associated acidosis, and besides they permitted
sufficient bile acid-mediated uptake of fats and especially lipophilic vitamins.
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INTRODUCTION
In Short Small Bowel (SSB) patients an extensive part of the small bowel has been
resected, and therefore they may have malabsorption [1]. The microbiological con-
sequence in our patients was a change from the normal intestinal flora to one of
mainly lactobacilli. Several species abundantly produce D-lactic acid from easily
fermentable carbohydrates [2]. Consequently, D-lactic acidemia and aciduria may
arise daily [3]; at times D-lactic acidosis can be seen, and less frequently, D-lactic
acidosis-associated encephalopathy [1]. SSB-patients may be severely diseased by
lactobacilli, which are generally known to be beneficial [2,3,4]. We report the fasci-
nating consequence of antibiotic therapy, which was applied to stop acidification of
the body due to lactobacilli. 
PATIENT
Our patient is a girl born in 1989. Her ileum and ileocaecal valve were resected at the
age of 9 and 15 months because of an ileocolic invagination and later an ileus; most
of the colon remained present. The final length of the jejunum was 50 cm after the
second resection. Initially, she was on a combination of parenteral and enteral drip-
feeding, next on continuous nasogastric drip-feeding and finally on a lactose-free oral
diet at the age of four years. She got dextrin-maltose mixtures as main carbohydrate
source. During enteral and later oral nutrition, she had D-lactic acidemia and suffered
frequently from acidosis. 
METHODS
Microbiological analysis was performed as previously described [3]. Percentages of
bacteria and yeasts in faecal samples were determined by microscopy after Gram-
staining. In spite of the about 10-fold difference between the bacterial and yeast size,
the percentages concern the numbers of the Gram-stained rod-shaped or spherical
(small) bacteria, or of the Gram-positively stained (large) yeasts seen under the
microscope. Total lactate in serum and urine was studied by use of capillary gas chro-
matography-mass spectrometry, and D- and L-lactate in serum and urine by enzy-
matic assay [3,5].
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Acidotic characteristics 
In January 1992 and May 1993, while short periods of acidosis with somnolence
occurred, we measured total serum lactate values of 10 and 15 mM (N: 0-2 mM),
respectively. During similar periods in November 1992 and in November 1993 base
excess values were -12.9 mM and -20 mM (N: -3 mM to +3 mM). In November 1993
we found the faecal microbial flora not only characteristic for SSB-patients, but even
rather extreme, since it contained 97% Gram-positive rods, which appeared to be
mainly lactobacilli, and further 1% Gram-positive cocci, 1% Gram-negative rods, and
1% yeasts. In February 1995 during an acidotic period, in a small urine sample a very
high D-lactate excretion of 34 mol/ mol creatinine was measured (concomitant L-lac-
tate excretion was 0.1 mol/ mol creatinine). In 1995 the range of measured D-lactate
concentrations in various serum samples in non-acidotic periods was 2-5 mM (N: <0.1
mM). In May 1995, as she was acidotic again, we observed a very high serum D-lac-
tate concentration of 15.5 mM (concomitant serum L-lactate was 1.5 mM). 
Management of antibiotic treatment 
In SSB-patients with enteral feeding and antibiotic mono-therapy (e.g. vancomycin
or neomycin) susceptible lactobacilli have been found to be replaced by other, resis-
tant, lactobacilli [2]. Therefore, from summer of 1992 till now her bowel flora was
regularly treated according to Vanderhoof et al. [1] with an oral antibiotic cocktail
containing metronidazole, gentamicin, and initially colistin (till summer of 1994),
which was later replaced by vancomycin, for a course of 5-7 days, every 4 to 6 weeks
to decontaminate the bowel. In episodes of severe acidosis, feeding was stopped,
bicarbonate given, and antibiotic therapy started [4]. Antibiotic therapy soon reduced
the acidosis-associated symptoms. 
Effects of antibiotic therapy
In August 1995 faecal samples, produced during and after antibiotic therapy, revealed
strongly increased yeast percentages (up to 40%). Because of these preliminary
results, in April 1996 we started a study on the beneficial effect of the antibiotic cock-
tail in this patient. Because of the great distance between the patient (in Austria) and
our laboratories (Nijmegen, The Netherlands) the study was limited to the faecal
microbial composition and the urinary excretion of lactic acid (at about 16.00 h) dur-
ing acidotic periods. During this study patient's faecal flora remained characteristic
(45-70% Gram-positive rods, which have been proved mainly to be lactobacilli, 0-5%
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Gram-positive cocci, and 0-10% Gram-negative rods), but had still changed, since it
contained also 25-50% yeasts. This high concentration was probably selected by the
regular antibiotic therapy courses.
The percentage of yeasts during two successive antibiotic courses increased from
25 to 50%, and the percentage of Gram-positive rods decreased from 70% to 45%.
Within the next 2-3 weeks the reverse process took place. These data have been par-
alleled by remarkable lactate excretions in small urine samples (15-50 ml). During
the mentioned two successive antibiotic courses D-lactate excretion decreased from
3.5 and 19.0 mol D-lactate/ mol creatinine, respectively, to <0.1 mol D-lactate/ mol
creatinine. After the antibiotic courses they strongly increased again to 19.0 and 6.4
mol/ mol creatinine, respectively (all concomitant L-lactate excretions were <0.1
mol/ mol creatinine). Patient's mood, activity and condition increased concomitantly
not only with the decrease of faecal lactobacilli and the urinary excretion of D-lac-
tate, but also with the increase of faecal yeast. During the next years the frequency of
acidotic/ encephalopathic episodes decreased. In December 2000 and January 2001
faecal samples contained 80-95% lactobacilli, 0-10% Gram-positive cocci, 0-5%
Gram-negative rods, and 5-20% yeasts. The effect of the antibiotic cocktail on the
microbial composition was lower than in 1995 and 1996, but still essentially the same. 
Identification of yeast isolates
From 6 different faecal samples produced between the start and the end of 1996 and 4
samples produced in 2000 and 2001 we isolated and identified the yeast. All samples
yielded identical isolates with the same biochemical profile in the Auxacolor test
(Biorad; Marnes la Coquette, France; cf. 6); they were identified as Candida glabrata.
DISCUSSION
Lactobacilli are generally considered to be non-pathogenic bacteria. However, this
patient demonstrated that the massive intestinal overgrowth of lactobacilli in SSB-
patients (maximal count: 1011 - 1012 cfu/g wet faeces) may disease the body due to the
systemic acidification after massive uptake of especially D-lactic acid that is abun-
dantly produced in the remaining bowel after resection. As SSB-patients become older,
both the frequency and the height of D-lactic acid levels strongly decrease [3] proba-
bly due to the increase in the human body tissues of the enzyme D-2-hydroxyacid
dehydrogenase that converts D-lactic acid to pyruvic acid [7,8]. This may explain why
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in 2000/2001 the frequency of acidotic episodes was rather low. Consequently, the fre-
quency of oral antibiotic therapy decreased, and also the intestinal yeast. C. glabrata
is generally recognised as potentially pathogenic yeast, which may cause intestinal
infections. However, this patient demonstrated that during the antibiotic therapy the
massive intestinal overgrowth of C. glabrata (maximal count: 109 - 1010 cfu/ g wet
faeces) did not cause disease. As we observed no signs of fungaemia during the anti-
bacterial therapy, patient's intestinal defence mechanism was considered adequate.
The antibiotic cocktail inhibited the intestinal growth of lactobacilli and thus the lac-
tobacilli-mediated lactic acid production. This enabled the yeast to grow out mas-
sively. Immediately after an antibiotic course the abundant intestinal concentration of
yeast delayed the renewed outgrowth of lactobacilli, since the yeast consumed the
major part of the substrates available for microbial growth. The more the lactobacil-
li acidify the intestinal environment and pH decreases again, the more the lower pH
will inhibit the yeast to grow. With this explanation we want to emphasise that spe-
cific, metabolic processes of intestinal microbes are of essential importance in health
and disease. 
This case demonstrates that a massive amount of an intestinally present potentially
pathogenic yeast, e.g., C. glabrata does not cause disease, if the body is in a healthy
condition, and/or has body defence mechanisms. The main function of the selected
yeast is even to act as both a metabolic and a microbiological buffer: in the competi-
tion for substrates, the majority of yeast prevents the minority of lactobacilli to grow
out rapidly, and thus to acidify the body. The yeast also prevents lactobacilli to decon-
jugate cholic acids [9,10] and thus it strongly prevents the inhibition of cholic acid-
mediated uptake of fats and especially of lipophilic vitamins. 
This case also supports our hypothesis concerning the intestinal events of both pro-
biotic bacteria and yeasts [11], and the use of probiotic yeast as alternative for anti-
biotic therapy [12,13]. Simultaneously, the question rises whether especially during
childhood it may be a good choice to treat similar acidotic SSB-patients with a non-
pathogenic yeast, e.g., the probiotic Saccharomyces boulardii [14,15], concomitantly
with the antibiotic cocktail courses. 
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CONCLUSION
This case study explains by an ecological competitive mechanism why the empirical
procedure of intermittent antibiotic cocktail therapy mentioned above is effective to
combat the symptoms of the SSB-syndrome, e.g., D-lactic acidosis and lack of
lipophilic vitamins, and so justifies its use. However, this antibiotic therapy promotes
massive outgrowth of yeast, possibly pathogenic. It can be considered to replace this
yeast by a non-pathogenic one, like the probiotic Saccharomyces boulardii [16]. 
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ABSTRACT
Many septic periods during parenteral nutrition were observed in five young children
with a short small bowel. Immunological studies were performed in these patients.
Serum immunoglobulins and T-cell subpopulations were normal according to age. In
an ex-premature girl a normal development of mucosal immunity was demonstrated
in the bowel. After removal of central venous catheters, sepsis did not occur in these
children. Translocation due to enteric stasis, bacterial overgrowth, a central venous
catheter and parenteral nutrition play a more decisive role in developing septicaemia
than does immunity.
INTRODUCTION
Protection of an individual against harmful agents entering the digestive system
occurs in the first place via non-immune mechanisms like vomiting, gastric acid,
small intestinal mucus, intestinal motility and colonic defense mechanisms like the
balanced ecological system of the commensal flora.
Gut-associated lymphoid tissue (GALT), an important part of the lymphocyte based
adaptive immune system, needs specific recognition of cells and memory. The
immune response is predominantly humoral with IgA most prevalent in intestinal
secretions. Gut associated immunity develops parallel with other lymphoid organs
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and the development of the spleen and peripheral lymph nodes parallels the develop-
ment of Peyer's patches in the intestine. T- cells do not populate the intestine until the
thymus is ready to prime T-lymphocytes. This process starts during foetal develop-
ment and further maturation continues after birth. Gastrointestinal immune function
of the human infant is immature and remains so for the first months [1]. Within 1 or
2 weeks after birth IgA and IgM producing plasma cells are abundant in the lamina
propria and T-cells also develop. The immaturity of the neonatal gut barrier may
facilitate the passage of enteric bacteria across the intestinal mucosa [2]. GALT plays
an integral role in regulating transepithelial passage of bacteria by synthesizing more
immunoglobulins than any other lymphoid organ [3,4] and 80-90 % of this is secre-
tory IgA. A significant level of IgA is produced by neonates at the end of the second
week of life [1]. 
Short small bowel (SSB) is characterized by malabsorption and malnutrition as a
result of inadequate bowel length. In children we consider the diagnosis SSB as a
length of less than 75 cm for neonates born after 35 weeks of gestation and less then
50 cm at an earlier gestational age as measured during surgery [5]. 
In patients with an SSB, an extensive part of the mucosal immune system is removed
together with the intestine. In most children resection has been performed shortly
after birth when the mucosal immune system is immature. Systemic sepsis with gas-
trointestinal bacteria or fungi is frequently found [4,6]. It is generally assumed the
reason for these multiple infections is a diminished immunologic capacity after
extended resection. We therefore studied the immune competence in some children
with an SSB (Table 1) and report the findings.
Table 1. Patient data
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Patient year of birth gestational age length of bowel age on resection
CH 4 1990 at term 45 cm and colon 4 years
CH 5 1996 34 weeks 25 cm and colon 1 day 
CH 7 1996 33 weeks 50 cm and sigmoid 11 days 
CH 8 2001 at term 50 cm and colon 3 weeks
CH 9 2001 31 weeks 45 cm and colon 1 day
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PATIENTS
CH 4, a girl, was admitted at the age of four years with sepsis and fever caused by an
ischaemic intestinal accident. She developed multiple abscesses both around the
wound and intra-abdominally. After surgery she was totally parenteral nutrition (PN)
dependent and growth was delayed.
After the bowel resection, she suffered from sepsis due to Staphylococcus epider-
midis on six, and Enterococcus faecalis on three occasions. Klebsiella oxytoca,
Escherichia coli, Pseudomonas aeruginosa, a fungus, Rhodotorula species, and the
yeast, Candida guilliermondii were also identified in blood cultures at later occa-
sions. Gram-positive rods, one time identified as Lactobacillus species were cultured
on three occasions. In the last case she was on treatment with probiotic lactobacilli.
CH 5, a boy with a jejunal atresia developed diarrhoea and malabsorption after sur-
gery. He became totally PN-dependant. Several episodes of sepsis occurred. On
abdominal X-rays distended loops of bowel were often visible. Physical growth was
delayed. Blood cultures at different times revealed Klebsiella oxytoca, Enterococcus
faecalis, Enterobacter cloacae and Citrobacter freundii. Later Staphylococcus aureus
was isolated from an implantable vascular access system and Staphylococcus epider-
midis from a central venous line.
CH 7, a boy was born prematurely at gestational age of 33 weeks and a weight of
1510 grams. As a result of perinatal asphyxia he developed periventricular leucoma-
lacia. He was mentally retarded, blind and deaf. The indication for surgery was necro-
tizing enterocolitis on day 11. His physical growth was delayed. He suffered from
recurrent septic episodes with Enterobacter cloacae and Enterococcus faecalis
during the first 14 months, with multiple positive cultures of Staphylococcus aureus
from his gastrostomy.
CH 8, a boy, had only two umbilical vessels. At the age of three weeks he developed
acute abdominal problems due to malrotation and volvulus. A bowel resection was
performed. He received both PN and breast milk orally. Abdominal X-rays at the age
of 1 and 2 years showed dilated intestinal loops. Between the ages of one and 18
months he suffered on nine occasions from a Staphylococcus epidermidis infection,
as diagnosed by blood culture. At the point of skin entry of several central venous
lines he was however, colonised with Staphylococcus aureus.
CH 9, a girl, prematurely born at 31 weeks, had a deteriorating condition in utero
due to an antenatal volvulus because of a malrotation. Immediately after birth, sur-
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gery was performed with resection of necrotic bowel and construction of a jejuno-
stomy and ileostomy. PN was started and she was fed with breast milk.
Table 2. Immunological data of the patients Immunoglobulins in g/l, cells in 109/l 
At the age of three weeks she had a sepsis with Candida albicans isolated in three
blood cultures within one week and was treated with fluconazol. At the age of six
weeks, after closure of her ileostomy, she again developed sepsis with Morganella
morganii, isolated from eight blood cultures as well as from a culture of abdominal
fluid. Despite treatment according to antibiotic susceptibility testing, eradication
failed and she died two weeks later from ongoing sepsis.
85
Patient age IgG IgA IgM CD3+ CD4+ CD8+ 
CH 4 4 y 8.26 0.46 0.70
12 y 10.10 0.97 2.00 1.65 0.77 0.42
CH 5 8 m 4.12 0.64 0.77
2 y 2.7 1.0 0.57
4 y 12.5 1.74 0.82
CH 7 10 m 1.47 0.13 1.23
15 m 4.0 0.7 1.1
3 y 4.3 0.7 0.7
CH 8 2m 4.02 0.24 0.88 2.40 1.84 0.44
5 m 3.76 0.22 0.94
CH 9 1 m 2.05 <0.07 0.56 3.28 2.44 0.80
1.5 m 3.16 0.67 0.43
2 m 3.80 0.44 2.12
Normal values 
age IgG IgA IgM CD3+ CD4+ CD8+ 
newborn 6.1-15.4 0.01-0.04 0.06-0.3 2.8-6.5 2.1-4.9 0.5-1.6 (1 wk-2 m)
3 months 1.7-5.6 0.05-0.5 0.3-1.0 2.3-6.5 1.5-5.0 0.5-1.6 (2 m-6 m)
6 months 2.0-6.7 0.08-0.7 0.3-1.0
1 year 3.3-11.6 0.1-1.0 0.4-1.7
2-6 year 4.0-11.0 0.1-1.6 0.5-1.8
7-12 year 6.0-12.3 0.3-2.0 0.5-2.0 1.0-2.0 0.5-1.3 0.3-0.8
adult 7-16 0.7-4 0.4-2.3
Normal immunity in short bowel
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Figure 1. All figures are from the small bowel of CH9, figure a-e are 400 x, figure f is 200x
enlarged. Fig. 1a. Normal small intestinal villus at birth showing only an occasional lymphocyte
but no plasma cells. Fig. 1b. Normal villus at six weeks showing lymphocytes and plasmacells in
the lamina propria and several intra-epithelial lymphocytes. Fig. 1c. Normal small intestinal villus
at birth lacking lymphocytes and plasmacells. IgA staining is negative. Fig. 1d. Lamina propria at
six weeks showing IgA-positive plasmacells. Fig. 1e. Normal villus at six weeks stained for CD 3
showing positive T- lymphocytes in the epithelium and the lamina propria. Fig. 1f. CD 20 staining
showing the B- cells of a Peyer's patch in intimate relationship with the epithelium.
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Immunological results 
Immunological studies in all these children revealed normal values for immuno-
globulins according to age and normal T-cell immunity (Table 2). 
CH 9 showed a normal development of bowel immunity according to age.
Lymphocyte and plasma-cell development and the IgA-presentation at six weeks with
T- and B-cells are clearly visible (Figure 1). She also developed normal serum IgA
levels at two months despite her prematurity. She had excretion of IgA and some IgG
in the faecal fluid at the age of six weeks. All the children presented above had several
episodes of sepsis, both with intestinal and skin flora. They all had central venous
catheters and PN during this period. When parenteral feeding could be stopped and
the lines removed, the septic episodes ceased. 
DISCUSSION
Development of serum immunoglobulins and T cell immunity was normal according
to age in these young children. However, septicaemia was frequently demonstrated.
The age at which bowel resection is performed appears to be unimportant. The eldest
child CH 4 had similar problems with infections as the younger ones. 
Even in young infants the immunity of the remaining bowel develops normally after
surgery as CH 9 showed with normal mucosal immunity according to age (Figure 1,
table 2). However, despite development of mucosal immunity and excretion of secre-
tory IgA, she developed a fatal sepsis with species derived from intestinal flora.
Despite the normal development of the immune system, sepsis was common in the
children with SSB. The microorganisms most frequently determined were Gram-
negative rods and enterococci, originating from the bowel. These findings are in
agreement with a significantly higher incidence of catheter sepsis described in children
with SSB, with enteric organisms being responsible in 62% of these cases (6). Even
S. epidermidis can originate in the intestines (7). Children with a small bowel shorter
than 50 cm have a higher frequency of catheter-related sepsis, particular by enteric
microorganisms. Terra and co-workers have proposed a relationship between the
remaining length of the bowel and catheter-related sepsis (8). However, the length of
the remaining bowel below a certain length did not appear to be an important factor
in our patients. Extended small bowel resection is related to extensive loss of lym-
phoid tissue. Terra also suggested that the sepsis might be evidence of the occurrence
of bacterial translocation (8). Bacterial translocation can be defined as the migration
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of viable endogenous bacteria from the gastrointestinal lumen to the mesenteric
lymph nodes of other organs (9). It is related to rupture of the gastrointestinal barrier,
which occurs in situations as endotoxaemia, malnutrition, trauma and burns (10,11).
PN is also described as a predisposing factor (12). A reduced villous height and fre-
quent bacterial translocation in the group with a central venous catheters and PN has
been described (13).
Our oldest patient CH 4 had lost a major part of her small bowel at the age of four
years when she had already developed a normal immune response. Despite this, she
had sepsis with intestinal microorganisms similar to the youngest child suggesting
that immunity may be less important in translocation. 
Animal studies have shown that translocation increases with enteric stasis, bacterial
overgrowth and PN (2,11). Both enteric stasis and microbial overgrowth increase the
contact and contact time between the luminal wall and microbes, such as bacteria and
yeasts. This increases the chance that rupture of the gastrointestinal barrier may occur
and microbes translocate. Reduced gut motility may therefore be a more important
cause of translocation than reduced immunity. Our patients had dilatation of the
bowel when septicaemic. This dilatation can be seen as indicative of both enteric sta-
sis and bacterial overgrowth. However, after stopping PN and removal of the central
venous catheters the children did not have septicaemia any more, even when they still
showed dilatation of the small bowel.
These case histories suggest that the combination of a central venous catheter with
PN and the poor condition of the remaining small bowel play a more decisive role in
developing septicaemia due to microbial translocation than does a reduced immune
response. 
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ABSTRACT
Four children with a short small bowel and dependent on parenteral nutrition for more
than six months received short-term treatment with growth hormone for seven to
eighteen weeks in 1997. They all gained weight. One child achieved intestinal auto-
nomy. Three other children stopped parenteral nutrition temporarily, two during the
course and one three months later. Three years later these three children received fur-
ther treatment with growth hormone for one and a half to three years. One of them
almost achieved nutritional autonomy and a second child remained dependent on par-
enteral nutrition. In the third case parenteral nutrition did not need to be restarted.
Growth hormone had a positive effect on anabolism and height in all children.
Conclusion: Treatment with growth hormone contributed to improving the intestinal
function in these children with a short small bowel. There was an increase in height
even though the children did not reach target height. 
INTRODUCTION
Short small bowel (SSB) is characterized by malabsorption and malnutrition as a
result of inadequate bowel length. It can be defined either as resection of more than
70% of the small bowel, or as the need for parenteral nutrition (PN) for more than six
weeks after small bowel resection [17,22]. We consider 75 cm remaining jejuno-ileal
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segment for an infant born at term, and 50 cm for infants born between 28 and 35
weeks gestational age as our limits for an SSB. This is in accordance with the 30%
remaining intestinal length according to the measurements of Touloukian and Walker
Smith [20]. For children older than one year we keep 100 cm as the limit. 
Due to the loss of intestinal absorptive surface, children develop malabsorption and
malnutrition, which may lead to intestinal failure and dependency on PN. Frequent
complications of long-term PN are infections, thrombosis and cholestasis [19].
The prognosis of children with SSB depends mostly on the length and function of the
remaining part of the intestine and its adaptation. Patients who are dependent on PN,
even when it is administered at home and at night, experience a reduced quality of
life due to the impact of the administration of PN on daily life and the possible com-
plications [10]. 
Since the publication by Byrne [6] in 1995, the short-term use of growth hormone
(GH) has been proposed as a new treatment for children with SSB. The theoretical
basis is that GH has an insulin-like growth factor (IGF) mediated skeletal effect and a
direct non-IGF-mediated anabolic effect on muscle and fat tissue and thus probably
also on intestinal tissue. In a meta-analysis of all trials published up till 2001 Ling con-
cluded that the benefit of growth hormone and glutamine administration with or with-
out a high carbohydrate low fat diet, was marginal or nonexistent [12]. In a six months
trial on glucocorticosteroid-dependent children performed in 2002, Mauras showed
that GH could influence body composition, bone metabolism and linear growth [13]. 
Scolapio commented on the lack of any significant increase in fat absorption in all
published studies and advised against using growth hormone in patients with the short
small bowel syndrome [16]. In one of our previous studies [5] we found an explana-
tion for the disturbed fat absorption viz., the overwhelmingly high concentration of
lactobacilli in the intestines of patients with SSB is able to deconjugate bile acids.
This means that only small amounts of conjugated bile acids are available to facili-
tate the intestinal micellar uptake of triglycerides, fatty acids, cholesterol and
lipophilic vitamins.
PATIENTS AND METHODS
We studied treatment with growth hormone in SSB children dependent on PN for
more than six months. All the patients have been described previously [4]. Below
they are numbered in the same way.
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Table 1 summarizes the history of the four children and the age at which they started
GH treatment. 
Table 1. Histories of the four patients treated with GH for intestinal failure
CH 4 was a healthy girl until the age of four years when she suffered an acute intes-
tinal ischaemic accident and underwent bowel resection and several laparotomies.
She spent six months in hospital and received PN via a central venous catheter. It was
necessary to replace the central venous catheter eight times due to infections. She was
discharged home where she received home-PN for 3 years. In 1997 she was treated
with GH for a short term and 3 months later, after stopping PN a lack of growth
occurred. In 1999, PN was reinstituted initially via central venous catheters, but this
again caused frequent occlusion and infections, including one episode with a fungus
(Candida guilliermondii) thrombus in the heart. An arteriovenous shunt was con-
structed in 2001 and several revision procedures were necessary. After removal of the
central venous catheters, there were no more infections or septic episodes. 
CH 5 was born with intestinal atresia. At the initial laparotomy stomata were created
because of the difference in size between the jejunum and ileum. They could be
closed after five weeks. A resection of the ileocaecal valve was performed later
because of a nearly complete intestinal obstruction and suspected stenosis at that site.
At the age of 11 months, he underwent a bowel lengthening procedure according to
Bianchi [2] performed by professor K.L. Waag in Mannheim (Germany). This
improved intestinal passage and enabled enteral nutrition. Short-term GH and gluta-
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Year of Age at Small Ileo-caecal Parenteral Time short- Parenteral
birth resection bowel valve nutrition term GH- nutrition
length before treatment restarted 
short-term
GH treatment
CH 4 1990 4 years 45 cm + colon Present 3 years 9 weeks + after 15 months
CH 5 1996 1 day 25 cm + colon Resected 1 year 7 weeks + after 10 days
CH 6 1996 11 weeks 40 cm + colon Present 1 year 9 weeks -
CH 7 1996 11 days 50 cm + sigmoid Resected 1 year 18 weeks -
mine treatment for seven weeks was started two months later and because of the con-
tinuous need for PN, long-term GH treatment was started. He continuously receives, via
gastrostomy, Neocate Advance® an oligomeric nutritional formula based on amino
acids. This has improved bowel wall integrity, decreased the number of diarrhoeal
episodes and thus prevented dehydration, which was a common problem until that time. 
CH 6 was born prematurely at a gestational age of 31 weeks with a weight of 1185g.
He suffered from bloody stools in the first week of life and sepsis at seven weeks.
Necrotizing enterocolitis (NEC) was suspected. At laparotomy no necrosis or malro-
tation was discovered. He underwent seven more laparotomies for volvulus with
necrosis, abdominal abscesses and fistulae. While receiving PN central venous
catheters were replaced five times because of multiple infections and thrombosis of
the subclavian vein. 
CH 7 was born prematurely at a gestational age of 33 weeks with a weight of 1510
gram. After six days he was found to be suffering from NEC for which he underwent
multiple bowel resections. He also had cerebral damage due to perinatal asphyxia and
periventricular leucomalacia. We included this handicapped boy in the short-term and
long-term treatment programmes in an attempt to stop and later to prevent the
impending use of PN, as he had stopped growing in weight and height. 
In 1997, the four children received subcutaneous GH (Genotropin®) at a dose of
0.4 U/kg-1/day-1 (0.14 mg/kg-1/day-1) for 7 to 18 weeks and intravenous glutamine
(Dipeptiven®) 0.3 till 0.6 g/kg-1/day-1 in the PN solution depending on the amount of
PN the child received [21]. 
In 2000, we started long-term GH administration in three of these children: CH 4,
CH 5 and CH 7. They were treated with GH at a dose of 0.2 U/kg-1/day-1 (0.07 mg/
kg-1/day-1) for one and a half years (CH 7) and three years (CH 4 and CH 5).
Glutamine was not given in the long-term study. 
In all the cases, bowel length had been measured at the time of the most recent
intestinal resection (Table 1). 
During long-term GH, height and weight were measured every three months, and
IGF values were determined regularly. Patients CH 4 and CH 5 underwent total body
Dual Energy X-ray Absorptiometry (DEXA) to estimate the body composition on
four different occasions. For this purpose, a QDR4500 Elite (Hologic, Inc., Waltham,
MA, USA) was used. Bone mineral densities (BMD) of the lumbar spine (L1-L4) and
total body (tBMD) were determined, as well as the bone mineral content of the total
body (tBMC) and percentage of fat (%Fat). The DEXA scan was performed with the
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child lying lightly dressed on the pad. No sedation was used. Hologic's software and
database were used to process the data.
RESULTS
Table 1 summarizes the history of the four children and the age at which they started
GH treatment. They all had growth failure with height and growth beneath the 5th
percentile [1]. 
Short-term GH results 
CH 4 was still on PN at the end of the short-term treatment with GH, but later, the
central venous catheter was removed and PN stopped. She had gained 1.2 kg during
9 weeks of GH therapy. We tried to do without any parenteral therapy for 15 months,
but her condition deteriorated and we had to restart PN.
CH 5 showed a weight gain of 20% from 7.1 to 8.5 kg and we hoped he could
manage without PN but this proved impossible. After 10 days and a weight loss of
over 10%, he received another central venous catheter for PN.
CH 6 gained 20% in weight from 4.4 to 5.2 kg, he achieved intestinal autonomy and
it was possible to stop all PN after 9 weeks. He did not receive any further GH treat-
ment. He was discharged after spending ten months in hospital and has been doing
well ever since.
CH 7 gained 2.5 kg or 35% in weight and was managing without PN.
CH 4 and CH 6 did not suffer from oedema or hand pain, which are described as
side-effects of GH treatment [8, 18]. CH 7 showed a weight loss of 15% after stop-
ping GH treatment, but one week earlier PN had also been stopped. CH 5 showed a
10% weight loss after stopping GH.
After the short-term treatment, all four children could be weaned from PN.
Permanent intestinal autonomy was achieved in CH 6, while in CH 7 the result was
temporarily. In CH 4, PN was stopped after three months for a period of 15 months;
and in CH 5, PN could only be stopped for 10 days. 
Long-term results of GH treatment
Overall data recorded during the long-term treatment are presented in Table 2. Before
the start of long-term GH treatment the height standard deviation (SD) scores of CH
4, CH 5 and CH 7 decreased in one to three years by 0.8, 1.6 and 2.3 SD, respectively. 
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After the start of long-term GH therapy, increases were seen in height SD scores. These
were most obvious in the first year (0.7 to 1.0 SD) and became less in the second year
(0.2 to 0.4 SD).
Table 2. Height measurement and Body Mass Index in SSB-children on long-term GH treatment 
At the age of 12 years CH 4 is still dependent on PN for over 50% of her caloric
needs, but she has an anabolic status, reflected by greater muscular strength in
sporting activities, such as swimming. She is also feeling much better, but her walking
distance is restricted. 
At the age of seven years, CH 5 is still on PN for 5-10%, but at the start he required
over 50%. He receives home PN 1-2 nights a week.
CH 7 was treated with PN till the short term GH treatment and then stopped.
Without PN his condition worsened but the severe difficulties with earlier central
venous catheter insertion and complications made us decide to postpone PN admini-
stration and start GH again in an attempt to avoid restarting PN. He responded well
and was kept on enteral nutrition only. Growth hormone treatment was stopped after
one and a half years after reaching our goal of keeping him without PN. 
The three patients showed an increase in height SD score of 0.85, 1.46 and 1.37,
respectively. However, none of them reached the anticipated growth curve or target
height. BMI values increased in all patients (Table 2). 
Body composition was measured in two patients (Table 3). This could not be done
in CH 7, because of psychomotor retardation. CH 4 showed an increase in BMD of
the lumbar spine and total body. The increase in BMD of the lumbar spine was nor-
mal for her age; she remained on the same percentile. Total BMD did not increase as
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Age at Height Target height Weight for Body Mass Index
start long- SD score SD score height SD score
term GH SD score
treatment
Start End Start End Start End
CH 4 9 years - 2.62 - 1.77 + 0.21 - 0.51 0.30 - 0.51 0.31 
CH 5 4 years - 3.24 - 1.78 - 1.54 - 0.28 0.50 - 0.28 0.50
CH 7 4 years - 4.29 - 2.92 - 0.74 - 0.87 0.06 0.86 0.91 
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much as was expected for a girl of that age [23]. Her total fat percentage decreased
7.2%. CH 5 showed an increase in Body Mass Index (BMI) and a decrease in fat of
6.5%. Bone mineral content values did not increase significantly when corrected for
age. Indeed, the decreased. BMD of the lumbar spine did not increase over time,
which is abnormal and the tBMD even decreased.
IGF values varied during long-term GH treatment, but showed an overall increase:
in CH 4 from 9.4 to 16.6 nmol/l, in CH 5 from 11.1 to 19.5 and in CH 7 from 6.5 to
13.2 nmol/l. There were no significant changes in the other laboratory measurements
during the treatment period. 
Table 3. DEXA (Dual Energy X-ray Absorptiometry) body composition during long-term GH
DISCUSSION
All children had positive effects from GH therapy since they could endure more
enteral nutrition, and needed less PN, both in short and long-term treatment. Both
high and low doses of GH had positive effects.
Most of the previous publications on this subject were short-term studies with GH
dosages ranging from 0.024 [8] to 0.14 mg/kg-1/day-1 [23]. It was reported that 40%
of the patients could be weaned from PN. Double blind studies [15, 18], however, did
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CH 4 Bone Mineral Standard Bone Mineral Bone Mineral Fat %
Density lumbar deviation of Density total Content (g)
spine (g/cm2) the mean body (g/cm2)
Start 0.441 -2.7 0.784 754.0 26.2
6 months 0.462 -2.6 0.770 765.8 18.2
11 months 0.502 -2.4 0.778 819.3 17.4
16 months 0.517* -2.8 0.811 1035.5 19.0
CH 5
Start 0.420 -1.8 - - -
8 months 0.419 -2.0 0.723 416.2 19.5
10 months 0.436 -1.8 0.693 409.7 18.2
16 months 0.428 -2.4 0.678 410.5 13
* means significant increase
not confirm these results. In our short-term study, we used GH dosages of 0.4
U/kg-1/day-1 (0.14 mg/kg-1/day-1) in combination with glutamine and could wean the
patients from PN for some time. 
Glutamine is described as preferential nutrition for the small intestine in infants. It
provides energy for the enterocytes, promotes electrolyte absorption and supports
immune function [9]. Intravenous glutamine treatment may be of value to support
enterocyte metabolism in an effort to prevent infections from bacterial translocation
while enteral intake and absorption is still restricted. When total intestinal autonomy
has been reached after short-term GH and glutamine therapy it is not clear how much
either of these products contributed to the process.
In our long-term GH treatment program for SSB children, we prescribed the dosage
used normally in GH deficiency of 0.2 U/kg-1/day-1 (0.07 mg/kg-1/day-1) for one and
a half years (CH 7) to three years (CH 4 and CH 5) without glutamine. 
Long-term GH treatment may succeed in stimulating enteral absorption. This was
the case in CH 7 in whom treatment could be stopped after one and a half years upon
reaching our goal of intestinal autonomy. GH treatment without adequate enteral
feeding will not help to improve bowel function. In CH 4, PN was necessary despite
GH therapy. This might be explained on the basis of the nutritional problems of the
patient. Continuous abdominal problems, possibly caused by CO2 production of the
lactobacilli [3], contributed to the decision to stop enteral nutrition and restart PN in
the year before long-term GH therapy. She suffered frequent abdominal pain during
enteral nutrition and regularly refused to eat.
CH 5 is currently almost without PN despite the very long adaptation period of
seven years. This is in accordance with the hope of Schwartz et al. [14] that growth
factors may lead to permanent enhancement of intestinal function, eliminate the need
for PN and avoid intestinal transplantation. 
Ladd et al. also observed a late effect of GH supplementation on nutritional inde-
pendence in two children after treatment periods of 2.5 and 8 years respectively. One
patient became independent of PN, in the other patient PN requirements were great-
ly reduced [11].
We saw fewer episodes of sepsis in CH 5 and after adding GH at the age of four
years, they almost ceased. We are therefore not convinced that GH therapy facilitates
bacterial translocation as was suggested by Eizaguirre et al. [7]. The combination of
PN and a central venous catheter in children with SBB almost certainly leads to an
increased susceptibility to infections and sepsis, especially if insufficient enteral nutri-
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tion is provided to maintain integrity of the intestinal tract wall. No further infections
were seen after the construction of an arterio-venous shunt for PN administration.
GH treatment increased height SD scores in our patients, but not to target height. 
Decreases in fat mass and increases in BMI were measured, suggesting an increase in
lean body mass and thus anabolic condition as a result of GH treatment.
CONCLUSION
On the basis of this very limited study, we advocate to try treatment with GH in chil-
dren with SSB if their height and weight are without any gain for more than three
months and the children are receiving at least 25% of their absorbed calories by the
enteral route. We suggest starting with a high dose of 0.14 mg/kg-1/day-1 GH for six
weeks to three months and continuing for as long as necessary, maybe for several
years with a restricted dose of 0.07 mg/kg-1/day-1 GH to avoid as many side-effects as
possible.
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ABSTRACT
Drug therapy may become difficult, when a significant amount of the small intestine
is resected as in patients with a short small bowel. Drug absorption from the gastro-
intestinal tract is altered in these patients. However, this effect is variable in patients
and differs with each drug. Literature regarding clinical outcomes of normal or alter-
native administration routes in patients with a short small bowel is limited. We
explored what is written about the normal absorption of commonly used drugs and
what difference the resection of different but substantial parts of the small intestine
makes. Changes in the gastrointestinal tract after resection of more than 50% of the
small intestine cause malabsorption of macronutrients and micronutrients and may
alter the drug absorption process. The metabolic activity of the abundantly present
intestinal lactobacilli also can affect the enteral drug absorption in patients with short
small bowel, as this results in production of lactic acid, gaseous CO2, ethanol and an
increased bile acid deconjugation. Accelerated intestinal luminal transit time causes a
reduction in absorption of certain antimicrobial agents, digoxin, hydrochlorothiazide,
cyclosporin, cimetidine, mesalazine, oral contraceptives and levothyroxine. Gastric
hypersecretion and lack of sufficient contact time with the intestinal mucosa in short
small bowel patients leads to insufficient absorption of drugs such as omeprazole.
Successful treatment with warfarin, tricyclic antidepressants, metronidazole, flu-
conazole, procainemide, sotalol and pindolol are reported in several studies. Many
different factors cause this variability in drug absorption in such patients. Monitoring
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the serum drug concentration in these patients may ease dealing with the management
problems.
INTRODUCTION
The American Gastroenterological Association writes in a medical position statement
on Short bowel syndrome and intestinal transplantation: "Oral medication absorption
is often impaired and larger doses, intravenous, or sublingual delivery may be
required; significant interpatient variability may be observed" [1].
The management of patients with malabsorption after massive resection of small
intestine and oral medication remains a difficult clinical problem. Many medications
are available only as oral dosage forms, which limits the pharmacotherapy choice. To
understand the absorption of orally administered drugs in patients with short small
bowel (SSB), it is essential to understand not only the concept of normal absorption
and factors contributing to this, but also the consequences of the changed intestinal
flora with up to 100% lactobacilli. For many drugs, it is not clear in what part of the
intestine the absorption takes place and what the contributing factors are. This article
will discuss studies that have investigated the concept of drug absorption in the
patients with SSB.
We count 75 cm remaining jejuno-ileal segment for an infant born at term, and 50
cm for infants born between 28 and 35 weeks gestational age as our limits for a short
small bowel in accordance with 30% remaining intestinal length according to the
measurements of Touloukian and Walker Smith [2]. For children above one year we
keep 100 cm as the limit of an SSB. The American Gastroenterological Assocation
states that less than 200 cm. of functional small intestine is its definition of short
bowel syndrome [1].
Malabsorption of orally administered nutrition, vitamins, minerals and drugs
occurs, because of the incapability of the remaining small intestine to absorb enough.
The consequences in an individual depend upon a variety of factors such as the loca-
tion and extent of the resection, the state of the remaining bowel and existence of
other systemic diseases.
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DRUG ABSORPTION FROM THE GASTROINTESTINAL TRACT
Sites of absorption
There is little absorption in the mouth, because it is difficult to keep solutions in con-
tact with the oral mucosa for any length of time. Sublingual administration is an
effective method of administration. Following absorption within the oral cavity, the
drug gains access to the general circulation without first passing the liver.
Nitroglycerin is administered sublingually for a rapid relief of the pain of angina pec-
toris. Some substances such as nicotine may be administered in chewing gum, con-
taining the substance [3].
The stomach primarily functions as an organ of digestion, but some drugs will be
absorbed [4].  At normal gastric pH, weak acids, such as aspirin, non- ionised drugs
and lipophilic substances are absorbed from the stomach [5].
The small intestine represents the area with the greatest absorptive capacity. The
upper small intestine (duodenum and jejunum) plays the most important role in the
process of absorption of drugs because of its large surface area, its generous blood
supply and its permeable mucosa. The rate at which the stomach empties its contents
into the intestine affects the rate at which drugs reach the blood and the hepatic cir-
culation. The absorption of weak bases, which constitute the majority of commonly
used drugs, is particularly dependent on the speed with which they reach the intes-
tine. Slowing the rate of stomach emptying decreases the overall rate of intestinal
absorption. Many agents are preferably administered on an empty stomach with suf-
ficient water to ensure their rapid passage into the intestine [4,6].
The main function of the colon is that of reabsorbing sodium and water. Even
though the function of the colon is not fundamentally that of absorption, drugs that
escape absorption in the small intestine may continue to be absorbed in the colon.
Drugs such as diclofenac, metoprolol, isosorbide nitrate, nifedipine and oxprenolol
are completely absorbed in the colon. So there will be a normal bioavailability of
these drugs when the colon is intact and that means that patients with a jejunocolic
anastomosis should not have problems when receiving these drugs [7]. 
The rectum can serve as a useful site for drug administration particularly when the oral
route is unsuitable. The ease of access makes this route popular. The bioavailability of
drugs given rectally is better because of the partial avoidance of the hepatic first- pass
metabolism. However, absorption is not as rapid or complete as in oral administration
because of the restricted mucosa surface area and not all drugs are available in this
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form [6]. Drugs that can be given rectally are antiemetics such as metoclopramide
and analgetics like indomethacin, diclofenac, paracetamol and morphine [7]. Other
commonly used modes of drug administration are intramuscular, subcutaneous,
inhalational, intravenous and transdermal. These forms of administration are not dis-
cussed in this paper.
Table 1. Factors affecting drug absorption from the gastrointestinal tract 
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1 Formulation and characteristics of drug product:
a)Tablet disintegration time
b) Drug concentration
c) Dissolution time
d) Presence of excipients in tablet or capsule formulation
e) Stability in gastrointestinal tract 
f) pH of the drug 
2 Patient characteristics:
a) pH of lumen  
b) Gastric emptying time
c) Intestinal transit time
d) Surface area of gastrointestinal tract and motility
e) Gastrointestinal disease
f) Mesenteric blood flow
g) Presence of bile salts
3 Presence of other substances in the gastrointestinal tract:
a) Interaction with other drugs, ions
b) Exogenous substances (Food)
4 Pharmacokinetic characteristics of drug:
a) Drug metabolism by gut bacteria
b) Drug metabolism in gut wall
c) Enterohepatic recycling
5 Effect of the lactobacilli
a) Acidification due to fermentative lactic acid production
b) Increased intestinal passage due to production of gaseous CO2
c) Effect of D- lactic acid on intestinal epithelia 
d) Effect of ethanol on intestinal epithelia
e) Deconjugation of primary cholic acid with decreased uptake of 
lipophilic compounds 
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Drug Absorption Process
Drug absorption is mostly a passive, first- order process. The bioavailability, being
the fraction of the administered dose which is absorbed into the bloodstream, is
another important parameter [4]. Many factors influence the absorption of drugs
across membranes (Table 1). Absorption is dependent on drug solubility and the con-
centration of the given drug. Drugs given in aqueous solution are more rapidly
absorbed than those given in oily solution, suspension or solid form, because
aqueous drug forms do not have to be disintegrated and dissolved [8]. Other fac-
tors influencing drug absorption are: the site of absorption and the length of the
(remaining) absorbing surface, the circulation at the site of absorption and the per-
meability of the absorbing membrane, gastric emptying time which affects the rate
and extent of the absorption, changes in pH, intestinal luminal transit time, ileocoecal
valve function and intestinal adaptation [9]. 
SHORT SMALL BOWEL AND DRUG ABSORPTION
The mean length of the normal human small intestine is 575 cm, ranging from 400 to
800 cm in adults [10]. The intestines have a large reserve capacity. When more than
50% of the midsection of the small intestine is resected there may be a few symp-
toms, however when smaller parts of duodenum or the terminal part of ileum are
resected malabsorption may follow. 
Common causes in adults are Crohn's disease and bowel infarction due to vascular
occlusion. Volvulus in patients with a malrotation, atresia and necrotizing enterocolitis
are common precipitants in children and infants [11]. 
Massive resection of the small intestine may result in clinical consequences known
as short bowel syndrome with malabsorption of nutrition, drugs and micronutrients
(vitamins, electrolytes and minerals). Macronutrient absorption of protein and carbo-
hydrates may be undisturbed, but fat malabsorption may lead to steatorrhoea. In patients
with SSB enteral drug absorption may be adversely affected by the consequences of the
metabolic activity of the abundantly present intestinal lactobacilli, producing lactic acid
from sugars. The enteral uptake of drugs that must be protonated may be affected due to
the lactic acid production. Some heterolactic lactobacilli produce also CO2 and ethanol.
The gas may accelerate intestinal passage of food and drugs and cause diarrhoea. 
When only a small part of the ileum, the site for lipid uptake by conjugated bile
acid, is left, the enterohepatic absorption of intact bile acid will be reduced and these
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molecules will arrive in the colon and influence absorptive capacity. Stasis is also a
pathological consequence of small bowel resection, that may interfere with adequate
absorption [12]. The degree of malabsorption after intestinal resection varies. It is not
only depen-dent on the extension of resection, but also on factors such as patient's age
at the time of the first resection [13].
Within 24 hours after its resection, the remaining small intestine begins to undergo
significant structural and physiologic changes leading to an increase in the absorptive
capacity [14-16]. Resection of the jejunum results in changes in the ileum, which
takes on the structural and functional characteristics of the jejunum. This great adap-
tive capacity of ileum may be due to the shorter villi and superficial crypts in the dis-
tal part of the small intestine. The jejunum shows less adaptive response after resec-
tion of the ileum [17]. 
Another significant change after bowel resection is the rate at which food passes
through the intestinal lumen, which affects the intestinal absorptive capacity.
Normally the motility in the ileum is three times slower than in the jejunum. A faster
intestinal motility after ileal or ileocaecal resection leads to diarrhoea and malab-
sorption [16].
Jejunostomy and ileum resection both can cause a loss of bile salt reabsorption
which can lead to a poor absorption of drugs because bile salts are necessary for
absorption of drugs such as cyclosporine [18-20]. Lactobacilli have comparable
effects [12]. In these situations enterocoated cholestyramine tablets that are not
absorbed can be given. These tablets minimise the diarrhoea induced by bile salts,
because they disintegrate in the colon and can sequester the bile salts there without
having any effect on jejunal fat absorption or bile salts malabsorption [21].
DRUGS AFFECTED BY SHORT SMALL BOWEL
Drugs affecting the gastrointestinal tract and metabolism
Cimetidine
Cimetidine is an H2-receptor antagonist, that inhibits the secretion of gastric acid.
One of the characteristics in patients with an SSB is gastric hypersecretion in the first
months because of the decreased gastrin activity and a decreased level of the intes-
tinal hormones that inhibit gastrin activity [22]. Animal studies suggest that cime-
tedine is absorbed in the ileum. Russo et al. reported a patient with a massive bowel
resection (20 cm distal to the duodenojejunal juncture to the midtransverse colon).
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This patient received cimetidine for gastrointestinal symptoms. A reduced bioavail-
ability of cimetidine due to the rapid transit time was seen. Slowing the emptying
time may improve drug bioavailability [23].
Cimetidine reduces the gastric acid load to the duodenum. In a pilot study, Aly et
al. showed a reduction of faecal fluid loss in patients with diarrhoea after massive
ileal resection. They also mentioned that because of decreased drug absorption a
higher dosage might be necessary [24] .
Inhibition of gastric acid secretion will make the intestine vulnerable to micro-
organisms and yeast. 
Omeprazole
Omeprazole is a proton pump inhibitor. It slows gastric acid secretion and suppresses
the actions of Helicobacter pylori [25]. Omeprazole absorption may not be adequate
in patients with SSB because of a lack of sufficient contact with the intestinal mucosa
and because of gastric acid hypersecretion, which leads to a low pH in the duodenum
and upper jejunum. Nightingale et al. showed a reduction of intestinal output in patients
with SSB and a net decrease of secretory output after taking omeprazole orally before
breakfast. This effect however, was not enough to replace parenteral fluid and elec-
trolyte supplements [26].
Mesalazine (5-Aminosalicylic Acid)
5-ASA is administered to patients with chronic inflammatory bowel disease like
ulcerative colitis or Crohn's disease. Tablets of 5-ASA are coated with a pH sensitive
enteric soluble film that is degraded in the distal part of the small intestine. Without
this coating 5-ASA is absorbed in the stomach and duodenum and would have little
effect in the treatment of distal small intestinal diseases. The absorbed fraction is
redelivered to the intestinal lumen via the enterohepatic circulation. 5-ASA itself can
cause systemic toxicity or irritation of the GI tract when given orally in effective
dosage to achieve sufficient effect in the colon [27]. 
Mcleod et al. found a release of 5-ASA in the small intestine after administration
of Rowasa I (a 5-ASA preparation) in patients with small bowel resection. However
the authors could not draw any conclusions about its therapeutic effectiveness [28].
Oral 5-ASA administered soon after resection of the distal small intestine and
proximal colon delays the recurrence of Crohn's disease of the neoterminal ileum
and reduces its severity. Frieri et al. studied two groups of patients who received pro-
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phylactic treatment with 5-ASA after surgery. The rate of recurrence was significantly
higher in the group with an end- to-end anastomosis compared with an end-to-side or
side-to-side anastomosis. The mucosal concentration of 5-ASA in the neoterminal
ileum was significantly lower in patients with an end-to-end anastomosis. Drug
absorption was increased in the patients with end-to-side and side-to-side anastomo-
sis, suggesting that increased segmental transit time leads to a higher mucosal con-
centration and absorption in these patients [29].
Loperamide
Loperamide is a synthetic anti-diarrhoea drug. It slows gastrointestinal motility,
accelerates gastric emptying and reduces gastrointestinal secretion and so it has an
antidiarrhoeal effect. This effect is opiate receptor mediated [30-32]. Loperamide is
widely used in the management of chronic diarrhoea in patients with SSB. It has no
extraintestinal opiate effects on the central nervous system and no addictive charac-
teristics. However there may be a reduction in pancreatic and biliary secretions in the
patients with extensive bowel resection and this is not desirable in such patients [33].
Several studies have suggested loperamide to be effective in the treatment of diar-
rhoea in patients with SSB [34-39]. The enhancing effect of produced CO2 gas on the
peristalsis may influence the effect of drugs that slow peristalsis. 
Other anti-diarrhoeal drugs
Other recommended agents in the treatment of diarrhoea in patients with SSB are
opiates and octroide. Opiates slow down the intestinal transit time but are addictive
so patients should be monitored closely. Octroide, a somatostatin analogue, acts by
slowing the intestinal transit, and has an anti-secretory effect but also inhibits intes-
tinal absorption. Octroide can not be administered orally [39,40]. Rectal and colonic
administration of medications in SSB patients with severe diarrhoea has an unpre-
dictable effect. 
Drugs affecting the Cardiovascular System 
Antiarrythmics
Procainamide is an antiarrythmic agent that is almost completely ionised in the stomach
and absorbed in the small intestine. In a male SSB patient 26 cm of small intestine was
left and the patient had ventricular arrhythmias. Despite a reduced intestinal transit
time, minimal absorptive area and insufficient time for adaptation, therapeutic levels
108
Chapter 4
of procainamide were achieved in this patient. This could be partly due to the absence
of other intestinal diseases and partly because of the possible contribution of colonic
absorption [41]. Sotalol is a non- selective hydrophilic beta- adrenergic blocking
agent that is almost completely absorbed after oral administration. It undergoes no
first-pass hepatic metabolism and therefore its bioavailability is 90%-100%.
Bioavailability is reduced by 20% when food is present in the gastrointestinal tract
[42]. In two patients with atrial fibrillation and reduced intestinal length, normal
plasma concentrations were achieved after oral administration. In patients with severe
SSB (stomach, duodenum and only 50cm of jejunum) adjustment of the daily dose
led to a substantial increase of sotalol plasma concentrations [43].
Cardiac Glycosides 
Digoxin, a cardiac glycoside is absorbed in the upper intestine and in small amounts
in the stomach. A minimal length of duodenum and upper jejunum is necessary for
absorption. In subjects with a normal functioning GI tract digoxin has a bioavailability
of almost 80%. Digoxin malabsorption seems to occur in patients with an extremely
short length of functioning small intestine [44,45]. 
Digoxin is partly absorbed when administered directly into the lower jejunum or
upper ileum, the transverse colon and the sigmoid colon. Its poor solubility is the
critical rate-limiting factor in its bioavailibility. Patients with SSB seem to have
altered blood levels of digoxin when they use digoxin in the tablet dosage form. This
may be related to inadequate dissolution of the tablet before it passes the absorption
sites and not necessarily to a defect at the absorption site. Several studies suggest that
digoxin absorption may be improved in patients with intestinal resection when given
in liquid dosage form such as elixir [46-48], also after radiation induced malabsorp-
tion [47]. Even in a patient with an end jejunostomy and only 12-15 cm of remaining
jejunum a diminished absorption of oral digoxin was observed, but digoxin elixir
achieved a therapeutic serum concentration [45]. 
In another study oral digoxin tablet absorption was investigated in 14 patients in
whom varying amounts of ileum were resected. No correlation was found between
drug absorption (measured as the area under the serum concentration-time curve after
oral administration of single 0.5 mg doses) and the length of the resected intestine
[44]. Other studies suggest that the compensatory ability of the colon to absorb digoxin
achieves therapeutic concentrations in patients after resection of the total small
intestine [7].
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Ehrenpreis et al. reported a patient with only 18 cm jejunum and without continuity of
small intestine and colon. The authors explain that patients with an end jejunostomy
experience severe digoxin malabsorption and may need intravenous administration,
because of the inability to achieve the efficient therapeutic concentration after oral
administration [49].
Digoxin absorption may be influenced by other drugs like propantheline, which
decreases gastrointestinal motility. Propantheline appears to increase contact time of
digoxin with the absorption site, thereby increasing the amount of digoxin absorbed
from the administered tablets. Metoclopramide, which increases the gastrointestinal
motility, seems to decrease the amount of digoxin absorbed [46].
Betablockers: Pindolol
Pindolol is a beta-adrenoreceptor antagonist, used for treatment of hypertension,
angina pectoris, cardiac arrhythmias and prevention of a second myocardial infarc-
tion. The bioavailability of pindolol is high because of a rapid digestive absorption
and its low first pass effect. Evard et al. studied the bioavailability of pindolol in
patients with malabsorption syndrome. The average length of the remaining small
intestine after resection was 137 +/- 15 cm. Their study subjects included 7 patients
with SSB after ileal or jejuno-ileal resection. Oral pindolol was well absorbed in the
majority of the patients. In two patients there was a decreased absorption of pindolol
after total ileal resection, the authors could not explain this [50].
Diuretics: Hydrochlorothiazide
Hydrochlorothiazide is a commonly used thiazide diuretic agent with a relatively
long half-life [51]. The major part of the hydrochlorothiazide absorption takes place
in the duodenum and upper jejunum [52]. Backman et al. investigated the absorption
of hydrochlorothiazide in patients with a jejunoileostomy and ileocaecostomy after
intestinal shunt operations for obesity. The mean length of the remaining jejunum was
43 cm and of the remaining ileum 14.4cm. The total urinary recovery of hydro-
chlorothiazide was measured to determine its gastrointestinal uptake. They found a
50 % decrease in uptake and suggest the malabsorption of hydrochlorothiazid may be
due to a shortened intestinal transit time [53].
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Anticoagulants: Warfarin 
Warfarin is an oral anticoagulant. Its bioavailibility is nearly complete when the drug
is administered orally, intramuscularly, intravenously or rectally. Warfarin is usually
detectable in the plasma within one hour after oral administration. Case reports claim
that warfarin absorption is not affected by SSB [54,55].
Drug-drug interactions may prevent absorption, increase metabolism or antagonise
the effects of warfarin. Antacids such as magnesium or aluminium hydroxide have no
effect on the therapeutic serum concentrations of warfarin [56].
A precipitating factor in warfarin resistance may be intravenous lipid administra-
tion. Warfarin is absorbed in the stomach and proximal the small intestine, the presence
of food in the gastrointestinal tract may decrease the rate of absorption. Excessive
vitamin K may cause prolonged warfarine resistance. In a patient with SSB the small
intestine was resected with only 30 cm of jejunum left. The patient received subcuta-
neous vitamin K1. The bioavailibility values for warfarin were normal, which ruled
out any decrease in warfarin absorption. The investigators suggested exogenous vita-
min K to be responsible for warfarin resistance [54]
Lehman et al reported a patient with 15 cm jejunum, the ileum and proximal right colon
were also resected, and warfarin was almost completely absorbed in this patient [57].
A more recent study reported warfarin resistance due to reduced surface area for drug
absorption secondary to resection of duodenum and gastrojejunostomy. A patient with
total duodenectomy and gastrojejunostomy, but with intact ileum was treated with
oral warfarin for deep vein thrombosis. The decreased absorptive surface area of his
upper small intestine could be the reason for the warfarin resistance in this case [58].
Lutomski suggests that it may be more practical to use intravenous or subcutaneous
warfarin in the patients with malabsorption and resistance [59].
Drugs affecting Behaviour, Psychotic State, Pain Sensation and Muscle Control
Tricyclic antidepressants
Amitriptyline is a tricyclic antidepressant widely used for the treatment of major
depression. It is absorbed through the stomach and small intestine and its elimination
half-life is 15 hours. A case study reported good oral absorption and therapeutic
serum concentrations of amitriptyline after crushing the dose and allowing the pow-
der to dissolve in the mouth of the patient, having only 40 cm of proximal small intes-
tine [60].
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Nortriptyline, also a tricyclic antidepressant, is rapidly absorbed in the gastrointesti-
nal tract and is almost completely ionised in the stomach. Little is known about the
exact site of nortriptyline absorption within the intestines. Nortriptyline was well
absorbed in a patient with SSB after oral administration [61].
Paracetamol
Paracetamol is absorbed rapidly from the small intestine. The rate of absorption of
paracetamol seems to be dependent on the gastric emptying [62,63]. The most impor-
tant absorption site of paracetamol is the jejunum [64,65]. Patient's posture influences
the absorption of paracetamol, when the patient is lying down the absorption is
slowed [66]. Ueno et al investigated the absorption of paracetamol in patients with
SSB who had a duodenostomy or a jejunostomy (15-60 cm left after resection).
Paracetamol was mixed with a 200 ml liquid meal. They found a decreased absorp-
tion of paracetamol in these patients. The authors concluded that jejunum distal from
the duodenojejunal flexure is the site of absorption for paracetamol [64]. Paracetamol
can be administered rectally, but the absorption is slower in healthy people. 
Hormones and Related Compounds 
Oral Contraceptives
Oral contraceptive steroids are mainly absorbed in the small intestine. The bioavail-
ability of these drugs depends on the absorptive capacity of the small intestine.
Higher risk for contraceptive failure is reported in women with an ileostomy because
of the rapid gastrointestinal passage and the loss of enterohepatic recirculation of
steroids. The lowest levels of levonorgestrel were found in the patients with the
largest small bowel resection. Jejunoileal bypass may lead to a reduced bioavailabil-
ity of norethisterone and levonorgestrel [67].
Levothyroxine
Levothyroxine (L-Thyroxine) is prescribed in patients with hypothyroidism. Stone et
al. studied the absorption of L-Thyroxine in patients with SSB. The patients had a nor-
mal functioning duodenum and variable lengths of jejunum with an absent ileum. After
receiving sodium L-T4, the amount of radiolabelled T4 was measured in the patient's
circulation. There was no absorption of labeled T4 in-patients with a duodenum only
and a lower T4 absorption in patients with shortened bowel. The authors concluded
that the duodenum is not an important site for the absorption of L-Thyroxine and that
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in the patients with resected bowel there may be malabsorption of T4. They suggest
treatment with a higher dosage of this hormone. The authors were unable to draw any
conclusion concerning the involvement of ileum in the absorption of T4, because none
of the patients had an intact ileum [68]. As L-T4 absorption is better in the fasting
state, food intake should be avoided with L- thyroxine medication [69].
Drugs affecting the immune system: Cyclosporin
Cyclosporin is an immunosuppressant that is used to prevent rejection of organ trans-
plants and to treat severe autoimmune diseases that are resistant to other therapeutic
agents [70]. After oral administration, its absorption is slow and incomplete [71].
Cyclosporin absorption takes place in the duodenum and the jejunum [72]. Factors
affecting cyclosporin absorption are food, bile flow, gastrointestinal drug metabo-
lism, small intestinal transit time and absorption surface area [73]. Oral cyclosporin
was given in two patients with SSB, one with a renal transplantation and Crohn's
disease in the other. The investigators compared the drugs pharmacokinetics after
intravenous and oral administration. A therapeutic serum concentration was achieved
after intravenous administration, but both cases failed to achieve therapeutic
cyclosporine serum concentrations after oral administration. The critical limiting fac-
tor in cyclosporine absorption in both cases was the rapid intestinal transit time [74].
Antimicrobial Agents
Cefaclor is a cephalosporin that is administered orally. It is well absorbed throughout
the whole intestinal tract and its bioavailability is not significantly affected by food.
Oral cefaclor was not rapidly absorbed in a child with SSB who suffered from otitis
media, because of rapid transit through the shortened intestine and its half-life (36-46
min) [75]. 
Under normal circumstances cephalexin is extremely well absorbed enterally.
Trimethoprim is an antibacterial agent that is well absorbed from the gastrointestinal
tract [76]. Oral cephalexin and trimethoprim-sulfa both are used in children with
SSB. This was investigated in a study of five children with extensive resection of
small intestine in the neonatal period. The authors observed a reduction in absorption
of 10% to 50%, although therapeutic serum concentrations were achieved. They
explained that the fast passage in the upper small intestine might be the reason for this
decrease. The investigators also found that aminopenicillin and drugs with compara-
ble absorption rates such as penicillin, acidocillin, isoxicillin and macrolides are not
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absorbed sufficiently in children with resection of more than 100 cm of the small
intestine. This means that therapeutic concentrations are not achievable and it is
advisable to give these medicines when necessary as parenteral therapy [77].
Fluconazole is soluble in water and rapidly absorbed from the gastrointestinal tract
after oral administration, with about a 90% bioavailability [78]. Fluconazole was
rapidly absorbed in a patient with SSB. The gastric antrum, duodenum and ileum
had been removed, but the jejunum and colon were left intact [79]. 
Iacono et al reported a successful treatment with orally administered metronizadol
(20-30 mg/kg/day) in an infant with only 11cm of the intestine remaining [80]. Parson
et al reported the absorption of several antimicrobial agents in patients with Crohn's
disease that had undergone intestinal resection. They noted a decrease in absorption
of cephalexin, lincomycin, erythromycin stearate and rifampicin. They found an
increase in absorption of clindamycin, sodium fusidate and sulfamethoxazole [81].
Massive resection of the small intestine may lead to the loss of activity of mucosal
enzymes and enzymes produced by bacteria. This results in a reduction of the bio-
transformation of ester prodrugs to the active form, such as erythromycin, chloram-
phenicol, pivampicillin, but also steroids and other esthers [82]. Successful treatment
with orally administered antimicrobial agents is reported in most of the mentioned
studies. However, the undesirable disturbing effect of these drugs on the intestinal
microflora should be taken in consideration. Probiotics (lactobacillus casei and bifi-
dobacterium brevis) and prebiotic galactooligosaccharides are suggested in the treat-
ment of antibiotic induced diarrhoea in patients with SSB [83].
CONCLUSION
There are a few case reports of drug absorption in single SSB patients and some studies
with only small populations. Their findings and conclusions cannot be reflected onto
a larger population. The major characteristics of SSB patients are the short bowel
itself and the intestinal flora with up to 100% lactobacilli. These bacteria may
adversely affect intestinal events including drug absorption. This effect should be
added to the already existing variability in drug absorption in patients with SSB.
Because of this and the different remaining lengths and function of the remaining
small intestine in these patients, predicting drug dosage is difficult.
A patient with SSB requires alert pharmacotherapeutic care. It is of a great impor-
tance for clinicians to be aware of the variable drug absorption and the pharmacoki-
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netics involved in the treatment of these patients. Monitoring of serum drug levels in
these patients with SSB is essential. 
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SUMMARY
Intestinal transplantation has been available in other countries since 1985, but has not
yet been introduced in the Netherlands. We reviewed the literature on: (a) causes of
intestinal failure in children; (b) indications for intestinal transplantation and com-
bined liver-intestinal transplantation; (c) transplantation technique; (d) post-trans-
plant immunosuppressive treatment and its complications; (e) clinical course after
transplantation; (f) short-term and medium-term results of intestinal transplantation.
Implications of these data and developments for patients in the Netherlands with
permanent intestinal failure and dependency on total parenteral nutrition (TPN) are
discussed. We emphasize that close cooperation between the two centres that are
planning to perform the transplantations and the centres with expertise in the field of
TPN at home and in hospital is absolutely essential for the success of the national
intestinal transplantation programme. It is expected that in the Netherlands, the first
intestinal transplantation will take place in the year 2000.
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INTRODUCTION
A child with small bowel failure must be fed parenterally, so-called total parenteral
nutrition (TPN). If TPN is not started immediately, persistent diarrhoea and steatorrhoea
can lead to growth retardation, vitamin and trace element deficiencies, hypopro-
teinaemia, electrolyte disturbances and metabolic acidosis [1-3]. The aim of total or
partial parenteral nutrition is to achieve adequate growth, prevent malnutrition and
metabolic disturbances, while maintaining an optimal quality of life. If a child has
permanent intestinal failure, the prognosis of survival depends fully on being able to
administer TPN in the long-term with as few complications and side-effects as possible
[1-4]. Complications associated with the means of administration, chiefly via a central
venous catheter (CVC), include thrombosis and catheter infections. These can be fatal
owing to embolism and sepsis, respectively.
In young children, a major side-effect of TPN is disturbed liver function with
cholestasis; its pathophysiological mechanism is as yet unknown. Both intestinal and
TPN-associated factors seem to play a role. Examples of the former are multiple sur-
gical interventions, hypoperistalsis, bacterial overgrowth and disturbance of the
enterohepatic circulation. TPN-associated factors include catheter sepsis, inadequate
administration of glucose, fat and amino acids, macrophage activation by fats and
toxicity from trace elements (e.g. Al, Mn and Fe) [4-7].
In older children and adults, cholestasis is far less common; their complaints are
almost exclusively fatty degeneration of the liver and liver fibrosis.
TPN-associated cholestatic liver disease in young children is usually progressive
and leads irrevocably to biliary cirrhosis and ultimately to liver failure. This compli-
cation is a major cause of death in patients with permanent intestinal failure. Over the
past 15 years, children who could no longer receive TPN, whether or not they had
reached end stage liver failure, had a chance of further survival if they underwent
intestinal transplantation or combined liver-intestinal transplantation [7-13].
CAUSES OF PERMANENT INTESTINAL FAILURE
In children, there are important, but fairly rare, causes of permanent intestinal failure
besides the well-known short bowel syndrome (SBS), microvillus inclusion disease
(MID) and the chronic intestinal pseudo-obstruction (CIPO) syndrome. For example,
epithelial dysplasia is an extremely rare cause, in which intestinal failure occurs in the
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same way as in MID, as a result of massive intestinal malabsorption. Total agan-
glionosis of the small and large intestine leads to symptoms that resemble the CIPO.
Table 1. Causes of the short bowel syndrome in children 
The short bowel syndrome
This is the most important cause of permanent intestinal failure in children and adults.
The length of the small bowel in full-term neonates is 250 to 300 cm, increasing to
600 to 800 cm in adults. Its absorptive surface is 950 and 7500 cm2, respectively. The
presence of intestinal villi and microvilli greatly increase the surface area [2]. In the
SBS, the small bowel is so short that its functional loss leads to complaints and
abnormalities. Insufficient absorption of nutrients causes growth retardation,
micronutrient deficiencies and metabolic disturbances. A short small bowel is nearly
always the result of extensive intestinal resection and is very seldom a congenital
anomaly. In children, the indication for resection is a congenital anomaly of the diges-
tive tract or damage to the intestinal wall by inflammation, ischaemia or sometimes
trauma (Table 1). The presence of volvulus can inhibit the blood supply to the intes-
tine and lead to infarction (ischaemic necrosis). Intestinal infections caused by arte-
riosclerosis are very uncommon in children. Severe abdominal trauma can sometimes
necessitate extensive intestinal resection. Children with the SBS have the best prog-
nosis when their duodenum, distal ileum and the ileocaecal valve (Bauhini's valve)
remain intact [1-3,14]. By leaving the ileocaecal valve in situ there is less risk of bac-
terial overgrowth. In young infants, even the presence of 10-20 cm residual small
bowel, including the ileocaecal valve, improves their prognosis of becoming inde-
pendent of TPN. If the ileocaecal valve is removed, at least 40 cm of residual small
bowel is necessary. In a study on 27 neonatal intestinal resections, the presence or
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Congenital anomalies Acquired disorders
Gastroschisis Necrotizing enterocolitis
Intestinal atresia Crohn's disease
Malrotation/volvulus Trauma
Aganglionosis Infarction (arteriosclerosis)
Meconium ileus (in cystic fibrosis)
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absence of the ileocaecal valve was not a determining factor in whether or not the
children became independent of TPN in the long-term [15]. Besides the length of the
remaining intestine, its state is also important (normal or abnormal calibre, presence
of inflammation, bacterial overgrowth) and plays a role in whether or not TPN is per-
manent. If a child with the SBS is still dependent on TPN at the age of 36 to 48
months, then there is no chance at all that he or she will be able to function without
it in the future [15]. Intestinal transplantation might ultimately be the only solution.
Microvillus inclusion disease
The congenital anomaly MID was first described in 1978 [16]; it is a hereditary intes-
tinal disease. The microvilli of the enterocyte are morphologically abnormal in num-
ber and form. With the aid of electron microscopy, intracytoplasmic inclusions are
visible, in which the microvilli are partly recognisable. In addition, the enterocyte dis-
plays an increase in secretory granules, especially apical and lysosomal bodies [2,17].
Research into the genetic defect underlying this autosomal recessive hereditary
disease is well underway. The syndrome presents with secretory diarrhoea from birth
or shortly afterwards and threatened dehydration or weight loss if parenteral rehy-
dration and nutrition are not started immediately. In 1992, more than 30 patients were
reported to have MID worldwide [17]. Until now, six cases of MID have been
encountered in the Netherlands, of whom five died at the age of one or two years [18].
The chronic intestinal pseudo-obstruction syndrome
The CIPO syndrome refers to a heterogeneous group of disorders that are all charac-
terised by signs and symptoms of intestinal obstruction, without there being any indi-
cations of mechanical obstruction [19-21]. In children, the CIPO is mainly a primary
disorder that is congenital or acquired. Secondary CIPO occurs in a number of sys-
temic diseases (e.g. scleroderma) and chiefly affects adults. Depending on the patho-
anatomical substrate, the disease is classified as neuropathic, myopathic or idiopathic.
The small bowel is always involved, but other parts of the digestive tract can also be
affected. Complaints and signs of functional intestinal obstruction dominate the clinical
symptoms. In 50% of the children, the first symptoms arise in the neonatal period and
vary from ileus (bilious vomiting, swollen abdomen) and total food intolerance, to
severe chronic recurrent abdominal pain and persistent constipation. In some cases,
secretory diarrhoea occurs instead of constipation. The myopathic form involves
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more risk of intestinal perforation. Primary CIPO can be accompanied by a
megabladder and megaureters.
INDICATIONS FOR INTESTINAL TRANSPLANTATION
In children, the major indication for transplantation of the small bowel is the SBS
when it is very difficult to treat or untreatable [7-13]. In addition, intestinal trans-
plantation is chiefly applied to children with MID or CIPO [22-26]. If it is no longer
possible to administer TPN for permanent intestinal failure, then intestinal transplan-
tation is the only option left. The former indication arises when there are no more
venous access points for TPN; the second indication arises when life-threatening
complications occur repeatedly, such as recurrent sepsis. In order to avoid being pre-
sented with a fait accompli, it is necessary to consult the transplantation team at an
early stage to establish whether the patient should be and is a suitable candidate for
such a procedure. In children with comorbid liver disease and liver failure associated
with the administration of TPN, it must also be established whether it would be
better to perform combined liver-intestinal transplantation instead of intestinal
transplantation alone [11,27].
INTESTINAL TRANSPLANTATION TECHNIQUE
The abdominal viscera can be compared with a bunch of grapes. It is possible to
replace any organ (one grape) or a group of organs (a sprig of grapes) by means of
transplantation [28]. Blood is supplied to the abdominal viscera via two main routes:
the coeliac axis and the superior mesenteric artery. Both blood steams can be anasto-
mosed with the aorta in the supracoeliac area or intrarenal area. Venous drainage of
the combined liver-intestinal transplant occurs via the hepatic vein, which runs from
the isolated small bowel transplant via the portal vein, splenic vein, or directly into
the inferior vena cava (mesocaval shunt). It is possible to transplant the ileocaecal
valve and the colon of the donor at the same time. This promotes the absorbtion of
water and electrolytes.
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POST-TRANSPLANT TREATMENT WITH IMMUNOSUPPRESSIVE
DRUGS
It was not until after the introduction of the powerful immunosuppressive drug
tacrolimus (FK506) that intestinal transplantation became reasonably successful.
Tacrolimus is much more powerful than cyclosporine and moreover, is absorbed in
the upper part of the digestive tract [11,29,30].
Just as cyclosporine, tacrolimus is a T-cell inhibitor that depresses the production of
interleukins 2, 3 and 4 and also granulocyte factor and interferon-alpha. Just as
cyclosporine, tacrolimus has many side-effects. Well-known side-effects from
tacrolimus are increased susceptibility to infection, tremors, headaches, paraesthesia,
hyperglycaemia, diabetes mellitus, hypertension and renal function disorders. Less
frequent are electrocardiographic changes, tachycardia, peripheral oedema, elec-
trolyte imbalance and central disturbances, such as agitation, anxiety, confusion and
depression. In young children who are Epstein-Barr-virus seronegative, there is an
increased risk of lymphadenopathy and lymphomas [29]. Very rare side-effects are
(usually reversible) white matter disorders (leukoencephalopathy) that are associated
with the occurrence of convulsions [31]. Blood serum levels of tacrolimus must be
checked periodically. They must be checked frequently under the following condi-
tions: directly after transplantation, after adjusting the dosage, after switching to a dif-
ferent immunosuppressive drug and after the administration of any drugs that (might)
interact with tacrolimus. Examples of these are cyclosporine, amphotericin B
(nephrotoxic), acyclovir and ganciclovir (neurotoxic). In the initial stages, tacrolimus
is given intravenously (IV administration). As soon as possible after the disappearance
of postoperative ileus, oral administration should be started. Target blood serum levels
should not exceed 20 ng/ml (ELISA assay) [29]. Besides tacrolimus, cortico-steroids
are administered for several weeks. To support immunosuppression, prostaglandin EI
is administered for five days. In addition, support treatment with azathioprine is
given, initially intravenously [11,30].
COURSE AFTER TRANSPLANTATION
The condition of the liver transplant is monitored regularly by analysing the liver
enzymes and periodically by taking biopsies. Findings suspicious of intestinal trans-
plant rejection are: deterioration in clinical condition, increase or decrease in stomal
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production, abnormal endoscopic findings and histological changes that correlate
with rejection. Biopsies can be taken endoscopically by means of gastroduo-
denoscopy, endoscopy via the stoma or colonoscopy. In the initial stages or if the
patient's condition weakens, biopsies should be taken twice a week [11,33]. Rejection
is characterised by macroscopic and microscopic changes in the intestinal mucosa.
Initially, there is merely oedema, erythema, mucosal membrane fragility and loss of
peristalsis. This is followed by the development of aphthoid ulcerations and ulti-
mately by broad-based ulceration covered by pseudomembranes. Histologically there
is an increase in lymphocytes in the epithelium of the crypts and patchy epithelial
apoptosis. In the case of severe rejection, epithelial desquamation occurs together
with diffuse pseudomembranous enterocolitis [34]. Threatened rejection requires
adjustment of the immunosuppressive drugs and a short course of steroids. In some
patients, OKT3 is administered, which is a monoclonal mouse antibody directed
against the CD3 antigen of T-lymphocytes [11,29,30].
Infection prevention plays a central role in the success of intestinal transplantation
[11,27]. The compromised condition of the intestine and weakened defence easily
lead to Gram-negative bacterial infections. Translocation of Escherichia coli,
Klebsiella and Pseudomonas may cause life-threatening sepsis. To prevent this, selec-
tive intestinal decontamination can be applied, i.e. reducing the numbers of Gram-
negative aerobes in favour of the proliferation of anaerobes. To prevent infection
from Pneumocystis, cytomegalo virus and herpes, prophylactic medication can be
administered in the form of cotrimoxazole, ganciclovir and acyclovir, respectively. As
mentioned above, the latter two drugs can increase the neurotoxic action of
tacrolimus [30]. Once the postoperative ileus has subsided, feeding can begin via the
jejunostomy [11]. Preference is given to continuous drip-feeding with oligomeric
nutrition; its constitution depends on the age of the patient. Absorption capacity of the
transplant is reflected by the quantity and constitution of the stoma production. Fat
balance is useful once enteral long chain fatty acids administration has started. In the
absence of TPN, an increase in serum albumin level and the onset of body growth
indicate adequate intestinal function. Other useful parameters for the onset of absorp-
tion by the small bowel are serum levels of calcium, phosphate, magnesium, iron and
trace elements and the serum tacrolimus level with oral administration. As long as the
absorption capacity remains below par, TPN must be continued [11,27].
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RESULTS OF INTESTINAL TRANSPLANTATION IN THE SHORT AND
MEDIUM-TERM
In 1996, Grant reported the results of intestinal transplantation over the period 1985 to
June 1995 on behalf of the International Intestinal Transplantation Registry [8]. A total
of 180 intestinal transplantations were conducted on 170 patients in 24 programmes;
two thirds of the patients were children. The most important indication for intestinal
transplantation was SBS (64% of the cases), in 13% it was a malignancy (Table 2). In
38% of the patients, the small bowel was transplanted with or without large bowel, in
46% the intestine and liver, while 16% underwent multivisceral transplantation.
Table 2. Data from the International Transplantation Registry on 180 intestinal transplantations 
in 178 patients (52% male, 48% female), 1985-1995 [8] 
In the latter case, abdominal evisceration was necessary because of aggressive
tumours. In the total group of intestinal transplantations, survival of the transplant and
patient survival were considerably poorer in the patients treated with cyclosporine
(n=49, 28% of the cases) than in the patients treated with tacrolimus immunosup-
pression (n=129, 72% of the cases). Table 3 summarizes the results. In the total group
of 86 survivors, 78% were no longer on TPN, but were receiving oral nutrition. The
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Age (yrs) No. Indications (n=178) Year No.
0-5 79 Short bowel 114 (64%) 1985 1
> 5-10 19 Malabsorption 23 (13%) 1986 1
> 10-20 19 Motility disorder 15 (8%) 1987 3
> 20-40 44 Rejection 10 (6%) 1988 7
> 40 17 Tumour 23(13%) 1989 11
Other 1 1990 11
1991 14
1992 27
1993 40
1994 34
1995 (June) 31
majority of patients in the report had been followed-up for a relatively short time.
Survival was better after isolated intestinal transplantation than after combined liver-
intestinal transplantation or multivisceral transplantation. This might be related to the
difference in technical complexity of the interventions (isolated intestinal transplanta-
tion is in principle "more simple"), or to differences in the condition of the patients.
Nevertheless the mortality rate two years after isolated intestinal transplantation was
only 40%.
Table 3. Results of 180 intestinal transplantations (isolated bowel, liver-intestine and multi-
visceral) in 178 patients (52% male, 48% female), 1985-1995. Survival of transplant and
patient with cyclosporine or tacrolimus [8].
The next report from the International Transplantation Registry was published in
1999 [9]. In the last two years of the period from 1985 to February 1997, the number
of transplant centres increased from 24 to 33, the number of transplants increased
from 180 to 273 and the number of patients increased from 170 to 260; two thirds of
whom were children or adolescents. Since 1990, there has been a linear increase in
the number of transplantations, with a total of 58 in 1996. After February 1995, the
one-year survival rates for the transplant and patient in patients with isolated intes-
tinal transplants were 55% and 69%; in liver-intestinal transplants these rates were
63% and 65% and in multivisceral transplant patients, 63% and 63%, respectively.
Transplants carried out since 1990 and centres that had conducted at least 10 trans-
plants had significantly better transplant survival rates and patient survival rates; 77%
of the survivors no longer required TPN. The five-year survival rates were similar to
those for lung transplantation. An important aspect to prevent mortality in the case of
rejection was to remove the transplant at an early stage and restart TPN. The more
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Cyclosporine After 1 yr % After 3 yrs % Tacrolimus After 1 yr %   After 3 yrs %
(n=49) Trpl.*&pat.** Trpl.*&pat.** (n=129) Trpl.*&pat.** Trpl.*&pat.**
Intestine 17 and 57 11 and 50 Intestine 65 and 83 29 and 47
Liver-intestine 44 and 44 28 and 28 Liver-intestine 64 and 66 38 and 40
Multiviscera 41 and 41 41 and 41 Multivisceral 51 and 59 37 and 43
* transplant survival; ** patient survival
complicated clinical course had clear repercussions in the occurrence of more com-
plications than in heart, liver and kidney transplantation. Recently published results
from the major European intestinal transplantation centre that forms part of the
Hospital Necker-Enfants Malades in Paris on 26 children over the period 1987-1998
also showed improvement in the survival of both the transplant and the patient after
the introduction of tacrolimus [13]. In addition, less rejection was observed in com-
bined liver-intestinal transplantations, without increased mortality and morbidity. On
the basis of these results, it can be concluded that (liver-)intestinal transplantation is
a valid option for patients with permanent intestinal failure and life-threatening com-
plications from TPN.
An important consideration in intestinal transplantation is the burden on the child
and family. None of the studies mentioned above explicitly investigated quality of life
after intestinal transplantation. However, there is evidence that intestinal transplanta-
tion is associated with a clearly higher burden on the family [34]. On the other hand,
dependency on home-TPN is also associated with a considerable psychological bur-
den and decreased quality of life [35,36].
DEVELOPMENTS IN EUROPE AND THE NETHERLANDS
Only a limited number of European centres perform intestinal transplantation in chil-
dren. This also reflects a limited need. At the end of 1998 there were eight centres: in
Paris, Birmingham, London, Geneva, Strasbourg, Uppsala, Kiel and Coimbra
(Portugal). The vast majority of (liver-)intestinal transplantations in children (n=26)
were performed in Paris. At the end of 1998, seven children were still on the waiting
list for the intervention. In Birmingham, a total of seven transplants had been con-
ducted, but at the other centres only two, one or none [7].
In the Netherlands, policy regarding organ transplantation is prescribed by the
Guidance Committee on Organ Transplantation (Begeleidingscommissie Orgaan-
transplantatie (BOTX)). It is probable that the first Dutch intestinal transplant will
take place in the year 2000 and it is very unlikely to be in a child. Two Dutch centres
will perform intestinal transplants: University Hospital Groningen (UHG) and Leiden
University Medical Centre (LUMC). Working groups have been formed at both cen-
tres and have identified themselves via symposia, publications in popular scientific
literature and the lay press. It is of great importance that both groups have formulated
clear selection criteria and that both centres work in close collaboration with Dutch
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centres that have wide experience in the field of TPN, at home and in hospital. The
University Medical Centre Nijmegen St. Radboud supervises about two thirds of all
Dutch adults on long-term TPN at home. In addition, over the course of time, exten-
sive knowledge has been built up in the field of the metabolic aspects of the SBS in
children and adults [37,38]. Close cooperation between the transplant centres and the
centres with TPN expertise is of importance for several reasons. Firstly, candidates
for intestinal transplantation must be selected from the group of patients receiving
TPN. Secondly, it is necessary to continue TPN for some time after transplantation.
Thirdly, if intestinal failure recurs because of rejection of the transplant, then TPN
must be restarted at an early stage.
The Netherlands Society for Gastroenterology (NVG), the Section
Gastroenterology and Nutrition of the Netherlands Paediatric Association (NVK) and
the Netherlands Society for Paediatric Surgery are attempting to formulate and intro-
duce national protocols for TPN in children and adults. This is intended to contribute
to achieving optimal administration of TPN, with as few complications as possible.
Only patients with permanent intestinal failure, in whom TPN administration is
impossible or no longer desirable, form suitable candidates for transplantation. In
children with permanent intestinal failure and threatened total liver failure, liver-
intestinal transplantation should be considered at an early stage [7,11,13].
CONCLUSION
World-wide, two thirds of all the intestinal transplantations for permanent intestinal
failure are carried out on children. Despite improvements in immunosuppression,
intestinal transplantation and combined liver-intestinal transplantation are still asso-
ciated with considerable mortality, particularly in the medium-term. None of the
major studies published in the literature explicitly evaluated quality of life. However,
it can be assumed that in survivors, being able to live at home without TPN will at
the very least lead to clear improvements in quality of life. Intestinal transplantation
causes a heavy burden on the family. At present, intestinal transplantation cannot be
considered the standard treatment for permanent intestinal failure and should only be
reserved for a carefully selected group of patients. TPN must be totally impossible in
these patients, or clearly no longer desirable. Children with permanent intestinal failure
who develop early threatened liver failure should be considered for combined liver-
intestinal transplantation.
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ABSTRACT
A 9-year-old boy lost almost all his small bowel after an acute volvulus due to a con-
genital, but previously unsuspected malrotation. Survival using total parenteral nutri-
tion is possible in these cases, but the medical burden is heavy. Small intestinal trans-
plantation was performed for the first time in the Netherlands in 2001 and this patient
was treated 3 years earlier. The results of bowel transplantation are not as good as in
kidney or liver transplantation. A method of Ethical Case Deliberation helped to elu-
cidate the importance of each contribution in the discussion and provided space and
a broad basis for decision-making. The parents refused to allow parenteral nutrition
to be started because of the bad prospects for quality of life in the future and the med-
ical team, after thorough deliberation with specialists throughout the country, and
consultation of the literature, agreed. 
Conclusion: Despite the many different opinions, the parents felt accepted in their
refusal of treatment for their son and the team accepted the decision. 
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INTRODUCTION
When the whole small bowel is lost, treatment with total parenteral nutrition (PN) and
small bowel transplantation in the future should be considered. The results of intes-
tinal transplantation are not as good as for other organ transplants in terms of mortal-
ity and certainly not in morbidity [1,2]. How can we reach a decision to maintain a
child on PN and await transplantation or to deny such ''extraordinary'' treatment? [1]. 
In a 9-year old boy with sudden loss of the entire small bowel, a choice had to be
made whether to start treatment of the intestinal failure or not. The quest for optimal
treatment requires careful evaluation of all factors surrounding the child [1].
Discussion in the team according to a model of Ethical Case Deliberation (ECD) gave
everyone involved adequate time to discuss and contribute and in the end to reach a
decision with the parents. The decision led afterwards to much discussion on the ward. 
The Nijmegen method of ethical case deliberation
The Nijmegen method of ECD was developed in the Department of Ethics in co-oper-
ation with different clinical departments of our hospital in the early 1990s to facili-
tate decision-making through multidisciplinary case discussions (see Appendix). It
allows professionals to articulate, analyse and evaluate medical, psychological, social
and ethical aspects of problems in medical decision-making in clinical practice. The
aim is to improve the quality of medical decision-making in ethically difficult situa-
tions [7]. The deliberation procedure consists of four steps: 1. The formulation of the
ethical problem; 2. Gathering the relevant facts from the different professional view-
points, taking into account the medical, nursing, social, psychological and organisa-
tional dimensions; 3. Weighing the relevant moral considerations; 4. Decision-making.
The moderator, preferably an ethicist and not a member of the team, has the impor-
tant role of giving members of each professional group equal opportunity to express
their views. Because the facilitation follows a systematic protocol, the different pro-
fessional perspectives (of physicians, nurses, psychologists and social workers) can
be articulated at a foreseeable point in the process, thereby conveying the active par-
ticipation of all the relevant professional groups. In this way, the Nijmegen method
structures moral reflections into multidisciplinary team conferences. It aims to find
what is an acceptable and responsible action in what are often open and new situa-
tions. As such, the method is not based on a specific normative theory in ethics. The
assumption, however, is that there is intuitive access to moral questions. Moral ques-
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tions and problems arise in daily life and practice. Almost everyone has some sense
of right and wrong and, as a rule, perceives the moral dimension of actions and situ-
ations. ECD tries to shed light on this dimension. 
Both in ordinary language and in moral philosophy, the phenomenon of the intu-
itively accessible moral dimension of life has been interpreted in various ways. One
way depicts moral issues as questions of conscience which is understood both as a
reservoir of intuitive moral knowledge and as a trial court of ethical arguments. An
ECD using the Nijmegen protocol always starts on an intuitive level of moral con-
science. After that, it gathers all the necessary facts in order to think about the moral
problem being presented in a well-informed way. Next, it proceeds to more rational
arguments in favour of or against certain moral assumptions. In this way, initial moral
assumptions are critically assessed and weighed in a structured multidisciplinary
process of moral reflection. 
CASE REPORT
A 9-year-old boy experienced acute severe abdominal pain one evening. On exami-
nation in the local hospital that night the boy was in shock and had a painful
abdomen. At emergency laparotomy, a volvulus of the entire small bowel with necro-
sis due to a malrotation, was found. After an unavoidable resection, a duodenostomy 
was created and the ileum was closed 2 cm proximal to the ileocaecal valve. For post-
operative ventilation and treatment of septic shock, the child was transferred to the
paediatric intensive care unit of our university hospital. The next day a planned rela-
parotomy was performed and the duodenum sutured to the last centimetre of ileum to
avoid high output stoma problems. 
After the second operation the parents considered all the information provided and
chose to refuse treatment of the intestinal failure as proposed by the medical team.
The firmness of the parents' view to withhold treatment and the problems with this
decision of the nursing and medical team, led to the consultation of a psychologist to
facilitate the deadlocked positions [14]. On the 6th day after prolonged and intensive
discussions between the parents, the hospital ethics team, doctors and nurses, medical
treatment and artificial respiration were stopped. Sedation and pain treatment were
continued. The boy died the next morning with a high fever due to ongoing sepsis. 
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DISCUSSION
The moral problem 
The choice was to agree with the parents' wish to stop treatment or to start the usual
treatment with total PN against the parents' will [15]. All possible medical strategies
were considered [3,6] including total PN or as long as the boy should live or starting
PN and considering small bowel transplantation in the future. The last possibility was
to keep the child under sedation and see what happened without active treatment by
PN or respiratory support, offering only ''comfort care'' [1]. 
Medical dimension
The duodenum alone is not enough to survive on without intravenous nutrition, even
if the whole colon is present [8]. After survival of the acute illness the child could be
kept alive for a long time on PN, but normal feeding and drinking would be restricted
for the rest of his life. The quality of life in these cases is dominated by the complica-
tions of intravenous access to the great vessels. Liver failure occurring as another com-
plication of long-term PN, may require a combined liver and intestinal transplant.
Without total PN this patient would soon die. 
The results of intestinal transplantation in 1998 were reported to lead to a 55%
patient survival [11], and the morbidity is still very high [5]. The first bowel trans-
plantation on an adult in the Netherlands was performed in 2001, 3 years after this
child was treated. With little possibility at that time of future bowel transplantation,
starting a child on PN for an unknown number of years needs careful consideration
[4,12]. 
Nursing dimension 
Optimal care for children in the Paediatric Intensive Care Unit requires good co-
operation between parents and nurses and the confidence they have in each other can
help the child to withstand the severe illness that led to the admission to the intensive
care unit. In this patient, the parents believed there was no cure only palliation and
prolonged illness with the possibility of an unpleasant life and death. The nurses
invited the parents, who were present all the time, to assist with the daily care, but
this was too much for them. It made communication with the parents difficult [9]. The
parents also did not want the sedation of their child to be stopped. 
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Social and psychological dimension 
After gaining the confidence of the parents, the psychologist started the discussion
about ''to treat or not to treat''. The patient was a healthy boy, with a normal develop-
ment but few social contacts. His parents assessed that he would never accept and
cope with chronic disease, physical limitations, dependency on medical and invasive
treatment without any prospect of a normal life and being ''not the same'' as other chil-
dren of his age. They expected that he would blame his parents for having agreed to
prolong his life. They were very concerned about the way in which he would cope
with the fear for death and about their own coping with their son's illness. They also
worried about the emotional impact on the development and functioning of their 14-
year-old son. 
The patient was brought up in a rather closed family in a small traditional commu-
nity. The parents were only formally affiliated to a protestant community. The social
network consisted of the father's family and neighbours, from whom the parents
experienced practical but not strong emotional support. The father used few words
but showed his grief and emotions and underlined his concern and doubts about his
son's coping capacity. The mother was the only child of parents who both suffered
from serious chronic diseases. She cared for her parents until they died and had seen
her father suffer a great deal. She attributed his suffering to what she called mean-
ingless inhuman medical treatment that prolonged his life without any perspective.
She was determined not to treat her son likewise. Both parents gave the impression
that they fully understood the information of the doctors and they consulted their
general practitioner twice for additional information and support. 
The conclusion of the psychologist was that both parents, each from a different
frame of reference, were sincere and convinced that no treatment should be in their
son's interest. They said: if we were told that there would be a good chance for success-
ful transplantation in the long-term, we would never leave him and wait for a better
life. Now we are convinced death means a better outcome for him and we have to
cope with our grief and loss.
Organisational dimension 
After survival of the acute postoperative and respiratory care on the paediatric inten-
sive care unit, a transfer to a paediatric ward should be possible. When the medical
conditions were stable and the boy and his parents were accustomed to the ''life-line'',
parents can be taught the care of the central venous catheter and home administration
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of PN was foreseen. The medical system in The Netherlands o.ers every possibility
to start these children on PN and if necessary to continue this at night at home for the
rest of their lives, whatever the financial cost. 
Ethical considerations 
In the multidisciplinary discussion, some members of the team argued that active
treatment should be withheld while others pleaded to the contrary [13]. Arguments
in favour stated that if this boy would receive further lifesaving treatment, he would
be confronted with continuous medical care for the rest of his life and the parents of
the boy refused this [2]. To further assess the future quality of life, advice was sought
from paediatric surgical centres throughout the Netherlands, and the literature was
consulted. Nearly all consultants agreed that the quality of life would be strongly
diminished. PN is a medical treatment such as ventilation and its use should be clear-
ly decided upon. Therefore it should not be assumed that the patient or in this case the
parents wanted this without official consent [4,6]. Other members, arguing against
withholding active treatment, stated that everybody has a right to live. According to
them, the parents in this case should not deny this and decide for him. Because short-
term cure seemed possible and long-term support of life was available, treatment
should be started. They did not consider PN to be an ''extraordinary'' treatment [1].
Moreover, they were of the opinion that the benefits would outweigh the burdens for
the patient. 
Decision
The more important role of the parents arguments in cases where there is a strong
doubt about prognosis and outcome, are supported by Molenaar [10]. The right of the
parents to refuse PN without consulting their 9-year old son is in accordance with the
law in the Netherlands. Allowing the child to regain consciousness so that he could
express his feelings and participate in the decisionmaking seemed unethical. It was
doubted whether a boy of his age would be able to take responsibility in such a com-
plex and burdening decision. 
After difficult deliberations, the nurses, physicians, psychologist and the ethicist
decided to comply with the parents' wish not to start nutritional treatment and conse-
quently accept the inevitability of death. The alternative was a judicial review which
would have led to the responsibility for the child being temporarily removed from the
parents and given to the Council for Child Protection. After the acute hospital treat-
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ment, the care of the child, then dependent on PN and continuous medical interven-
tion, would have been returned to the parents and they would have had to live and
cope with that for the rest of the child's life.
The parents' decision did not alter after extensive discussions with the doctors,
nurses or the psychologist. The information on the subject of a future transplantation,
which was weighed and explained by different doctors was most important for their
decision [9]. Structured analysis of all the arguments and conflicting values made it
possible to reach an agreement with the present members of the team and with the
parents. Despite that, the death of this young boy placed a heavy burden on all mem-
bers of the team. The quality of life in children with a gastroenterological handicap
can be poor, but in most cases there is no opportunity to take a decision not to treat.
This boy was being actively treated for sepsis and kept sedated whilst on the ventila-
tor. This artificial support made it possible to choose carefully the option to stop treat-
ment and not to start unwanted PN. 
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APPENDIX: THE NIJMEGEN METHOD OF ETHICAL CASE DELIBERATION
PROBLEM
What is the moral problem? 
FACTS
Medical dimension 
How has the patient been diagnosed and what is the prognosis? 
What kind of treatment can be suggested? 
Does this treatment have a positive effect on the prognosis? To what extent? 
What will be the prognosis when this treatment is not prolonged? 
What are the chances of success with the treatment? 
Could the treatment be harmful to the patient's health? 
How do these positive and negative aspects lie with each other? 
Nursing dimension 
What is the nursing diagnosis of the patient? 
What kind of nursing plan is suggested? 
To what extent is the patient able to take care of him/herself? Is volunteer aid available? 
What arrangements have been made with regard to the division of tasks in care? 
Patient's values and social dimension
What is known about the patient's outlook on life? 
Is the patient a member of a religious community? 
How does the patient view illness? Has a need for pastoral care been expressed? 
What is the patient's social background? 
What are the consequences of the illness and treatment for the family, lifestyle and social position? 
Do these consequences go beyond the strength of the patient and his/her environment? 
Organisational dimension 
Can the patient's need of care be realised? (capacity, staff, equipment)
ASSESSMENT
Welfare of the patient 
What are the consequences of illness and treatment for the wellbeing of the patient? (joy in life, free-
dom of movement, physical and mental wellbeing; pain, shortening of life, fear etc.) 
Autonomy of the patient
Has the patient been well informed about his/her situation?
Has the patient been sufficiently involved in the decision-making process until now? 
What is his/her judgement on the pros and cons of the treatment?
Which values and opinions of the patient are relevant? 
What is his/her view on life-sustaining or intensive therapy? 
Is it right to leave the decision whether to treat or not to the patient? 
Chapter 4
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Responsibility of the health care professionals 
Are there differences of opinion between physicians, other health care professionals, the patient and
relatives about what should be done? 
Is it possible to solve this conflict by choosing a particular kind of health care policy? Has there been
sufficient consultation between the health care professionals involved? 
Have their responsibilities been sufficiently demarcated? 
How do health care professionals deal with confidential information (confidentiality)?  
Has the patient been truthfully informed of his/her situation (sincerity)?
Has the case given rise to tensions within the team the health care institute? (collegiality)? 
Can the suggested policy be accounted for in relation to other patients (justice)? 
Should health care providers take into account the interests of a third party? What are the relevant
guidelines of the health care institute?
Decision-making 
What is the moral problem in this case? 
Are there important facts still unknown? Is it nevertheless possible to take a responsible decision?  
Could the problem be interpreted in terms of (conflicting) values?  
Is there a way out of this dilemma? 
Which alternative way of acting is most in keeping with the patient's values? 
What other arguments are relevant to this decision? 
Which act is preferable, on the basis of the afore mentioned arguments? (treatment, changes in care,
consultation, referral, awaiting etc.)  
What are the actual obligations of the persons involved? 
Which questions remain unanswered? 
In which cases should the decision be revised? 
In what way can the decision and the evaluation be summarised?
Special circumstances
Incapable patients
How and by whom has incapability been established? 
In what way is the patient incapable? 
Is it of a temporary or a permanent character? 
Is there a prospect of recuperation of capability? 
Is it possible to postpone decisions until that time? 
What is known about the values the patient holds? 
Is there a capable representative of the interests of the patient? 
Children 
Has the child been given enough attention? 
Is the child capable of deciding for itself with regard to the treatment? 
Which alternative way of acting is most in keeping with the parents' set of values? 
What are the consequences for the child if the parents' view is or is not adhered to? 
Long-term treatment 
In which situations does the policy of care need to be evaluated and possibly revised? 
What is the patient's attitude with regard to policy changes? 
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GENERAL DISCUSSION
Children suffering from a short small bowel are often hospitalised for long periods.
They suffer from invasive medical treatment and are exposed to many complications.
This disturbs their physical and mental development and restricts and reduces the
quality of life of these children and their families. 
Every effort should be made to achieve nutritional autonomy in children with a
short small bowel. We have learned over the years to start enteral feeding early in all
these children by gradually increasing the amount and frequency of food. Since the
enteral absorption is abnormally low, the decrease in intravenous nutrition should not
be of equal caloric or fluid amounts as the increase of enteral feeding. Extra enteral
feeding may be needed to compensate for this insufficient absorption. 
After neonatal intestinal resection and sometimes also in older children, the infant
is started with mother's milk and this is continued for the first year or even longer.
Oligomeric nutrition on an amino acid basis can be provided if a child cannot tolerate
other enteral nutrition, such as protein hydrolysates [1]. For adequate adaptation more
complex enteral feeding is necessary. Glutamine is described as preferential nutrition
for the small intestine in infants. It provides energy for the enterocytes, promotes
electrolyte absorption and supports immune function [2]. As the amino acid based
enteral nutrition such as Neocate® contains over 10% of glutamine as part of its total
protein content, no additional glutamine administration is necessary.
All enteral nutrition, especially if the child needs continuous feeding over 24 hours,
is administered by gastrostomy to avoid the negative effects of a nasogastric tube,
such as gastrooesophageal reflux, pulmonary infections and feeding or speech distur-
bances. Still a small amount is always presented orally, but in some cases this may not
be enough to teach the child to eat everything by mouth when we think the stomach
and intestines can handle normal oral feeding. A child's feeding team consisting of
a paediatric gastroenterologist, dietician, specialised nurse, psychologist, speech
language therapist, paediatric physiotherapist and paediatric surgeon, is necessary
to advise how to overcome the eating problems of these children who have lost the
ability to eat normally. 
Surgery
Animal experiments were performed to evaluate at that time recommended opera-
tive techniques to improve the rapid small bowel transit and the reduced absorption
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of nutrients. The results showed the best way to repair the intestines, was an end-
to-end anastomosis and we decided after that not to perform any extra surgery in
children to improve absorption.
As loss of fluids and nutrients from a jejunostomy is difficult to deal with in
children, we close intestinal stomas early, 3-4 weeks after their construction, if the
condition of the child allows it. Since then we have had no child with a short
bowel syndrome and persistent jejunostomy or ileostomy.
Various operations are advocated nowadays to combat intestinal dilatation and
improve absorption. We very occasionally taper the small bowel but only when stasis
makes enteral feeding impossible, an operation is necessary. 
In 1997 in a case of extreme dilatation and stasis of the intestine in a boy of 11
months a lengthening procedure of the distended small bowel with longitudinal split-
ting according to Bianchi was performed in Mannheim, Germany. In 2002 we per-
formed the same operation in our clinic in a girl of 6 months. Both children amelio-
rated with regard to the passage of intestinal contents and it became possible to start
enteral feeding. 
Parenteral nutrition, if possible at night and at home is the first choice of treatment
if intestinal autonomy cannot be achieved. This can be given to adult patients for pro-
longed periods if no complications occur, as is proven in the University Medical
Centre Nijmegen, where some adults are treated for over 25 years with home par-
enteral nutrition (Naber, personal communication). 
The choice for intestinal transplantation might be made if all intravenous access
possibilities fail or there is no prospect of reaching intestinal autonomy in the coming
years after maximal supporting medical and surgical measures like lengthening
operations.
Bacterial flora 
The major part (up to 100%) of the intestinal flora in our children with a short small
bowel consists of non-pathogenic lactobacilli. These bacteria are generally considered
to be beneficial for the health of our patients. For this reason these bacteria should not
be killed by antibiotics. 
The explanation for this highly characteristic flora in children with a short small
bowel lies in the appropriate environment for the acid-tolerant lactobacilli in the duo-
denum. The pH is still low and there is - with enteral nutrition - enough malabsorbed
sugar available, which can be fermented by lactobacilli to lactic acid. This increases
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the acidic surroundings and promotes further growth of lactobacilli. The neutralizing
capacity of the pancreatic juice may soon be overcome and the acidic contents will
result in faeces with up to 100% of lactobacilli in a number of 1012 cfu/g faeces (nor-
mal count: 1011 cfu/g faeces) and a pH that may be as low as 3.9. Lactobacilli need
sugars for growth, which may intestinally have been produced from polymerised car-
bohydrates, e.g. starch; otherwise their numbers decrease rapidly. We observed this in
a child who, after stopping oral feeding when her abdominal distension caused
unbearable pain, had quick symptomatic relief.
It is just the high molecular volume of CO2 gas (22,4 l/mole gas) produced by
heterolactic lactobacilli that leads to a distended abdomen and diarrhoea. 
The produced lactic acid (two moles lactic acid from one mole glucose by homo-
lactic strains, one by heterolactic strains) may be D- or L-lactic acid. L-lactic acid is
harmless and broken down easily in children. In neonates and young children we
observed a very high serum D-lactic acid and a high urinary D-lactic acid excretion.
In contrast in adults only high serum D-lactic acid values were found. This is due to
the enzyme D-2-OH-acid dehydrogenase, which seems to clear D-lactic acid from the
blood in adults and children from about four to five years of age. If too much of the
produced D-lactic acid is not excreted in time, it causes D-lactic acidosis.  
Abdominal complaints, acidosis and even encephalopathy may occur. In the past
patients with a short small bowel and these complaints were treated with antibiotics
or starvation. However, the selection of other bacteria or even yeast by antibiotic
treatment can also be harmful and this brought us to probiotic treatment. When nor-
mal intestinal flora is disturbed by antibiotics, or when lactobacilli cause D-lactic aci-
dosis and gas problems, oral administration of probiotic Lactobacillus casei that pro-
duce only limited amounts of CO2, as replacement of the naturally occurring lacto-
bacilli, may alleviate the problem.
Lactobacilli in the duodenum resist the killing effect of bile acids by producing a
cholic acid deconjugating enzyme. The deconjugated cholic acid cannot be absorbed
by the intestine and so the normal enterohepatic cycle of cholic acids is severely dis-
turbed. This makes fat absorption difficult and creates steatorrhoea with loss of
absorptive capacity for the lipophilic vitamins, A, D, E and K. As lactobacilli do not
degrade proteins like many other bacteria, their effect on mucin is limited and this
spares the intestinal defence mechanism of mucin on the intestinal wall. 
If proton pump inhibitors are used to treat the gastric hyperacidity that occurs ini-
tially after bowel resection, they should be stopped as soon as possible after an adap-
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tation period. These inhibitors disturb the natural protection of the gastrointestinal
tract against all kinds of ingested microorganisms. Abnormal bacterial growth in
the small bowel may disturb the already compromised absorption of nutrients and
medicine.
If antibiotics are used to treat lactobacilli overgrowth and acidosis, a change of the
intestinal flora and thus of patient's metabolism is quite normal. During such long-
term treatment pathogenic yeasts, e.g. Candida glabrata may emerge. In such cases
we advocate the yeast Saccharomyces cerevisiae subspecies boulardii as a useful pro-
biotic that may be safer than the naturally occurring yeasts in a child.
Treatments should be aimed at dietary manipulation of the natural lactobacillus
flora or at replacement of this flora by a probiotic lactobacillus flora. In children with
a short small bowel and oral feeding consisting of a high carbohydrate, low fat diet
the major part of the intestinal flora consists of non-pathogenic lactobacilli as long as
no oral antibiotic treatment, neutralisation of gastric acid or inhibition of gastric acid
production has been induced. Replacement of the high carbohydrate low fat diet by a
low carbohydrate high fat diet may greatly reduce the many typical symptoms related
to lactobacilli-mediated sugar fermentation and even the percentage of lactobacilli in
the intestinal flora.  
Replacement of the natural lactobacillus flora of patients with a short small bowel
by probiotic L-lactic acid producing facultative heterolactic lactobacilli will reduce
also problems, which are due to intestinal sugar fermentation. 
Venous access and infections
The administration of parenteral nutritional solutions requires intravenous catheters,
subcutaneous portals or arterio-venous shunts, all with their own problems and com-
plications. The parenteral solution itself may also be harmful and may lack some
necessary nutrients. Technology is constantly improving these solutions but intra-
venous access remains the greatest challenge in such children. 
Children with a short small bowel often suffer from serious systemic bacterial or
mycotic infections. Septicaemia is often due to translocation of intestinal bacteria.
The infection may cause a temporary ileus, and so enteral feeding has to be stopped.
It worsens liver function and promotes cholestatic icterus. A disturbance in the develop-
ment of immune reactivity in some children could not be demonstrated. The combi-
nation of parenteral nutrition by a central venous catheter and bacterial translocation
from distended bowel seems to be the main problem since infections did not occur
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after removal of the central venous catheter, despite the continuing bowel dilatation.
Subcutaneous portals produce the same problems. Repeat intravenous antibiotic treat-
ments and selective intestinal decontamination may also lead to unwanted and resistant
bacteria or yeasts. These can be difficult to treat and can be life threatening to the
patient. Selective intestinal decontamination has to be used, when the antimicrobial
action of the spontaneously occurring lactobacilli will not suffice for eradication of
possible pathogens, or when a small bowel biopsy shows a villous atrophy, ascribed
to bacterial overgrowth.
Growth
Children with a short small bowel are in general shorter than children with a normal
length of intestine. Growth hormone treatment was used in a child to increase her
restricted length. Later four children were treated with growth hormone for a short
term in combination with glutamine and complete intestinal autonomy could be
achieved in one child, temporarily in the others. In our long-term use of growth hor-
mone alone in three children, height could be improved in all three. All children
achieved a better anabolic condition. The exact contribution of growth hormone to
intestinal autonomy needs further study.
Different strategies are often applied together when treating children with an SSB.
The bowel lengthening operation in a boy at 11 months (CH 5) improved the peri-
stalsis and made enteral feeding possible. The start of enteral oligomeric amino acid
solution at the age of two and a half years improved bowel wall integrity, decreased
the number of diarrhoeal episodes and prevented dehydration, which had been a com-
mon problem until that time. We also saw fewer episodes of sepsis and after adding
growth hormone at the age of four years, they almost ceased. Therefore, we are con-
vinced that growth hormone therapy is not facilitating bacterial translocation.
However, it was only after the start of selective intestinal decontamination that par-
enteral nutrition could be diminished from seven to two times a week. Since then
there have only been a few periods of serious illness. We assume that in order to
achieve complete intestinal autonomy, it will be necessary to change to another oral
diet, which contains more nutrients that are known to stimulate bowel adaptation, as
this boy is currently almost on complete enteral nutrition after a very long adaptation
period of seven years. 
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Ethics
In an ethical study we considered the rights and motives of parents who refused the
starting of parenteral nutrition for their child. This was done in complete accordance
with Dutch law. This decision was taken by the parents and supported in the end by
the team. This family and boy would have been subjected to the long and difficult
administration of prolonged parenteral nutrition and even eventually transplantation.
Stopping all active treatment led to the death of the child and this was very difficult
for all the involved health care workers. A good functioning ethical team with proper
judgement of all viewpoints was essential in reaching a decision acceptable to all
people involved. 
CONCLUSIONS
Each patient with a short small bowel needs individual judgment and individual
therapy by a dedicated committee for nutrition and feeding problems in order to pre-
vent complications, achieve an early anabolic state and help to reach the ultimate goal
of complete intestinal autonomy.
Satisfactory height and weight growth on enteral nutrition remains the cornerstone
of the evaluation of children with a short small bowel. A careful estimation of the
child's wellbeing by an experienced team not only of nurses and doctors, but also
many other child health care providers involved, is essential. Maximal support for
these children and their families is invaluable. 
FUTURE PERSPECTIVES
Prevention of a short small bowel will not be possible in all cases. Improvements in
neonatal care with attention to an adequate intestinal circulation in premature babies
may help to prevent loss of intestine. Volvulus of the bowel in malrotation can some-
times be recognised earlier especially when associated with other anomalies and
operated in time.
Increased interest in diet therapy with a high fat diet in contrast to high carbohy-
drate might help to improve intestinal function faster than at this moment.
Growth hormone therapy deserves another trial as a general anabolic medicament
with an increased growth and improvement of bowel absorption.
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Further study of the microbiological flora in the intestines of children with a short
small bowel during parenteral nutrition is necessary. It may help to prevent the
disastrous effects of translocation and sepsis or present a better insight in therapeu-
tic possibilities. Probiotics such as Lactobacillus casei or Saccharomyces boulardii
reduce gas formation and thus abdominal complaints and dilatation [3].
Severe dilatation without stasis is no indication to operate but stasis of intestinal con-
tents with severe dilatation of the bowel may be treated surgically by serial transverse
enteroplasty, a novel bowel lengthening procedure described by Kim [4]. This
operation seems to improve bowel passage even better than the longitudinal splitting
and lengthening operation described by Bianchi [5]. 
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Summary
SUMMARY
In the introduction the definition of a short bowel syndrome and the normal length of
small bowel is described. The causes and some consequences in children with a short
small bowel are explained. The aim of the study and the contents of the different
chapters are also presented. 
Chapter 2.1 describes our work on dogs in the animal laboratory where we tried to
find ways to slow down the rapid transit through the short small bowel and improve
intestinal absorption. Creating antiperistaltic segments or circular loops did not help.
Stasis of the intestinal contents that occurred in the reversed segments worsened the
condition of the dogs. A simple end-to-end anastomosis was best. We therefore decided
not to add any constructive surgical techniques to the end-to-end anastomosis.
Chapter 2.2 explains our definition of a short small bowel and how surgical treat-
ment can contribute to the short small bowel and the vascular access problems. We
identify the paediatric patients, as they appear numbered in the different studies. An
overview is presented of the problems we had to deal with and the important mor-
bidity and mortality we encountered in these children. 
Chapter 2.3 presents the results of 33 children who underwent surgery for malrota-
tion within a study period of one year. In two infants, resection of the twisted part of
the intestine led to a short small bowel. We think that all children with malrotation
should undergo surgery in order to prevent life-threatening volvulus. However, the
intestinal motility problems that these children have will not be cured by this opera-
tion and this should be explained to the parents.
Chapter 3 is the heart of our work and explains the important role of the microbio-
logical flora in patients with a short small bowel. 
Normal intestinal flora development is discussed in Chapter 3.1.
Chapter 3.2 gives biochemical and microbiological explanations for the high con-
centrations of intestinal lactobacilli flora found in our patients. 
Chapter 3.3 explains the role of lactobacilli in the mechanism that involves decon-
jugation of the bile acids. 
Chapter 3.4 describes a side-effect of heterolactic strains of lactobacilli i.e., the pro-
duction of CO2. This gas formation causes abdominal pain and diarrhoea.
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Treatment with antibiotics is often necessary in children with acidosis but this may
lead to the overgrowth of yeast, which is considered to be detrimental. In the case
presented in Chapter 3.5, the girl improved and functioned well despite a high con-
centration of potentially pathogenic yeast in her intestinal flora.
Chapter 4 describes various consequences of a short small bowel.
Chapter 4.1 considers the immune status of some children, because we thought it
would be disturbed by the lack of a large part of the small bowel. Despite the fact that
we observed normal development of the immune system in a premature child, she
died of untreatable septicaemia. We assume that the combination of bacterial translo-
cation with parenteral nutrition and a central venous catheter contributed to the problem
of sepsis. Development of immunity was normal in the children studied.
In Chapter 4.2 four children with a short small bowel received short-term treatment
with growth hormone. Three of them later had long-term treatment in an attempt to
improve intestinal absorption and to find a solution for their catabolic state. Their
height improved, but two of them have not yet obtained intestinal autonomy and still
need parenteral nutrition.
Patients with a short small bowel also need medication. However, after enteral
administration, no one knows whether it is absorbed or how it will work. In Chapter
4.3 we review the limited literature to find an answer to this question.
If all treatments fail, bowel transplantation can be performed. We considered the
results achieved with intestinal transplantation in children worldwide in Chapter 4.4.
In a very low birth weight infant with a completely necrotic intestine, the decision not
to treat may seem reasonable. But, what do you do if the parents of a school-age boy,
with acute loss of all small bowel, refuse parenteral nutrition? Options are discussed
in Chapter 4.5.
Chapter 5 describes what we have learned from our biochemical and microbiological
examinations and considers various strategies for the future. The treatment of chil-
dren with a short small bowel must be performed within a team of different profes-
sionals and will continue to be a long and difficult process.
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Samenvatting
SAMENVATTING
In de inleiding wordt een definitie van het korte darm syndroom gegeven en onder-
zoek naar de normale lengte van de dunne darm bekeken. De oorzaak en enkele
gevolgen van een korte dunne darm bij kinderen worden besproken. Het doel van de
studie en de richting van de verschillende bijdragen worden hier aangegeven.
Hoofdstuk 2.1 beschrijft ons werk in het dierenlaboratorium, waar we een manier
zochten om de absorptie in de darm te verbeteren door de versnelde darmpassage te
vertragen. Antiperistaltische of cirkelvormige darmlissen maken, bleek niet te helpen.
Stasis van de darminhoud als gevolg van het omgekeerde stukje van de dunne darm,
werd slecht verdragen. Een eenvoudige directe verbinding tussen de darmuiteinden
na verwijderen van het grootste deel van de dunne darm, functioneerde het beste.
Daarom hebben we besloten geen andere operaties erbij te verrichten. 
Hoofdstuk 2.2 geeft onze definitie van een korte dunne darm en legt de chirurgische
bijdrage aan het probleem van de korte dunne darm uit en de problemen met de toe-
gang tot het vaatstelsel. Het geeft meer uitleg over de kinderen, zoals ze onder num-
mer in de verschillende publicaties voorkomen en een overzicht van de belangrijkste
ziekteproblemen en de oorzaak van het overlijden van sommige kinderen.
Hoofdstuk 2.3 presenteert de 33 kinderen die wij in 2001 behandelden voor een mal-
rotatie. Twee baby's hielden na resectie van de gedraaide en afgestorven darm een
korte dunne darm over. De vraag of alle kinderen met een malrotatie geopereerd
moeten worden, moet volgens ons bevestigend beantwoord worden. Hiermee kan een
levensbedreigende draaiing worden voorkomen. Ouders moeten gewaarschuwd wor-
den dat problemen van obstipatie door een verminderde beweeglijkheid van de darm,
niet opgelost worden door de operatie.
Hoofdstuk 3 vormt de basis van ons werk en geeft een verklaring voor de zeer belang-
rijke rol van darmbacteriën bij patiënten met een korte dunne darm.
De normale ontwikkeling van de darmflora wordt besproken in hoofdstuk 3.1.
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De biochemische en microbiologische verklaring voor de flora met een zeer grote
hoeveelheid melkzuurbacteriën, die wij in de darm van onze patiënten ontdekten,
wordt in hoofdstuk 3.2 beschreven.
De rol die de melkzuurbacteriën spelen in het mechanisme van de afbraak van
galzuren en de gevolgen daarvan wordt in hoofdstuk 3.3 uitgelegd.
Een van de bijkomende effecten van bepaalde stammen van melkzuurbacteriën is het
maken van koolzuurgas: de klachten van buikpijn en diarree, die daardoor worden
veroorzaakt, worden in hoofdstuk 3.4 beschreven.
Behandeling met antibiotica is vaak nodig en kan leiden tot een schadelijke overgroei
van gisten in de darm. Het meisje in hoofdstuk 3.5 werd juist beter en voelde zich
goed met een grote hoeveelheid mogelijk schadelijke gisten in de darm.
Hoofdstuk 4 behandelt de gevolgen van een korte dunne darm.
In hoofdstuk 4.1 hebben we de afweer van sommige kinderen onderzocht, omdat
we aannamen dat die gestoord zou zijn als een groot deel van de dunne darm,
waarin een belangrijk deel van het immuunweefsel zit, verwijderd werd. Ondanks
een normale ontwikkeling van de afweer overleed een te vroeg geboren kind aan
een onbehandelbare sepsis door een normaal in de darm voorkomende bacterie.
Voeding via een infuus verandert de doorlaatbaarheid van de darm voor bacteriën.
Bij een direct in de bloedbaan gelegen lijn kunnen de bacteriën daarop gaan groeien.
Om de opname van voedingsmiddelen in de darm, de katabole toestand en de ver-
minderde lengtegroei te verbeteren, beschrijven we in hoofdstuk 4.2 een proef waar-
bij vier kinderen  kortdurend en drie ervan later langdurig groeihormoon toegediend
kregen. Hun lengtegroei nam wel toe, maar een complete aanpassing van de darm,
zodat voeding via het infuus niet meer nodig was, werd niet bereikt bij twee kinderen.
Patiënten met een korte dunne darm hebben soms ook geneesmiddelen nodig, maar
niemand weet wat de opnamemogelijkheden zijn en wat daar invloed op heeft. We
hebben uitgezocht hoe weinig en wat er over geschreven is. Dat staat in hoofdstuk 4.3.
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Als iedere behandeling mislukt, kan nog een dunne darmtransplantatie worden ver-
richt. We hebben de resultaten bij kinderen van een darmtransplantatie in de literatuur
bestudeerd en beschreven in hoofdstuk 4.4.
Bij een te vroeg geboren kind met een heel laag geboortegewicht en een totaal
afgestorven dunne darm, kan de beslissing om niet te behandelen moeilijk zijn. Bij
een kind op de lagere school met plotseling verlies van zijn hele dunne darm,
weigerden de ouders levensreddende behandeling met voeding via een infuus. Dit
veroorzaakt ethische vragen. Deze worden in hoofdstuk 4.5 behandeld.
Hoofdstuk 5 beschrijft wat we geleerd hebben van alle biochemische en microbiolo-
gische onderzoekingen en geeft een aanwijzing voor toekomstig beleid. Behandeling
van kinderen met een korte dunne darm zal altijd in multidisciplinair verband moeten
gebeuren en langdurig en moeizaam blijven.  
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DANKWOORD
Professor Kees Festen wil ik bedanken voor de gelegenheid om onder zijn leiding het
uiterst boeiende vak van kinderchirurg te leren. Zijn absolute toewijding aan de
kinderen en het vak vormde de basis, waaruit dit proefschrift is voortgekomen. 
Zonder de inspiratie tijdens ons wekelijkse overleg in de afgelopen 16 jaar met co-
promotor Ger Bongaerts zouden veel ideeën in dit proefschrift niet zijn uitgewerkt. 
In Corry Weemaes vond ik een stimulerende co-promotor, die met haar aanwij-
zingen en ondersteuning absoluut noodzakelijk was om het werk tot een goed einde
te brengen.  
Professor Jan Jansen bedank ik voor zijn bereidheid om als promotor bij dit voor
een belangrijk deel gastro-enterologische werk op te treden.
Jules Tolboom leverde aan veel artikelen en bij bijna alle patiënten een grote bij-
drage. Hij controleert de kinderen nog vele jaren, als wij allang weer met andere
kinderen bezig zijn.
Mijn collega's Frans van der Staak en Paul Rieu hebben een zeer groot aandeel in
de dagelijkse klinische behandeling en operaties van deze kinderen gehad. Aan de
jongere collega's René Wijnen, Marc Wijnen en Ivo de Blaauw zullen wij onze
kennis zo overdragen dat de kinderen met een korte dunne darm, ook als wij met
pensioen zijn, een optimale behandeling krijgen in het Radboud Kinderziekenhuis.
De stimulerende hulp van Eric Robertson  was niet alleen  tijdens vele nachtelijke
gezamenlijke operaties, maar ook verder als "native speaker" onmisbaar voor veel
aanpassingen en vaker ook aanvullingen van de Engelse tekst.
Binnen de operatiekamers laten wij de directe zorg voor een belangrijk deel over
aan anesthesiologen en hun assistenten, terwijl wij ons concentreren op onze ope-
ratie met hulp van de operatieassistenten. Dankzij de hulp en bijstand, die aan beide
kanten geboden wordt, kunnen wij heel veel bereiken bij heel zieke kinderen.
Aan laboratoriumpersoneel zijn in de tijd van computers en telefoons vaak geen
gezichten gekoppeld, maar de vele bepalingen op klinisch-chemische en microbiolo-
gische laboratoria zowel tijdens de acute problemen als erna tijdens de langdurige
follow-up, zijn onmisbaar voor een kwalitatief hoogstaande zorg. Ook binnen de
klinische farmacie werd veel zorg besteed aan de parenterale voeding en medicatie
voor deze kinderen met regelmatig overleg als wij weer iets wilden veranderen aan
de samenstelling. Bedankt voor de samenwerking.
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Ook de vele andere dienstverleners in ons ziekenhuis zoals de radiologen, die altijd
voor ons klaarstonden en hun laborantes, die steeds weer mochten opdraven voor de
zoveelste centraal veneuze lijn bij deze kinderen, bedank ik hartelijk voor de prettige
samenwerking. 
Darm en voeding zijn onlosmakelijk verbonden, wij pretenderen er iets van te
weten, maar zonder de hulp van diëtisten, zouden wij toch erg tekort schieten in onze
begeleiding met name bij de overgang van parenterale naar enterale voeding. Ook het
eet- en voedingsteam voor kinderen met zijn deelnemers uit uiteenlopende specia-
lismen is soms nodig voor de uiteindelijke zorg, als kinderen weer mogen eten,
maar vergeten zijn hoe dat moet.
Als kinderen met parenterale voeding naar huis mogen, is voor het regelen van
de parenterale voeding thuis de hulp van de afdeling gastro-enterologie met hun
voedingsteam onmisbaar.
Intensieve samenwerking met alle kinderspecialisten en vooral de assistenten in
opleiding tot kinderarts, die een groot deel van de dagelijkse zorg op hun nek krijgen,
is noodzakelijk om deze kinderen een leven te verschaffen dat de moeite waard is om
geleefd te worden. Ik kan niet alle kinderspecialismen en - specialisten noemen, maar
we hebben ze hard nodig bij de zeer uiteenlopende problemen van deze kinderen.  
Zonder de liefdevolle begeleiding van toegewijde en uitstekend geschoolde ver-
pleegkundigen op onze kinderchirurgische afdeling maar ook op de neonatale
intensive care, de intensive care voor kinderen en de andere kinderafdelingen, die
deze kinderen verplegen en daarnaast oog hebben voor de noden van de ouders, zou
het niet mogelijk zijn voor ons als artsen, deze groep kinderen adequaat te behande-
len. Met het noemen van enkele namen zou ik teveel verpleegkundigen tekort doen,
daarom van ganser harte, bedankt allemaal. 
Zonder steun van alle anderen bij de behandeling betrokkenen, waaronder peda-
gogisch medewerkers, kinderfysiotherapeuten en psychologen, die de natuurlijke
ontwikkeling van de kinderen in het ziekenhuis voor zover mogelijk ondersteunen,
zou het meestal langdurig en vaak terugkomende ziekenhuisverblijf een nog veel
grotere invloed gehad hebben. 
De zorg, in het dierenlaboratorium besteed aan het welzijn van de te opereren dieren
onder de leiding van Theo Arts, was voortreffelijk.
In dit ziekenhuis werken heel veel mensen van schoonmakers tot leden van de Raad
van Bestuur en van de staf Financiën en Economie tot medewerkers van de telefoon-
167
Dankwoord 
centrale. Zonder de inzet van elk van hen zou ons klinische werk niet mogelijk zijn
en dan waren studies als deze ook niet mogelijk.
Omdat onze tijd voor wetenschap vaak uiterst beperkt is, prijzen we ons gelukkig
dat verschillende studenten in een wetenschappelijke stage een stukje van de proble-
men wilden uitzoeken.
Mijn kinderen Karen en Maaike hebben altijd gezegd, dat ze paranimf wilden
worden: het gaat dan eindelijk gebeuren.
Zonder de stimulans van mijn vrouw Assina Haan zou dit proefschrift niet tot stand
zijn gekomen. Zij forceerde de beslissing: doen, maar dan ook doorzetten of niet
doen, maar er dan ook niet meer over praten. 
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Marilyn French  
Our Father 
1994 Belles-Lettres, Inc
Little, Brown and company, Boston
So many wonderful things in life, she leaves all that out of her accounting. Economics
she calls it, a science she says, it's a peculiar science if it leaves out half of the exis-
tence, more than half, but maybe all sciences do that, certainly medicine does it,
watch the doctors at St. Mary's, they forget the spirit, they forget how important it is
to be held and touched and consoled. Also they forget nutrition, at St. Mary's at least.
The terrible food they serve patients, don't they think they would get better faster with
healthier food? All they can see is medication and surgery, well my clinic will do
a better job, will have fresh food there for patients who need that more than they
need a pill. Fruit, vegetables, rice and beans, and there will always be a pot of soup
cooking in my clinic.
Marilyn French 
Onze Vader
1994 JM Meulenhoff bv. Amsterdam
Zoveel heerlijke dingen in het leven, die laat ze allemaal buiten beschouwing.
Economie noemt ze het, een wetenschap zegt ze, een merkwaardige wetenschap als
die de helft van het bestaan negeert, meer dan de helft, maar misschien doet iedere
wetenschap dat, vast, geneeskunde doet het zeker, ik zie de artsen in het St.-Mary, ze
vergeten de geest, ze vergeten hoe belangrijk het is omhelsd, aangeraakt en getroost
te worden. Ze vergeten ook de voeding, in het St.-Mary tenminste. Het vreselijke eten
dat ze de patiënten voorzetten, snappen ze niet dat ze sneller beter zouden worden met
gezonder voedsel? Ze hebben alleen oog voor medicijnen en chirurgie, nou, mijn
kliniek zal het beter aanpakken, wij zullen vers voedsel hebben voor de patiënten
die dat harder nodig hebben dan pillen. Vruchten, groenten, rijst, bonen, en in mijn
kliniek zal altijd een pan soep op het vuur staan.
169
170
Curriculum Vitae
CURRICULUM VITAE
René Severijnen was born in 1942 in Boekel (Noord-Brabant, the Netherlands). After
primary school, he attended the Episcopal College, a boarding school in Weert, where
he obtained at the Gymnasium ß  diploma in 1959. The medical study was followed at
the University of Utrecht and after an active student life, he graduated as a medical doc-
tor in 1969. He worked for one year at the surgical department of the St. Anna Hospital
in Oss and was taught the principles of surgery by dr. M. Bauer and dr. J. Logeman. 
After a course in tropical medicine, he was the only doctor in Igogwe, a 72-bed
mission hospital run by the Franciscan Sisters of Denekamp in the Mbeya district of
southwest Tanzania from 1970 till 1972. 
At the St Radboud Hospital of the Catholic University in Nijmegen he received his
surgical training from 1972 to 1978 under prof. dr. W. Schmidt and prof. dr. H. de
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2000 as head of the Department of Paediatric Surgery of the University Medical
Centre St Radboud in Nijmegen.
At the animal laboratory, he tried different operation techniques on pigs with anal
atresia to choose the best operation to perform later on children.
In the multidisciplinary team for children with defaecation problems after anal
atresia and Hirschsprung's disease, he looks after medication and surgery to comple-
ment the contributions of the psychologist and paediatric physiotherapist. He is also
a member of the paediatric feeding team.
As a teacher in general and paediatric surgery at all the hospitals, where he trained
and worked, he also contributed to the primary and secondary training of nurses and
operation assistants. He is actively involved in education programmes for medical
students and postgraduate programmes for doctors.
He has been serving on the Hospital Ethical Committee for eight years. 
In the founding of societies for the parents of children with anal atresia,
Hirschsprung's disease and oesophageal atresia, he took an active part.
He has two daughters, Karen and Maaike and four grandchildren, Tim, Sterre, Mees and
Nova. Assina Haan, creative regression and past lives therapist for children, is his wife.
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Stellingen bij het proefschrift “Short small bowel in children” van René Severijnen 2004 
 
 
1.  The man who made time, made plenty of it (Old Irish Proverb). 
 
2.  Moedermelk is ideale voeding, ook voor patiënten met een korte dunne darm. 
 
3.  Een kind met een korte dunne darm vormt een levend probiotisch model (Jules Tolboom). 
 
4. Spontane selectie van lactobacillen in patiënten met een korte dunne darm veroorzaakt door de 
lage pH een bijna ideale aanvulling op de natuurlijke verdedigingsmechanismen van de dunne 
darm, als artsen die groei niet verstoren door remming van het maagzuur en antibiotica. 
 
5. Transplantatie van de dunne darm is een acceptabele optie bij kinderen met een korte dunne 
darm die afhankelijk blijven van parenterale voeding, als na vele ja ren geen verdere adaptatie 
van de darmfunctie meer te verwachten is.  
 
6. Het is niet het verlies van de ileocoecaalklep en door de terugvloed van faeces veroorzaakte 
bacteriële overgroei, maar het verlies van de laatste ileumlis wat meestal ermee gepaard gaat, 
dat problemen veroorzaakt.  
 
7. Lichaam en geest zijn niet te scheiden, niet door “westerse” artsen en evenmin door patiënten, 
die alles van de arts verwachten en niet zelf een emotionele bijdrage willen of kunnen leveren. 
  
8. Artsen zijn onvoldoende toegerust om chronische pijn bij kinderen zoals veroorzaakt wordt 
door posttraumatische dystrofie (CRPS Complex Regionaal Pijn Syndroom) te behandelen, ze 
kunnen niet zonder de hulp van psychologen en fysiotherapeuten. 
  
9. Staande leren plassen kan onzindelijk blijven voor ontlasting in de hand werken (Agnes 
Brugman). 
 
10. Rode en kapotte billen bij kinderen die tanden krijgen, kunnen worden veroorzaakt door 
enzymen uit het speeksel, die normaal voor de doorbraak van de tanden zorgen en die als ze 
niet in de darm onschadelijk gemaakt worden, de huid op de billen aantasten. 
 
11. Kinderen zijn onze echte leraren. Luister zorgvuldig en ze zullen je leren over de verloren 
wereld van een bestaan zonder zorgen in het hier en nu (Tibetaanse wijsheid). 
 
12. De patiënt die goed eet, heeft geen medicijnen nodig en de patiënt die slecht eet ook niet 
(Handboek Ayurveda van Robert Swami Persaud).  
 
13. Zonder enthousiasme is het onmogelijk blijvend kennis over te dragen of om te inspireren. 
 
14. Een diepgaand gesprek op een onverwacht ogenblik is een te koesteren geschenk en een 
voortdurende inspiratiebron. 
 
15. Het Universitair Kinderziekenhuis in Nijmegen moet kiezen voor de naam “Radboud 
Kinderziekenhuis”om de bekende en goede naam van het “Radboud” in Nederland optimaal te 
gebruiken. Daarnaast zal een eenduidige keuze van het UMC St Radboud te Nijmegen voor 
dezelfde naam in binnen- en buitenland, Radboud Universitair Medisch Centrum Nijmegen 
veel verwarring in toekomstige publicaties kunnen voorkomen. 
